katphlab/pubtables-html · Datasets at Hugging Face

image imagewidth (px) 205 980	html stringlengths 86 21.5k	filename stringlengths 18 19
	<table border="1" class="dataframe"> <tr> <th> Name </th> <th> Description </th> </tr> <tr> <td> C2 </td> <td> complement component 2 </td> </tr> <tr> <td> PMP22 </td> <td> peripheral myelin protein 22 </td> </tr> <tr> <td> SDC1 </td> <td> syndecan 1 </td> </tr> <tr> <td> COL11A1 </td> <td> collagen, type XI, alpha 1 </td> </tr> <tr> <td> ITGB4 </td> <td> integrin, beta 4 </td> </tr> <tr> <td> DCN </td> <td> decorin </td> </tr> <tr> <td> THBS4 </td> <td> thrombospondin 4 </td> </tr> <tr> <td> COL1A1 </td> <td> collagen, type I, alpha 1 </td> </tr> <tr> <td> IFIT1 </td> <td> interferon-induced protein with tetratricopeptide repeats 1 </td> </tr> <tr> <td> LUM </td> <td> lumican </td> </tr> <tr> <td> MMP9 </td> <td> matrix metalloproteinase 9 </td> </tr> <tr> <td> COL3A1 </td> <td> collagen, type III, alpha 1 </td> </tr> <tr> <td> COL1A2 </td> <td> collagen, type I, alpha 2 </td> </tr> <tr> <td> JAK1 </td> <td> Janus kinase 1 </td> </tr> <tr> <td> MMP12 </td> <td> matrix metalloproteinase 12 </td> </tr> <tr> <td> TNFSF10 </td> <td> tumour necrosis factor (ligand) superfamily, member 10 </td> </tr> <tr> <td> HSPA4 </td> <td> heat shock 70 kDa protein 4 </td> </tr> <tr> <td> FBLN2 </td> <td> ﬁ bulin 2 </td> </tr> <tr> <td> SFRP2 </td> <td> secreted frizzled-related protein 2 </td> </tr> <tr> <td> COL15A1 </td> <td> collagen, type XV, alpha 1 </td> </tr> <tr> <td> FBLN1 </td> <td> ﬁ bulin-1 </td> </tr> <tr> <td> GEM </td> <td> GTP binding protein </td> </tr> <tr> <td> MATN2 </td> <td> matrilin 2 </td> </tr> <tr> <td> CCL21 </td> <td> chemokine (C-C motif) ligand 21 </td> </tr> <tr> <td> CCL19 </td> <td> chemokine (C-C motif) ligand 19 </td> </tr> <tr> <td> SLCO2A1 </td> <td> solute carrier organic anion transporter family, member 2A1 </td> </tr> <tr> <td> MFAP5 </td> <td> microﬁ brillar-associated protein 5 </td> </tr> <tr> <td> CXCL14 </td> <td> chemokine (C-X-C motif) ligand 14 </td> </tr> <tr> <td> PRG4 </td> <td> proteoglycan 4 </td> </tr> <tr> <td> CCL13 </td> <td> chemokine (C-C motif) ligand 13 </td> </tr> <tr> <td> CCL14 </td> <td> chemokine (C-C motif) ligand 14 </td> </tr> <tr> <td> CCL15 </td> <td> chemokine (C-C motif) ligand 15 </td> </tr> </table>	PMC2716678_table_3
	<table border="1" class="dataframe"> <tr> <th> </th> <th> True normal tissues </th> <th> True tumor tissues </th> </tr> <tr> <td> Predicted as normal tissues </td> <td> 1 </td> <td> 1 </td> </tr> <tr> <td> Predicted as tumor tissues </td> <td> 5 </td> <td> 41 </td> </tr> </table>	PMC2716681_table_0
	<table border="1" class="dataframe"><tr><td></td><td></td><td>Batch I Analysis</td><td></td><td></td></tr><tr><td></td><td>Organ donor (N)</td><td>Adjacent to tumor (A)</td><td>Tumor (T)</td><td>Total</td></tr><tr><td>Liver</td><td>21</td><td>30</td><td>43</td><td>94</td></tr><tr><td>Prostate</td><td>23</td><td>59</td><td>66</td><td>148</td></tr><tr><td></td><td></td><td>Batch II Analysis</td><td></td><td></td></tr><tr><td></td><td>Organ donor (N)</td><td>Tumor (T)</td><td></td><td>Total</td></tr><tr><td>Liver</td><td>21</td><td>43</td><td></td><td>64</td></tr><tr><td>Prostate</td><td>23</td><td>66</td><td></td><td>89</td></tr><tr><td>Lung</td><td>17</td><td>134</td><td></td><td>151</td></tr><tr><td>Bladder</td><td>5</td><td>57</td><td></td><td>62</td></tr></table>	PMC2716681_table_1
	<table border="1" class="dataframe"><tr><td></td><td colspan="2">Liver vs. Prostate</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>pro→liv</td><td>pro→pro</td><td>liv→pro</td></tr><tr><td>All genes</td><td>96.5%</td><td>66.3%</td><td>93.9%</td><td>47.4%</td></tr><tr><td>Common signature</td><td>96.5%</td><td>93.0%</td><td>98.8%</td><td>96.3%</td></tr><tr><td></td><td colspan="2">Liver vs. Prostate</td><td></td><td></td></tr><tr><td>All genes</td><td>92.6%</td><td>77.9%</td><td>96.6%</td><td>54.6%</td></tr><tr><td>Common signature</td><td>98.2%</td><td>96.0%</td><td>98.3%</td><td>96.6%</td></tr><tr><td></td><td colspan="2">Liver vs. Prostate</td><td></td><td></td></tr><tr><td>All genes</td><td>79.9%</td><td>51.9%</td><td>71.4%</td><td>55.7%</td></tr><tr><td>Common signature</td><td>75.6%</td><td>74.7%</td><td>66.7%</td><td>65.1%</td></tr></table>	PMC2716681_table_2
	<table border="1" class="dataframe"><tr><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>pro→liv</td><td>pro→pro</td><td>liv→pro</td></tr><tr><td>All genes</td><td>96.51%</td><td>66.28%</td><td>93.94%</td><td>47.36%</td></tr><tr><td>Common signature</td><td>97.67%</td><td>97.67%</td><td>95.55%</td><td>94.14%</td></tr><tr><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>lun→liv</td><td>lun→lun</td><td>liv→lun</td></tr><tr><td>All genes</td><td>96.51%</td><td>56.98%</td><td>90.72%</td><td>45.32%</td></tr><tr><td>Common signature</td><td>95.23%</td><td>93.02%</td><td>95.94%</td><td>94.72%</td></tr><tr><td></td><td colspan="2">Lung</td><td></td><td></td></tr><tr><td></td><td>lun→lun</td><td>pro→lun</td><td>pro→pro</td><td>lun→pro</td></tr><tr><td>All genes</td><td>90.72%</td><td>69.03%</td><td>93.94%</td><td>62.88%</td></tr><tr><td>Common signature</td><td>94.82%</td><td>94.45%</td><td>79.61%</td><td>72.76%</td></tr><tr><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>bla→liv</td><td>bla→bla</td><td>liv→bla</td></tr><tr><td>All genes</td><td>96.51%</td><td>62.79%</td><td>88.60%</td><td>49.65%</td></tr><tr><td>Common signature</td><td>91.74%</td><td>91.86%</td><td>98.25%</td><td>98.25%</td></tr><tr><td></td><td colspan="2">Prostate</td><td></td><td></td></tr><tr><td></td><td>pro→pro</td><td>bla→pro</td><td>bla→bla</td><td>pro→bla</td></tr><tr><td>All genes</td><td>93.94%</td><td>36.30%</td><td>88.60%</td><td>42.63%</td></tr><tr><td>Common signature</td><td>92.92%</td><td>86.86%</td><td>97.81%</td><td>88.25%</td></tr><tr><td></td><td colspan="2">Lung</td><td></td><td></td></tr><tr><td></td><td>lun→lun</td><td>bla→lun</td><td>bla→bla</td><td>lun→bla</td></tr><tr><td>All genes</td><td>90.72%</td><td>51.87%</td><td>88.60%</td><td>50.88%</td></tr><tr><td>Common signature</td><td>89.38%</td><td>85.91%</td><td>97.37%</td><td>85.61%</td></tr></table>	PMC2716681_table_3
	<table border="1" class="dataframe"> <tr> <th> </th> <th> </th> <th colspan="4"> Test data </th> </tr> <tr> <th> </th> <th> </th> <th> Liver </th> <th> Prostate </th> <th> Lung </th> <th> Bladder </th> </tr> <tr> <td rowspan="4"> Training data </td> <td> Liver </td> <td> 96.5% (69)* </td> <td> (225)+ 94.1% </td> <td> (119)+ 94.7% </td> <td> (53)+ 98.3% </td> </tr> <tr> <td> Prostate </td> <td> (225)+ 97.7% </td> <td> 93.9% (55)* </td> <td> (288)+ 94.5% </td> <td> (10)+ 88.3% </td> </tr> <tr> <td> Lung </td> <td> (119)+ 93.0% </td> <td> (288)+ 72.8% </td> <td> 90.7% (57)* </td> <td> (19)+ 85.6% </td> </tr> <tr> <td> Bladder </td> <td> (53)+ 91.9% </td> <td> (10)+ 86.9% </td> <td> (19)+ 85.9% </td> <td> 88.6% (135)* </td> </tr> </table>	PMC2716681_table_4
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> A2780 </th> <th colspan="2"> A2780/CDDP </th> <th colspan="2"> SKOV3 </th> </tr> <tr> <th> </th> <th> control </th> <th> BRCA1 si </th> <th> control </th> <th> BRCA1 si </th> <th> control </th> <th> BRCA1 si </th> </tr> <tr> <td> G1 </td> <td> 52.57±5.11% </td> <td> 50.03±4.88% </td> <td> 48.87±4.76% </td> <td> 44.77±5.71% </td> <td> 45.07±4.1% </td> <td> 43.03±2.71% </td> </tr> <tr> <td> S </td> <td> 16.43±3.18% </td> <td> 19.33±2.81% </td> <td> 10.89±2.18% </td> <td> 10.40±3.23% </td> <td> 9.43±5.18% </td> <td> 9.39±1.86% </td> </tr> <tr> <td> G2/M </td> <td> 19.73±2.50% </td> <td> 21.37±2.76% </td> <td> 28.83±2.44% </td> <td> 29.39±3.50% </td> <td> 23.03±1.50% </td> <td> 23.99±2.90% </td> </tr> </table>	PMC2716781_table_0
	<table border="1" class="dataframe"> <tr> <th> Group </th> <th> Site </th> <th> n </th> <th> Women/Men </th> <th> Age (years) </th> <th> BMI (kg/m2) </th> </tr> <tr> <td rowspan="4"> Control </td> <td> UK </td> <td> 21 </td> <td> 20/1 </td> <td> 40.5 ± 11.0 </td> <td> 25.4 ± 3.8 </td> </tr> <tr> <td> Australia </td> <td> 16 </td> <td> 12/4 </td> <td> 44.5 ± 12.1 </td> <td> 24.3 ± 5.1 </td> </tr> <tr> <td> Spain </td> <td> 23 </td> <td> 17/6 </td> <td> 38.5 ± 11.1 </td> <td> 23.0 ± 2.6 </td> </tr> <tr> <td> Total </td> <td> 60 </td> <td> 49/11 </td> <td> 40.8 ± 11.4 </td> <td> 24.2 ± 3.8 </td> </tr> <tr> <td rowspan="4"> Routes </td> <td> UK </td> <td> 21 </td> <td> 19/2 </td> <td> 43.8 ± 10.2 </td> <td> 25.2 ± 4.1 </td> </tr> <tr> <td> Australia </td> <td> 19 </td> <td> 13/6 </td> <td> 43.3 ± 10.0 </td> <td> 26.7 ± 4.4 </td> </tr> <tr> <td> Spain </td> <td> 20 </td> <td> 13/7 </td> <td> 39.4 ± 7.0 </td> <td> 23.5 ± 2.8 </td> </tr> <tr> <td> Total </td> <td> 60 </td> <td> 45/15 </td> <td> 42.1 ± 9.2 </td> <td> 25.1 ± 4.0 </td> </tr> <tr> <td rowspan="4"> Incidental </td> <td> UK </td> <td> 21 </td> <td> 18/3 </td> <td> 39.8 ± 10.4 </td> <td> 25.1 ± 3.4 </td> </tr> <tr> <td> Australia </td> <td> 14 </td> <td> 11/3 </td> <td> 43.2 ± 10.3 </td> <td> 28.1 ± 6.0 </td> </tr> <tr> <td> Spain </td> <td> 24 </td> <td> 18/6 </td> <td> 40.8 ± 8.9 </td> <td> 24.0 ± 3.1 </td> </tr> <tr> <td> Total </td> <td> 59 </td> <td> 4712 </td> <td> 41.0 ± 9.7 </td> <td> 25.4 ± 4.3 </td> </tr> </table>	PMC2717045_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="5"> Risk groups </th> <th> </th> </tr> <tr> <th> Country </th> <th> MSM </th> <th> IDUs </th> <th> Heterosexuals </th> <th> Others </th> <th> Unknown </th> <th> Sum </th> </tr> <tr> <td> United Kingdom (GBR) </td> <td> 59 (66%) </td> <td> 0 (0%) </td> <td> 6 (7%) </td> <td> 0 (0%) </td> <td> 25 (28%) </td> <td> 90 </td> </tr> <tr> <td> Austria (AUT) </td> <td> 18 (20%) </td> <td> 5(6%) </td> <td> 7 (8%) </td> <td> 0 (0%) </td> <td> 60 (67%) </td> <td> 90 </td> </tr> <tr> <td> Belgium (BEL) </td> <td> 56 (65%) </td> <td> 3 (3%) </td> <td> 11 (13%) </td> <td> 4 (5%) </td> <td> 12 (14%) </td> <td> 86 </td> </tr> <tr> <td> Denmark (DNK) </td> <td> 15 (17%) </td> <td> 4 (4%) </td> <td> 7 (8%) </td> <td> 0 (0%) </td> <td> 64 (71%) </td> <td> 90 </td> </tr> <tr> <td> Spain (ESP) </td> <td> 46 (51%) </td> <td> 21 (23%) </td> <td> 17 (19%) </td> <td> 0 (0%) </td> <td> 6 (7%) </td> <td> 90 </td> </tr> <tr> <td> Germany (DEU) </td> <td> 85 (94%) </td> <td> 0 (0%) </td> <td> (0%) </td> <td> 0 (0%) </td> <td> 5 (6%) </td> <td> 90 </td> </tr> <tr> <td> Greece (GRC) </td> <td> 39 (53%) </td> <td> 3 (4%) </td> <td> 8 (11%) </td> <td> 1 (1%) </td> <td> 22 (30%) </td> <td> 73 </td> </tr> <tr> <td> Israel (ISR) </td> <td> 15 (44%) </td> <td> 8 (24%) </td> <td> 7 (21%) </td> <td> 1 (3%) </td> <td> 3 (9%) </td> <td> 34 </td> </tr> <tr> <td> Italy (ITA) </td> <td> 31 (34%) </td> <td> 15 (17%) </td> <td> 32 (36%) </td> <td> 0 (0%) </td> <td> 12 (13%) </td> <td> 90 </td> </tr> <tr> <td> Luxembourg (LUX) </td> <td> 50 (56%) </td> <td> 15 (17%) </td> <td> 19 (21%) </td> <td> 0 (0%) </td> <td> 6 (7%) </td> <td> 90 </td> </tr> <tr> <td> Netherlands (NLD) </td> <td> 57 (68%) </td> <td> 7 (8%) </td> <td> 15 (18%) </td> <td> 0 (0%) </td> <td> 5 (6%) </td> <td> 84 </td> </tr> <tr> <td> Norway (NOR) </td> <td> 19 (73%) </td> <td> 1 (4%) </td> <td> 5 (19%) </td> <td> 0 (0%) </td> <td> 1 (4%) </td> <td> 26 </td> </tr> <tr> <td> Poland (POL) </td> <td> 12 (13%) </td> <td> 42 (47%) </td> <td> 19 (21%) </td> <td> 0 (0%) </td> <td> 17 (19%) </td> <td> 90 </td> </tr> <tr> <td> Portugal (PRT) </td> <td> 27 (30%) </td> <td> 16 (18%) </td> <td> 35 (39%) </td> <td> 0 (0%) </td> <td> 12 (13%) </td> <td> 90 </td> </tr> <tr> <td> Serbia </td> <td> 22 (50%) </td> <td> 6 (14% </td> <td> 16 (36%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 44 </td> </tr> <tr> <td> Sweden (SWE) </td> <td> 44 (49%) </td> <td> 3 (3%) </td> <td> 10 (11%) </td> <td> 0 (0%) </td> <td> 33 (37%) </td> <td> 90 </td> </tr> <tr> <td> Switzerland (CHE) </td> <td> 48 (53%) </td> <td> 10 (11%) </td> <td> 28 (31%) </td> <td> 0 (0%) </td> <td> 4 (4%) </td> <td> 90 </td> </tr> <tr> <td> Sum </td> <td> 643 (48%) </td> <td> 159 (12%) </td> <td> 242 (18%) </td> <td> 6 (0.5%) </td> <td> 287 (21%) </td> <td> 1337 </td> </tr> </table>	PMC2717046_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th> White (291) </th> <th> Hispanic (22) </th> <th> Black (12) </th> <th> Asian (5) </th> <th> Other (15) </th> </tr> <tr> <td> SNAP </td> <td> 0.709 </td> <td> 0.750 </td> <td> 1.240 </td> <td> 0.818 </td> <td> 0.659 </td> </tr> <tr> <td> PAML </td> <td> 0.839 </td> <td> 0.826 </td> <td> 1.411 </td> <td> 1.346 </td> <td> 0.751 </td> </tr> <tr> <td> HYPHY </td> <td> 0.949 </td> <td> 0.729 </td> <td> 1.453 </td> <td> 0.720 </td> <td> 1.202 </td> </tr> </table>	PMC2717047_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Race </th> <th colspan="2"> Race by treatment </th> </tr> <tr> <th> Method </th> <th> ANOVA </th> <th> Corrected pairwise t-tests </th> <th> ANOVA </th> <th> lm coefficient </th> </tr> <tr> <td> SNAP </td> <td> (0.011) </td> <td> black vs hispanic (0.020) black vs other (0.013) black vs white (0.004) </td> <td> (0.025) </td> <td> black placebo (0.001) </td> </tr> <tr> <td> PAML </td> <td> (0.019) </td> <td> black vs hispanic (0.047) black vs other (0.047) black vs white (0.033) </td> <td> </td> <td> black placebo (0.016) </td> </tr> <tr> <td> HYPHY </td> <td> </td> <td> </td> <td> </td> <td> black placebo (0.015) </td> </tr> </table>	PMC2717047_table_1
	<table border="1" class="dataframe"> <tr> <th> Analyte </th> <th> Collision energy (eV) </th> <th> Collision exit potential (V) </th> <th> Declustering potential (V) </th> <th> Entrance potential (V) </th> </tr> <tr> <td> myo-inositol </td> <td> -10.0 </td> <td> -5.0 </td> <td> -70.0 </td> <td> -10.0 </td> </tr> <tr> <td> [2H6]-myo-inositol </td> <td> -18.0 </td> <td> -9.0 </td> <td> -70.0 </td> <td> -10.0 </td> </tr> </table>	PMC2717050_table_0
	<table border="1" class="dataframe"> <tr> <th> Time </th> <th> Mean </th> <th> SD </th> <th> N </th> </tr> <tr> <td> 1 </td> <td> 6.33 </td> <td> 4.1 </td> <td> 45 </td> </tr> <tr> <td> 2 </td> <td> 3.16 </td> <td> 3.9 </td> <td> 32 </td> </tr> <tr> <td> 3 </td> <td> 0.88 </td> <td> 2.47 </td> <td> 17 </td> </tr> </table>	PMC2717051_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th rowspan="2"> Time 1 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 2 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 3 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> </tr> <tr> <th> </th> </tr> <tr> <td> Total Difficulties </td> <td> 20.15 </td> <td> 5.19 </td> <td> 46 </td> <td> 17.41 </td> <td> 6.31 </td> <td> 32 </td> <td> 15.06 </td> <td> 8.36 </td> <td> 17 </td> </tr> <tr> <td> Pro-Social Behaviour </td> <td> 6.09 </td> <td> 2.3 </td> <td> 46 </td> <td> 6.38 </td> <td> 2.67 </td> <td> 32 </td> <td> 6.2 </td> <td> 3.22 </td> <td> 17 </td> </tr> <tr> <td> Hyperactivity </td> <td> 5.8 </td> <td> 2.19 </td> <td> 46 </td> <td> 5.44 </td> <td> 2.42 </td> <td> 32 </td> <td> 4.71 </td> <td> 2.73 </td> <td> 17 </td> </tr> <tr> <td> Conduct Problems </td> <td> 4 </td> <td> 2.07 </td> <td> 46 </td> <td> 3.69 </td> <td> 2.15 </td> <td> 32 </td> <td> 2.76 </td> <td> 2.44 </td> <td> 17 </td> </tr> <tr> <td> Emotional Difficulties </td> <td> 6.93 </td> <td> 1.89 </td> <td> 46 </td> <td> 5.63 </td> <td> 2.86 </td> <td> 32 </td> <td> 4.88 </td> <td> 2.96 </td> <td> 17 </td> </tr> <tr> <td> Peer Problems </td> <td> 3.41 </td> <td> 2.15 </td> <td> 46 </td> <td> 2.66 </td> <td> 2.35 </td> <td> 32 </td> <td> 2.53 </td> <td> 2.24 </td> <td> 17 </td> </tr> </table>	PMC2717051_table_1
	<table border="1" class="dataframe"> <tr> <th> Time </th> <th> Mean </th> <th> SD </th> <th> N </th> </tr> <tr> <td> 1 </td> <td> 12.13 </td> <td> 3.21 </td> <td> 45 </td> </tr> <tr> <td> 2 </td> <td> 13.48 </td> <td> 3.48 </td> <td> 31 </td> </tr> <tr> <td> 3 </td> <td> 15 </td> <td> 3.48 </td> <td> 17 </td> </tr> </table>	PMC2717051_table_2
	<table border="1" class="dataframe"> <tr> <th> </th> <th rowspan="2"> Time 1 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 2 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 3 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> </tr> <tr> <th> </th> </tr> <tr> <td> Challenges </td> <td> 12.76 </td> <td> 3.84 </td> <td> 46 </td> <td> 8.88 </td> <td> 3.95 </td> <td> 24 </td> <td> 6.65 </td> <td> 3.82 </td> <td> 13 </td> </tr> <tr> <td> Goals </td> <td> 6.14 </td> <td> 2.93 </td> <td> 46 </td> <td> 10.66 </td> <td> 4.18 </td> <td> 22 </td> <td> 11.35 </td> <td> 4.65 </td> <td> 13 </td> </tr> </table>	PMC2717051_table_3
	<table border="1" class="dataframe"> <tr> <th> Parameters </th> <th> Oromo folksongs </th> <th> Remark </th> </tr> <tr> <td> Lyrics </td> <td> More than one issue is addressed </td> <td> With the exception to some of the folksongs, most of them describe various and more than one issues </td> </tr> <tr> <td> Vocal style </td> <td> Less ornamental to ornamental </td> <td> Sometimes melismatic or strophic forms exist </td> </tr> <tr> <td> Timber </td> <td> Soft to less harsh </td> <td> Occasionally strident and forced singing </td> </tr> <tr> <td> Performer arrangement </td> <td> Responsorial-leader chorus alternation is the dominant one </td> <td> At times chorus-chorus alternation style. Responsorial- leader chorus alternation of male songs is less often followed by acclamation of women group. Few Solo songs exist. </td> </tr> <tr> <td> Melody </td> <td> Have a narrow range up to a fifth interval; melodies are patterned in descending and ascending order; 2 or three melodies are used </td> <td> The melodic form of the folksong is strophic consisting of two to eight lines. The relationships among the lines do vary or are similar. Some of the folksongs have similar or different content. Most of the folk songs are monophonic and some are polyphonic (more than one melodic line). Most of the songs listed here for describing the bioecocultural heritages are sung without accompaniment of instruments and hence are predominantly vocal folksongs. </td> </tr> <tr> <td> Scale </td> <td> Major; natural minor; pentatonic major </td> <td> Most of the folksongs collected here are diatonic or pentatonic or prepentatonic </td> </tr> <tr> <td> Rhythm </td> <td> Hard to identify; not a major element; 3/4 or 6/8 </td> <td> The rhythm and metre are not similar throughout the folksongs described. Mostly they are non-metric as they are mostly vocal. The music has been described as primarily melodic with simple rhythmic accompaniments that can be similar or different. </td> </tr> <tr> <td> Song type </td> <td> Both secular and sacred </td> <td> Folksongs are impulsive creations which are not developed by artists in organized ways hence can have various foci. </td> </tr> <tr> <td> Qñt* </td> <td> Tzta and Bati </td> <td> Most of the folksongs are composed without notations. It might be the same composer or different who created both the words and the music. One of the major classes of the folksongs, the ballads are narrative songs for describing varieties which are identified by their texts. The instrumental folksongs commonly accompanied by drums in the region are used for dances. </td> </tr> </table>	PMC2717052_table_0
	<table border="1" class="dataframe"> <tr> <th> Patient characteristics 16 </th> <th> Number of patients </th> <th> HER 2 +(%) </th> </tr> <tr> <td> Total Patients </td> <td> 73 </td> <td> 21 (28.8) </td> </tr> <tr> <td> Sex </td> <td> </td> <td> </td> </tr> <tr> <td rowspan="2"> Male The </td> <td> 69 </td> <td> 19 (27.5) </td> </tr> <tr> <td> 4 </td> <td> 2 (50) </td> </tr> <tr> <td> Stage </td> <td> </td> <td> </td> </tr> <tr> <td> Stage IIIB </td> <td> 30 </td> <td> 9 (30) </td> </tr> <tr> <td> Stage IV </td> <td> 43 </td> <td> 12 (27.9) </td> </tr> <tr> <td> Histopathology </td> <td> </td> <td> </td> </tr> <tr> <td> Adenocarcinoma </td> <td> 27 </td> <td> 11 (40.7) </td> </tr> <tr> <td> Squamous cell (Epidermoid) </td> <td> 34 </td> <td> 5 (14.7) </td> </tr> <tr> <td> Not otherwise specified (NOS) </td> <td> 12 </td> <td> 5 (41.6) </td> </tr> </table>	PMC2717055_table_0
	<table border="1" class="dataframe"> <tr> <th> HER 2 </th> <th> CR+PR+SD </th> <th> PD </th> </tr> <tr> <td> HER 2 (+) </td> <td> 13 (63.9) </td> <td> 8(38.1%) </td> </tr> <tr> <td> HER 2 (-) </td> <td> 48 (92.3%) </td> <td> 4(7.7%) </td> </tr> </table>	PMC2717055_table_1
	<table border="1" class="dataframe"> <tr> <th> Patient characteristics </th> <th> Number of patients </th> <th> CR+PR+SD </th> <th> PD </th> </tr> <tr> <td> Total Patients </td> <td> 73 </td> <td> 61(83.6%) </td> <td> 12 (16.4%) </td> </tr> <tr> <td> Sex </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Male </td> <td> 69 </td> <td> 58 (84%) </td> <td> 11 (16%) </td> </tr> <tr> <td> Female </td> <td> 4 </td> <td> 3(75%) </td> <td> 1 (25%) </td> </tr> <tr> <td> Stage </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Stage IIIB </td> <td> 30 </td> <td> 29(96.6%) </td> <td> 1(3.4%) </td> </tr> <tr> <td> Stage IV </td> <td> 43 </td> <td> 32 (74.4%) </td> <td> 11 (25.6%) </td> </tr> <tr> <td> Histopathology </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Adenocarcinoma </td> <td> 27 </td> <td> 21(78%) </td> <td> 6(22%) </td> </tr> <tr> <td> Squamous cell (Epidermoid) </td> <td> 34 </td> <td> 31(91.2%) </td> <td> 3 (8.8%) </td> </tr> <tr> <td> Not otherwise specified (NOS) </td> <td> 12 </td> <td> 9 (75%) </td> <td> 3 (25%) </td> </tr> </table>	PMC2717055_table_2
	<table border="1" class="dataframe"> <tr> <th> GO term </th> <th> Level1 </th> <th> Genes2 </th> <th> ORFs3 </th> <th> Prot. DIP4 </th> <th> Prot.DIP/ ORFs (%) </th> <th> Prot. GOLD5 </th> <th> Prot.GOLD/ ORFs (%) </th> </tr> <tr> <td> Developmental process (BP) </td> <td> 1 </td> <td> 768 </td> <td> 757 </td> <td> 632 </td> <td> 83.5% </td> <td> 257 </td> <td> 34.0% </td> </tr> <tr> <td> Reproduction (BP) </td> <td> 1 </td> <td> 299 </td> <td> 298 </td> <td> 245 </td> <td> 82.2% </td> <td> 111 </td> <td> 37.3% </td> </tr> <tr> <td> Establishment of cellular localization (BP) </td> <td> 1 </td> <td> 573 </td> <td> 568 </td> <td> 452 </td> <td> 79.6% </td> <td> 188 </td> <td> 33.1% </td> </tr> <tr> <td> Response to stimulus (BP) </td> <td> 1 </td> <td> 670 </td> <td> 657 </td> <td> 514 </td> <td> 78.2% </td> <td> 207 </td> <td> 31.5% </td> </tr> <tr> <td> Ribonucleoprotein complex (CC) </td> <td> 2 </td> <td> 556 </td> <td> 459 </td> <td> 318 </td> <td> 69.3% </td> <td> 96 </td> <td> 20.9% </td> </tr> <tr> <td> Organelle envelope (CC) </td> <td> 2 </td> <td> 346 </td> <td> 345 </td> <td> 230 </td> <td> 66.7% </td> <td> 69 </td> <td> 20.0% </td> </tr> <tr> <td> Transcription regulator activity (MF) </td> <td> 1 </td> <td> 307 </td> <td> 303 </td> <td> 276 </td> <td> 91.1% </td> <td> 107 </td> <td> 35.3% </td> </tr> <tr> <td> Structural molecule activity (MF) </td> <td> 1 </td> <td> 307 </td> <td> 286 </td> <td> 231 </td> <td> 80.8% </td> <td> 75 </td> <td> 26.2% </td> </tr> <tr> <td rowspan="2"> Transporter activity (MF) </td> <td> 1 </td> <td> 380 </td> <td> 377 </td> <td> 297 </td> <td> 78.8% </td> <td> 63 </td> <td> 16.7% </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> Average: 78.9% </td> <td> </td> <td> Average: 28.3% </td> </tr> </table>	PMC2717056_table_0
	<table border="1" class="dataframe"><tr><td>GO term</td><td>N (P) DIP</td><td>N (P) GOLD</td><td>GO term</td><td>N (P) DIP</td><td>N (P) GOLD</td></tr><tr><td>Developmental process (32502)</td><td>632 (16)</td><td>257 (8)</td><td>Organelle envelope (31967)</td><td>230 (12)</td><td>69 (2)</td></tr><tr><td>Reproductive developmental process (3006)</td><td>26 (0)</td><td>13 (0)</td><td>Organelle inner membrane (19866)</td><td>105 (8)</td><td>27 (2)</td></tr><tr><td>Anatomical structure development (48856)</td><td>186 (15)</td><td>94 (8)</td><td>Organelle outer membrane (31968)</td><td>24 (0)</td><td>---</td></tr><tr><td>Cellular developmental process (48869)</td><td>450 (1)</td><td>169 (0)</td><td>Organelle envelope lumen (31970)</td><td>25 (0)</td><td>---</td></tr><tr><td rowspan="2">Aging (7568)</td><td>40 (0)</td><td>22 (0)</td><td>Nuclear envelope (5635)</td><td>86 (3)</td><td>35 (0)</td></tr><tr><td></td><td></td><td>Mitochondrial envelope (5740)</td><td>148 (9)</td><td>34 (2)</td></tr><tr><td>Reproduction (3)</td><td>245 (7)</td><td>111 (4)</td><td></td><td></td><td></td></tr><tr><td>Sexual reproduction (19953)</td><td>95 (0)</td><td>41 (0)</td><td>Transcription regulator activity (30528)</td><td>276 (14)</td><td>107 (5)</td></tr><tr><td>Asexual reproduction (19954)</td><td>74 (6)</td><td>44 (4)</td><td>Transcriptional activator activity (16563)</td><td>50 (0)</td><td>24 (0)</td></tr><tr><td>Reproductive process (22414)</td><td>207 (7)</td><td>88 (4)</td><td>Transcriptional repressor activity (16564)</td><td>35 (2)</td><td>13 (1)</td></tr><tr><td rowspan="2">Rep. of a single-celled organism (32505)</td><td>220 (7)</td><td>99 (4)</td><td>Transcription factor activity (3700)</td><td>45 (2)</td><td>13 (1)</td></tr><tr><td></td><td></td><td>RNA polymerase II transcription factor activity (3702)</td><td>112 (4)</td><td>44 (1)</td></tr><tr><td>Establishment of cellular localization (51649)</td><td>452 (21)</td><td>188 (10)</td><td>Transcriptional elongation regulator activity (3711)</td><td>14 (6)</td><td>---</td></tr><tr><td>Secretion by cell (32940)</td><td>206 (9)</td><td>84 (3)</td><td>Transcription cofactor activity (3712)</td><td>36 (1)</td><td>16 (0)</td></tr><tr><td>Establishment of nucleus localization (40023)</td><td>17 (0)</td><td>---</td><td></td><td></td><td></td></tr><tr><td rowspan="2">Intracellular transport (46907)</td><td>409 (21)</td><td>175 (10)</td><td>Structural molecule activity (5198)</td><td>231 (29)</td><td>75 (18)</td></tr><tr><td></td><td></td><td>Structural constituent of ribosome (3735)</td><td>115 (0)</td><td>21 (0)</td></tr><tr><td>Response to stimulus (50896)</td><td>514 (3)</td><td>207 (0)</td><td>Structural constituent of cytoskeleton (5200)</td><td>50 (29)</td><td>31 (18)</td></tr><tr><td>Response to endogenous stimulus (9719)</td><td>197 (3)</td><td>101 (0)</td><td></td><td></td><td></td></tr><tr><td>Cellular response to stimulus (51716)</td><td>13 (0)</td><td>---</td><td>Transporter Activity (5215)</td><td>297 (8)</td><td>63 (1)</td></tr><tr><td>Response to abiotic stimulus (9628)</td><td>83 (0)</td><td>32 (0)</td><td>Ion transport activity (15075)</td><td>111 (5)</td><td>16 (0)</td></tr><tr><td>Response to external stimulus (9605)</td><td>27 (0)</td><td>13 (0)</td><td>Carbohydrate transporter activity (15144)</td><td>26 (0)</td><td>---</td></tr><tr><td>Response to biotic stimulus (6907)</td><td>19 (0)</td><td>---</td><td>ATPase activity, coupled to movement of substances (43492)</td><td>41 (2)</td><td>---</td></tr><tr><td>Response to chemical stimulus (42221)</td><td>212 (0)</td><td>65 (0)</td><td>Amine transporter activity (5275)</td><td>27 (0)</td><td>---</td></tr><tr><td rowspan="2">Response to stress (6950)</td><td>370 (3)</td><td>159 (0)</td><td>Organic acid transporter activity (5342)</td><td>32 (0)</td><td>---</td></tr><tr><td></td><td></td><td>Carrier activity (5386)</td><td>67 (0)</td><td>13 (0)</td></tr><tr><td>Ribonucleoprotein complex (30529)</td><td>318 (64)</td><td>96 (12)</td><td>Intracellular transporter activity (5478)</td><td>28 (0)</td><td>17 (0)</td></tr><tr><td>Small nuclear ribonucleoprotein complex (30532)</td><td>58 (2)</td><td>24 (0)</td><td>Protein transporter activity (8565)</td><td>48 (1)</td><td>29 (1)</td></tr><tr><td>Preribosome (30684)</td><td>12 (4)</td><td>---</td><td>Lipid transporter activity (5319)</td><td>11(2)</td><td>---</td></tr><tr><td>Spliceosome (5681)</td><td>74 (12)</td><td>33 (2)</td><td></td><td></td><td></td></tr><tr><td>Small nucleolar ribonucleoprotein complex (5732)</td><td>49 (43)</td><td>10 (9)</td><td></td><td></td><td></td></tr><tr><td>Ribosome (5840)</td><td>156 (5)</td><td>45 (1)</td><td></td><td></td><td></td></tr><tr><td>Polysome (5844)</td><td>11 (0)</td><td>---</td><td></td><td></td><td></td></tr></table>	PMC2717056_table_1
	<table border="1" class="dataframe"> <tr> <th> GO TERMS </th> <th> Coverage </th> <th> Purity (Average) </th> <th> Ambiguity </th> <th> Φ(average ± s.e.m.) </th> </tr> <tr> <td> Developmental process (32502) </td> <td> 63.6% (402/632) </td> <td> 62.2% </td> <td> 13.0% (74/570) </td> <td> 0.46 ± 0.02 </td> </tr> <tr> <td> Reproduction (3) </td> <td> 58.4% (142/245) </td> <td> 94.1% </td> <td> 0% (0/25) </td> <td> 0.38 ± 0.11 </td> </tr> <tr> <td> Establishment of cellular localization (51649) </td> <td> 66.8% (302/452) </td> <td> 88.4% </td> <td> 1.1% (3/264) </td> <td> 0.43 ± 0.10 </td> </tr> <tr> <td> Response to stimulus (50896) </td> <td> 56.4% (290/514) </td> <td> 77.5% </td> <td> 19.5% (32/164) </td> <td> 0.46 ± 0.05 </td> </tr> <tr> <td> Ribonucleoprotein complex (30529) </td> <td> 59.7% (190/318) </td> <td> 77.8% </td> <td> 12.8% (31/242) </td> <td> 0.64 ± 0.06 </td> </tr> <tr> <td> Organelle envelope (31967) </td> <td> 39.6% (91/230) </td> <td> 84.9% </td> <td> 1.2% (1/83) </td> <td> 0.47 ± 0.09 </td> </tr> <tr> <td> Transcription regulator activity (30528) </td> <td> 43.5% (120/276) </td> <td> 67.6% </td> <td> 15.0% (30/200) </td> <td> 0.40 ± 0.08 </td> </tr> <tr> <td> Structural molecule activity (5198) </td> <td> 39.8% (92/231) </td> <td> 95.6% </td> <td> 0% (0/165) </td> <td> 0.53 </td> </tr> <tr> <td> Transporter Activity (5215) </td> <td> 33.7% (100/297) </td> <td> 72.5% </td> <td> 6.4% (12/186) </td> <td> 0.43 ± 0.06 </td> </tr> </table>	PMC2717056_table_2
	<table border="1" class="dataframe"> <tr> <th> GO TERMS </th> <th> Coverage </th> <th> Purity (Average) </th> <th> Ambiguity </th> <th> Φ(average ± s.e.m.) </th> </tr> <tr> <td> Developmental process (32502) </td> <td> 83.3% (214/257) </td> <td> 82.0% </td> <td> 7.2% (16/222) </td> <td> 0.51 ± 0.06 </td> </tr> <tr> <td> Reproduction (3) </td> <td> 96.4% (107/111) </td> <td> 82.5% </td> <td> 8.3% (1/12) </td> <td> 0.45 ± 0.03 </td> </tr> <tr> <td> Establishment of cellular localization (51649) </td> <td> 86.7% (163/188) </td> <td> 76.8% </td> <td> 46.2% (49/106) </td> <td> 0.37 ± 0.02 </td> </tr> <tr> <td> Response to stimulus (50896) </td> <td> 78.3% (162/207) </td> <td> 73.2% </td> <td> 32.1% (18/56) </td> <td> 0.48 ± 0.07 </td> </tr> <tr> <td> Ribonucleoprotein complex (30529) </td> <td> 82.3% (79/96) </td> <td> 70.7% </td> <td> 56.2% (41/73) </td> <td> 0.72 ± 0.03 </td> </tr> <tr> <td> Organelle envelope (31967) </td> <td> 87.0% (60/69) </td> <td> 79.5% </td> <td> 26.5% (9/34) </td> <td> 0.70 ± 0.05 </td> </tr> <tr> <td> Transcription regulator activity (30528) </td> <td> 39.3% (42/107) </td> <td> 64.7% </td> <td> 33.8% (26/77) </td> <td> 0.42 ± 0.03 </td> </tr> <tr> <td> Structural molecule activity (5198) </td> <td> 69.3% (52/75) </td> <td> 68.8% </td> <td> 42.3% (22/52) </td> <td> 0.91 </td> </tr> <tr> <td> Transporter Activity (5215) </td> <td> 87.3% (55/63) </td> <td> 93.6% </td> <td> 0.0% (0/50) </td> <td> 0.63 ± 0.13 </td> </tr> </table>	PMC2717056_table_3
	<table border="1" class="dataframe"> <tr> <th> </th> <th> A priori Genetic Group </th> <th> Geneclass </th> <th> </th> <th> </th> <th> Structure </th> <th> </th> <th> </th> </tr> <tr> <td> </td> <td> </td> <td> RFLP </td> <td> SSR </td> <td> RFLP </td> <td> </td> <td> SSR </td> <td> </td> </tr> <tr> <td> Individuals </td> <td> </td> <td> </td> <td> </td> <td> Ancestry (%) </td> <td> CI </td> <td> Ancestry (%) </td> <td> CI </td> </tr> <tr> <td> AC663 </td> <td> A </td> <td> E 1.445 </td> <td> </td> <td> E 43.5 A 39 B 14.2 </td> <td> 0–100 0–100 0–61 </td> <td> </td> <td> </td> </tr> <tr> <td> CC604 </td> <td> C </td> <td> - </td> <td> E 3.224 </td> <td> </td> <td> - </td> <td> E 49.1 C 47.4 </td> <td> 23.3–76.2 18.4–73.5 </td> </tr> <tr> <td> CC658 </td> <td> C </td> <td> - </td> <td> D 5.010 </td> <td> </td> <td> - </td> <td> D 56.3 A 21.2 </td> <td> 24.8–83.6 0–71.9 </td> </tr> <tr> <td> DC186 </td> <td> D </td> <td> - </td> <td> - </td> <td> D 64 E 16 A 16 </td> <td> 36.1–86.5 0–52.8 0–54.2 </td> <td> D 57.9 A 33.5 </td> <td> 29.6–84 0–68.3 </td> </tr> <tr> <td> DC194 </td> <td> D </td> <td> - </td> <td> - </td> <td> D 37.5 E 29.6 A 31.6 </td> <td> 0–66.1 0–85.8 0–94.2 </td> <td> D 72.6 E 25.3 </td> <td> 48.3–94.4 0–50.3 </td> </tr> <tr> <td> DC345 </td> <td> D </td> <td> A 0.579 </td> <td> E 0.526 </td> <td> D 33.7 E 30 A 34.3 </td> <td> 0–65.2 0–97.3 0–997 </td> <td> D 51.5 E 38.7 </td> <td> 26.7–74.7 12.9–65.2 </td> </tr> <tr> <td> DC350 </td> <td> D </td> <td> - </td> <td> E 1.553 </td> <td> D 54.5 E 20.7 A 21.7 </td> <td> 0–87.1 0–75.5 0–91.7 </td> <td> D 42.4 E 51.6 </td> <td> 19.8–65.5 14.2–76.9 </td> </tr> <tr> <td> DC358 </td> <td> D </td> <td> - </td> <td> - </td> <td> D 49.9 E 21 A 21.5 </td> <td> 12.1–77.9 0–66.6 0–68.5 </td> <td> D 64.3 E 21.2 </td> <td> 42.6–83.7 0–51.2 </td> </tr> </table>	PMC2717059_table_0
	<table border="1" class="dataframe"> <tr> <th> SSR\RFLP </th> <th> A </th> <th> B </th> <th> C </th> <th> D </th> <th> E </th> </tr> <tr> <td> A </td> <td> 0 </td> <td> 0.29 </td> <td> 0.50 </td> <td> 0.67 </td> <td> 0.30 </td> </tr> <tr> <td> B </td> <td> 0.33 </td> <td> 0 </td> <td> 0.51 </td> <td> 0.67 </td> <td> 0.30 </td> </tr> <tr> <td> C </td> <td> 0.30 </td> <td> 0.24 </td> <td> 0 </td> <td> 0.54 </td> <td> 0.41 </td> </tr> <tr> <td> D </td> <td> 0.50 </td> <td> 0.45 </td> <td> 0.32 </td> <td> 0 </td> <td> 0.52 </td> </tr> <tr> <td> E </td> <td> 0.31 </td> <td> 0.20 </td> <td> 0.25 </td> <td> 0.34 </td> <td> 0 </td> </tr> </table>	PMC2717059_table_1
	<table border="1" class="dataframe"> <tr> <th> Variable, % unless otherwise indicated </th> <th> EuroSCORE > 20, n = 237 </th> <th> EuroSCORE ≤ 20, n = 1,184 </th> </tr> <tr> <td> Critical preoperative state* </td> <td> 24.5 </td> <td> 1.0 </td> </tr> <tr> <td> Emergency surgery </td> <td> 10.1 </td> <td> 0.9 </td> </tr> <tr> <td> Concomitant thoracic aortic surgery </td> <td> 16.5 </td> <td> 5.7 </td> </tr> <tr> <td> Concomitant CABG </td> <td> 58.7 </td> <td> 42.2 </td> </tr> <tr> <td> Type of prosthesis </td> <td> </td> <td> </td> </tr> <tr> <td> Bioprosthesis (tissue valve) Mechanical valve Homograft </td> <td> 84.0 13.5 2.5 </td> <td> 81.7 17.6 0.8 </td> </tr> <tr> <td> Cardiopulmonary bypass time, mean min ± SD </td> <td> 178.5 ± 64.4 </td> <td> 148.8 ± 51.8 </td> </tr> <tr> <td> Aortic clamp time, mean min ± SD </td> <td> 122.8 ± 47.0 </td> <td> 106.7 ± 37.8 </td> </tr> <tr> <td> Prosthetic valve indexed EOA§<0.75 cm2/m2 </td> <td> 4.7 </td> <td> 10.4 </td> </tr> </table>	PMC2717063_table_0
	<table border="1" class="dataframe"> <tr> <th> Outcome, % </th> <th> EuroSCORE > 20, n = 237 </th> <th> ≤ EuroSCORE 20, n = 1,184 </th> <th> P </th> </tr> <tr> <td> Mortality (in-hospital or within 30 days of surgery) </td> <td> 11.4 </td> <td> 3.2 </td> <td> <0.0001 </td> </tr> <tr> <td> In-hospital events </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Ventilation > 24 hours </td> <td> 27.9 </td> <td> 9.3 </td> <td> <0.0001 </td> </tr> <tr> <td> Length of stay > 9 days </td> <td> 59.1 </td> <td> 28.1 </td> <td> <0.0001 </td> </tr> <tr> <td> Stroke </td> <td> 5.1 </td> <td> 2.3 </td> <td> 0.02 </td> </tr> <tr> <td> Atrial fibrillation (new onset) </td> <td> 31.7 </td> <td> 28.4 </td> <td> 0.31 </td> </tr> <tr> <td> Erythrocyte transfusion </td> <td> 73.0 </td> <td> 34.5 </td> <td> <0.0001 </td> </tr> <tr> <td> Permanent pacemaker implantation </td> <td> 10.1 </td> <td> 5.4 </td> <td> 0.01 </td> </tr> </table>	PMC2717063_table_1
	<table border="1" class="dataframe"> <tr> <th> WHO </th> <th> n </th> <th> Age (yr) </th> <th> MGb(%) </th> <th> Weight (g) </th> <th> Masaoka I </th> <th> Masaoka II </th> <th> Masaoka III </th> <th> Masaoka IV </th> </tr> <tr> <td> A </td> <td> 15 </td> <td> 64.0 ± 9.8 </td> <td> 26.6 </td> <td> 164.0 ± 293.0 </td> <td> 10 </td> <td> 4 </td> <td> 1 </td> <td> 0 </td> </tr> <tr> <td> AB </td> <td> 21 </td> <td> 58.5 ± 10.6 </td> <td> 14.2 </td> <td> 114.0 ± 131.4 </td> <td> 15 </td> <td> 2 </td> <td> 4 </td> <td> 0 </td> </tr> <tr> <td> B1 </td> <td> 13 </td> <td> 58.6 ± 6.3 </td> <td> 23.0 </td> <td> 103.0 ± 99.5 </td> <td> 9 </td> <td> 2 </td> <td> 1 </td> <td> 1 </td> </tr> <tr> <td> B2 </td> <td> 13 </td> <td> 51.8 ± 20.3 </td> <td> 53.0 </td> <td> 125.0 ± 108.6 </td> <td> 5 </td> <td> 6 </td> <td> 0 </td> <td> 2 </td> </tr> <tr> <td> B3 </td> <td> 3 </td> <td> 67.8 ± 23.4 </td> <td> 66.6 </td> <td> 166.0 ± 83.5 </td> <td> 1 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> C </td> <td> 19 </td> <td> 54.1 ± 13.4 </td> <td> 0 </td> <td> 139.0 ± 403.4 </td> <td> 2 </td> <td> 3 </td> <td> 3 </td> <td> 11 </td> </tr> <tr> <td> Total </td> <td> 84 </td> <td> - </td> <td> 22.6 </td> <td> - </td> <td> 42 </td> <td> 19 </td> <td> 9 </td> <td> 14 </td> </tr> </table>	PMC2717064_table_0
	<table border="1" class="dataframe"> <tr> <th> Masaoka </th> <th> n </th> <th> R0-status </th> <th> N1 </th> <th> M1 </th> <th> Recurrence </th> <th> 5-year survival (%) </th> </tr> <tr> <td> I </td> <td> 42 </td> <td> 42 (100%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 97.6 </td> </tr> <tr> <td> II </td> <td> 19 </td> <td> 18 (94.7%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 1 (5.3%) </td> <td> 94.7 </td> </tr> <tr> <td> III </td> <td> 9 </td> <td> 6 (66.7%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 66.7 </td> </tr> <tr> <td> IV </td> <td> 14 </td> <td> 5 (35.7%) </td> <td> 6 (42.8%) </td> <td> 8 (57.1) </td> <td> 1 (7%) </td> <td> 64.3 </td> </tr> </table>	PMC2717064_table_1
	<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> n </th> <th> Pseudocapsula complete </th> <th> Pseudocapsula incomplete </th> <th> Pseudocapsula no capsula </th> <th> p-valueb </th> </tr> <tr> <td> Masaoka I </td> <td> 42 </td> <td> 38 </td> <td> 4 </td> <td> 0 </td> <td> 0.001 </td> </tr> <tr> <td> II </td> <td> 19 </td> <td> 1 </td> <td> 16 </td> <td> 2 </td> <td> </td> </tr> <tr> <td> III </td> <td> 9 </td> <td> 1 </td> <td> 3 </td> <td> 5 </td> <td> </td> </tr> <tr> <td> IV </td> <td> 14 </td> <td> 0 </td> <td> 3 </td> <td> 11 </td> <td> </td> </tr> <tr> <td> N-status N0 </td> <td> 79 </td> <td> 40 </td> <td> 24 </td> <td> 15 </td> <td> 0.042 </td> </tr> <tr> <td> N1 </td> <td> 5 </td> <td> 0 </td> <td> 2 </td> <td> 3 </td> <td> </td> </tr> <tr> <td> M-status M0 </td> <td> 76 </td> <td> 40 </td> <td> 25 </td> <td> 11 </td> <td> 0.001 </td> </tr> <tr> <td> M1 </td> <td> 8 </td> <td> </td> <td> 1 </td> <td> 7 </td> <td> </td> </tr> <tr> <td> Vessel infiltration </td> <td> 13 </td> <td> 0 </td> <td> 3 </td> <td> 9 </td> <td> 0.001 </td> </tr> <tr> <td> Pericard infiltration </td> <td> 14 </td> <td> 1 </td> <td> 1 </td> <td> 12 </td> <td> 0.001 </td> </tr> <tr> <td> Recurrence </td> <td> 2 </td> <td> 0 </td> <td> 1 </td> <td> 1 </td> <td> 0.047 </td> </tr> <tr> <td> Age (yr)c </td> <td> 84 </td> <td> 40 </td> <td> 26 </td> <td> 18 </td> <td> 0.44 </td> </tr> <tr> <td> Sex Male </td> <td> 45 </td> <td> 14 </td> <td> 17 </td> <td> 14 </td> <td> 0.004 </td> </tr> <tr> <td> Female </td> <td> 39 </td> <td> 26 </td> <td> 9 </td> <td> 4 </td> <td> </td> </tr> <tr> <td> MGd </td> <td> 19 </td> <td> 10 </td> <td> 6 </td> <td> 3 </td> <td> 0.86 </td> </tr> </table>	PMC2717064_table_2
	<table border="1" class="dataframe"> <tr> <th> Risk factor </th> <th> Univariate analysis </th> <th colspan="3"> Multivariate analysisc </th> </tr> <tr> <th> </th> <th> p valueb </th> <th> Relative risk </th> <th> 95% Confidence interval </th> <th> p value </th> </tr> <tr> <td> R-status </td> <td> 0.0001 </td> <td> 3.9 </td> <td> 2.0 – 7.6 </td> <td> 0.001 </td> </tr> <tr> <td> Masaoka stagingd </td> <td> 0.0001 </td> <td> 2.0 </td> <td> 1.0 – 4.1 </td> <td> 0.020 </td> </tr> <tr> <td> Presence of a pseudocapsula </td> <td> 0.0002 </td> <td> - </td> <td> - </td> <td> 0.179 </td> </tr> <tr> <td> WHOd classificatione </td> <td> 0.0001 </td> <td> - </td> <td> - </td> <td> 0.181 </td> </tr> <tr> <td> Sex </td> <td> 0.562 </td> <td> - </td> <td> - </td> <td> 0.849 </td> </tr> <tr> <td> Age </td> <td> 0.360 </td> <td> - </td> <td> - </td> <td> 0.206 </td> </tr> </table>	PMC2717064_table_3
	<table border="1" class="dataframe"> <tr> <th> Examination subject </th> <th> Date </th> <th> Format </th> <th> Reliability (KR20) </th> </tr> <tr> <td rowspan="2"> Generic clinical knowledge </td> <td> March </td> <td> EMQ </td> <td> 0.758 </td> </tr> <tr> <td> August </td> <td> EMQ </td> <td> 0.730 </td> </tr> <tr> <td> Care of the Elderly and </td> <td> March </td> <td> SBA </td> <td> 0.760 </td> </tr> <tr> <td> General Medical Specialties </td> <td> August </td> <td> SBA </td> <td> 0.757 </td> </tr> <tr> <td rowspan="2"> General Medicine, Medicine in the Community and Surgery </td> <td> March </td> <td> SBA </td> <td> 0.760 </td> </tr> <tr> <td> August </td> <td> SBA </td> <td> 0.705 </td> </tr> </table>	PMC2717066_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Intervention group n = (%) </th> <th> Control group n = (%) </th> <th> Total n = (%) </th> <th> Group differences </th> <th> p value </th> </tr> <tr> <td> </td> <td colspan="2"> Total n = (%)Tutor </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Total </td> <td> 6 </td> <td> 6 </td> <td> 12 </td> <td> n/a </td> <td> n/a </td> </tr> <tr> <td> male </td> <td> 1 (16.7) </td> <td> 2 (33.3) </td> <td> 3 (25.0) </td> <td> n/a </td> <td> n/a </td> </tr> <tr> <td> white </td> <td> 6 (100.0) </td> <td> 5 (83.3) </td> <td> 11 (91.7) </td> <td> n/a </td> <td> n/a </td> </tr> <tr> <td> </td> <td colspan="2"> Student factors </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Total </td> <td> 177/348 (50.9) </td> <td> 171/348 (49.1) </td> <td> 348 (100.0) </td> <td> </td> <td> </td> </tr> <tr> <td> Mean age </td> <td> 22 yrs 4 months </td> <td> 22 yrs 4 months </td> <td> 22 yrs 4 months </td> <td> t(346) = 0.8 </td> <td> 0.94 </td> </tr> <tr> <td> white* </td> <td> 80/175 (45.7) </td> <td> 87/166 (52.5) </td> <td> 167/341 (49.0) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> Asian Indian, Pakistani, Bangladeshi </td> <td> 47/175 (26.9) </td> <td> 37/166 (22.3) </td> <td> 84/341 (34.0) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> Chinese </td> <td> 16/175 (9.1) </td> <td> 12/166 (7.2) </td> <td> 28/341 (8.2) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> All Other </td> <td> 32/175 (18.3) </td> <td> 30/166 (18.1) </td> <td> 62/341 (18.2) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> Male </td> <td> 69/176 (39.2) </td> <td> 59/171 (34.5) </td> <td> 128/347 (36.9) </td> <td> χ2 = 0.8; df = 1 </td> <td> 0.36 </td> </tr> <tr> <td> Graduate entry* </td> <td> 23/176 (13.1) </td> <td> 20/166 (12.1) </td> <td> 43/342 (12.6) </td> <td> χ2 = 0.1; df = 1 </td> <td> 0.75 </td> </tr> <tr> <td> With iBSC*** </td> <td> 107/176 (60.8) </td> <td> 101/166 (60.8) </td> <td> 208/342 (60.8) </td> <td> χ2 = 0.2; df = 1 </td> <td> 0.89 </td> </tr> <tr> <td> Oxford or Cambridge transfer </td> <td> 21/177 (11.9) </td> <td> 30/171 (17.5) </td> <td> 51/348 (14.7) </td> <td> χ2 = 2.2; df = 1 </td> <td> 0.13 </td> </tr> <tr> <td> Mean pre-intervention written z score </td> <td> 0.05 (SD = 1.0) </td> <td> -0.05 (SD = 1.0) </td> <td> 0.00 (SD = 1.0) </td> <td> t(343) = -0.9 </td> <td> 0.36 </td> </tr> <tr> <td> Mean Neuroticism score </td> <td> 8.1 (SD = 2.3) </td> <td> 7.8 (SD = 2.3) </td> <td> 8.0 (SD = 2.3) </td> <td> t(270) = -0.8 </td> <td> 0.45 </td> </tr> <tr> <td> Mean Conscientiousness score </td> <td> 11.3 (SD = 2.6) </td> <td> 11.3 (SD = 2.0) </td> <td> 11.3 (SD = 2.3) </td> <td> t(272) = 0.2 </td> <td> 0.86 </td> </tr> <tr> <td> Mean Openness score </td> <td> 11.1 (SD = 2.2) </td> <td> 10.9 (SD = 2.4) </td> <td> 11.0 (SD = 2.3) </td> <td> t(272) = -0.9 </td> <td> 0.39 </td> </tr> <tr> <td> Mean Agreeableness score </td> <td> 13.3 (SD = 1.6) </td> <td> 13.0 (SD = 1.6) </td> <td> 13.2 (SD = 1.6) </td> <td> t(268) = -1.8 </td> <td> 0.07 </td> </tr> <tr> <td> Mean Extraversion score </td> <td> 11.6 (SD = 2.1) </td> <td> 11.6 (SD = 1.8) </td> <td> 11.6 (SD = 1.9) </td> <td> t(271) = -0.13 </td> <td> 0.90 </td> </tr> <tr> <td> Mean Surface study score </td> <td> 14.9 (SD = 3.9) </td> <td> 14.7 (SD = 3.4) </td> <td> 14.8 (SD = 3.6) </td> <td> t(265) = -0.5 </td> <td> 0.61 </td> </tr> <tr> <td> Mean Strategic study score </td> <td> 18.5 (SD = 5.4) </td> <td> 17.7 (SD = 4.7) </td> <td> 18.1 (SD = 5.1) </td> <td> t(266) = -0.8 </td> <td> 0.45 </td> </tr> <tr> <td> Mean Deep study score </td> <td> 19.4 (SD = 4.1) </td> <td> 19.3 (SD = 3.9) </td> <td> 19.3 (SD = 4.0) </td> <td> t(267) = -0.3 </td> <td> 0.79 </td> </tr> <tr> <td> Mean GHQ (stress) score </td> <td> 11.4 (SD = 5.3) </td> <td> 10.2 (SD = 4.4) </td> <td> 10.8 (SD = 4.9) </td> <td> t(262) = -1.9 </td> <td> 0.06 </td> </tr> </table>	PMC2717066_table_1
	<table border="1" class="dataframe"> <tr> <th> Ethnic group </th> <th> Condition </th> <th> Mean written z-score (SD) </th> <th> Mean OSCE z-score (SD) </th> <th> N </th> </tr> <tr> <td rowspan="2"> W </td> <td> Intervention </td> <td> 0.063 (0.90) </td> <td> 0.271 (0.96) </td> <td> 79 </td> </tr> <tr> <td> Control </td> <td> 0.244 (1.00) </td> <td> -0.002 (0.96) </td> <td> 84 </td> </tr> <tr> <td rowspan="2"> EM </td> <td> Intervention </td> <td> -0.098 (1.09) </td> <td> 0.001 (1.00) </td> <td> 95 </td> </tr> <tr> <td> Control </td> <td> -0.175 (0.96) </td> <td> -0.286 (0.97) </td> <td> 77 </td> </tr> </table>	PMC2717066_table_2
	<table border="1" class="dataframe"> <tr> <th> Dimensions </th> <th> Word categories </th> <th> Type of word </th> <th> Group with highest frequency </th> <th> t </th> <th> Mean use by all students </th> <th> Mean Difference between groups </th> <th> p value </th> </tr> <tr> <td rowspan="2"> Standard linguistic dimensions </td> <td> % of dictionary words </td> <td> </td> <td> EM </td> <td> -2.0 </td> <td> 75.5 </td> <td> -1.2 </td> <td> 0.04 </td> </tr> <tr> <td> Total pronouns </td> <td> Pronoun </td> <td> EM </td> <td> -2.8 </td> <td> 10.9 </td> <td> -0.9 </td> <td> 0.01 </td> </tr> <tr> <td rowspan="4"> Psychologi-cal processes </td> <td> Affective or emotional processes </td> <td> Optimism and energy (certainty, pride, win) </td> <td> W </td> <td> 2.0 </td> <td> 0.9 </td> <td> 0.2 </td> <td> 0.05 </td> </tr> <tr> <td> Cognitive processes </td> <td> Cognitive processes </td> <td> EM </td> <td> -2.2 </td> <td> 0.1 </td> <td> -0.5 </td> <td> 0.03 </td> </tr> <tr> <td> Sensory and perceptual processes </td> <td> Hear (heard, listen, sound) </td> <td> EM </td> <td> -3.5 </td> <td> 0.9 </td> <td> -0.3 </td> <td> <0.001 </td> </tr> <tr> <td> Social Processes </td> <td> Communication (talk, share converse) </td> <td> EM </td> <td> -2.4 </td> <td> 2.2 </td> <td> -0.4 </td> <td> 0.02 </td> </tr> <tr> <td> Relativity </td> <td> Motion </td> <td> Motion (walk, move, go) </td> <td> EM </td> <td> -2.5 </td> <td> 0.9 </td> <td> -0.2 </td> <td> 0.01 </td> </tr> <tr> <td rowspan="2"> Personal Concerns </td> <td> Occupation </td> <td> Job or work (employ, boss, career) </td> <td> W </td> <td> 2.2 </td> <td> 1.1 </td> <td> 0.2 </td> <td> 0.03 </td> </tr> <tr> <td> Metaphysical issues </td> <td> Religion (God, church, rabbi) </td> <td> EM </td> <td> -2.1 </td> <td> 0.2 </td> <td> -0.2 </td> <td> 0.04 </td> </tr> </table>	PMC2717066_table_3
	<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> Study aggregate </th> </tr> <tr> <td> Age (year), Median (IQR) </td> <td> 35 (33–37) </td> </tr> <tr> <td> Gender (W:M) </td> <td> 43%/57% </td> </tr> <tr> <td> Married </td> <td> 65% </td> </tr> <tr> <td> Time from medical school to residency training (years), Median (IQR) </td> <td> 5 (4–7) </td> </tr> <tr> <td> Visa status (J1/H1/Employment authorization) </td> <td> 88% </td> </tr> <tr> <td> Asian origin </td> <td> 59% </td> </tr> <tr> <td> USMLE Step 1, Median (IQR) </td> <td> 85 (80–88) </td> </tr> <tr> <td> USMLE Step 2 Clinical skills, Median (IQR) </td> <td> 82 (79–87) </td> </tr> <tr> <td> Pre-GME Clinical experience, n (%) </td> <td> 43/51 (84) </td> </tr> <tr> <td> Pre-GME Research Experience, n (%) </td> <td> 34/51 (66.7) </td> </tr> <tr> <td> US Externship, n (%) </td> <td> 14/51 (27.5) </td> </tr> <tr> <td> Pre-GME Awards, n (%) </td> <td> 26/51(50.1) </td> </tr> <tr> <td> ABIM examination pass, n (%) </td> <td> 49/51(96) </td> </tr> <tr> <td> Fellowship aspirants, n (%) </td> <td> 12/51 (23.5) </td> </tr> <tr> <td> Fellowship within 3 years after graduation, n (%) </td> <td> 8/51 (16) </td> </tr> </table>	PMC2717068_table_0
	<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> Above PG level median (n = 18) </th> <th> Below PG level median (n = 33) </th> <th> *P value </th> </tr> <tr> <td> Age, median (range) in years </td> <td> 33 (31–40) </td> <td> 36 (31–47) </td> <td> < 0.05 </td> </tr> <tr> <td> Male:Female (ratio) </td> <td> 9:9 </td> <td> 20:13 </td> <td> NS </td> </tr> <tr> <td> Marital Status (unmarried: married) </td> <td> 5:13 </td> <td> 13:20 </td> <td> NS </td> </tr> <tr> <td> Asian/Others </td> <td> 3/5 </td> <td> 16/17 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 86 (76–97) </td> <td> 83 (75–96) </td> <td> NS </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 86 (77–93) </td> <td> 80 (75–92) </td> <td> < 0.05 </td> </tr> <tr> <td> Time from medical school to residency, median (range) in years </td> <td> 4 (1 – 14) </td> <td> 5 (1–17) </td> <td> NS </td> </tr> <tr> <td> Temporary Visa status (n) </td> <td> 16 </td> <td> 29 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Clinical Experience (n) </td> <td> 15 </td> <td> 28 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Research Experience (n) </td> <td> 12 </td> <td> 22 </td> <td> NS </td> </tr> <tr> <td> US Externship </td> <td> 7 </td> <td> 7 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Awards </td> <td> 9 </td> <td> 17 </td> <td> NS </td> </tr> </table>	PMC2717068_table_1
	<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> Above US Median (n = 13) </th> <th> Below US Median (n = 38) </th> <th> P value </th> </tr> <tr> <td> Age, median (range) in years </td> <td> 35 (32–42) </td> <td> 35.5 (31–47) </td> <td> NS </td> </tr> <tr> <td> *Male/Female (ratio) </td> <td> 11:2 </td> <td> 18: 20 </td> <td> < 0.05 </td> </tr> <tr> <td> Marital Status (unmarried/married) </td> <td> 8: 5 </td> <td> 25: 13 </td> <td> NS </td> </tr> <tr> <td> Asian/Others </td> <td> 9/4 </td> <td> 21/17 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 86 (76–97) </td> <td> 83 (75–96) </td> <td> < 0.05 </td> </tr> <tr> <td> USMLE step II Clinical Skills median (range) </td> <td> 86 (77–93) </td> <td> 80 (75–92) </td> <td> < 0.05 </td> </tr> <tr> <td> Time from medical school to residency, median (range) in years </td> <td> 4 (1 – 14) </td> <td> 5 (1–17) </td> <td> NS </td> </tr> <tr> <td> Temporary Visa status (n) </td> <td> 11 </td> <td> 34 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Clinical Experience (n) </td> <td> 15 </td> <td> 28 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Research Experience (n) </td> <td> 12 </td> <td> 22 </td> <td> NS </td> </tr> <tr> <td> US Externship </td> <td> 7 </td> <td> 7 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Awards </td> <td> 9 </td> <td> 17 </td> <td> NS </td> </tr> </table>	PMC2717068_table_2
	<table border="1" class="dataframe"> <tr> <th> #Characteristics </th> <th> Above US Median </th> <th> Below US Median </th> <th> P value </th> </tr> <tr> <td colspan="2"> (Above median </td> <td> </td> <td> </td> </tr> <tr> <td> Male/Female (ratio) (unadjusted analysis) </td> <td> 22:10 </td> <td> 7: 12 </td> <td> < 0.05 </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 85 (77–97) </td> <td> 82 (75–96) </td> <td> NS </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 85.5 (75–93) </td> <td> 81 (76–87) </td> <td> NS </td> </tr> <tr> <td colspan="2"> (Above median </td> <td> </td> <td> </td> </tr> <tr> <td> Male/Female (ratio) (unadjusted analysis) </td> <td> 11: 3 </td> <td> 18: 19 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 86.5 (76–97) </td> <td> 82.5 (75–90) </td> <td> < 0.05 </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 85.5 (75–93) </td> <td> 81 (76–87) </td> <td> < 0.05 </td> </tr> </table>	PMC2717068_table_3
	<table border="1" class="dataframe"> <tr> <th> Characteristics (units) </th> <th> Fellowship pursuing residents (n = 8) </th> <th> Others (n = 43) </th> <th> P value </th> </tr> <tr> <td> Age, median (range) in years </td> <td> 33 (31 – 39) </td> <td> 35 (31–47) </td> <td> NS </td> </tr> <tr> <td> Male/Female (ratio) </td> <td> 4:4 </td> <td> 25: 18 </td> <td> NS </td> </tr> <tr> <td> Marital status (unmarried/married) </td> <td> 6: 2 </td> <td> 27:16 </td> <td> NS </td> </tr> <tr> <td> Asian/Others </td> <td> 4/4 </td> <td> 26/17 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 85 (76–97) </td> <td> 85 (75–96) </td> <td> NS </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 82.5 (80–92) </td> <td> 82 (75–93) </td> <td> NS </td> </tr> <tr> <td> Time from medical school to residency, median (range) in years </td> <td> 5 (3 – 14) </td> <td> 5 (1–17) </td> <td> NS </td> </tr> <tr> <td> Visa status </td> <td> 7 </td> <td> 38 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Clinical Experience (n) </td> <td> 7 </td> <td> 36 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Research Experience (n) </td> <td> 5 </td> <td> 29 </td> <td> NS </td> </tr> <tr> <td> US Externship (n) </td> <td> 1 </td> <td> 13 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Awards (n) </td> <td> 5 </td> <td> 21 </td> <td> NS </td> </tr> <tr> <td> Fellowship aspirants (n) </td> <td> 7 </td> <td> 5 </td> <td> < 0.05 </td> </tr> <tr> <td> GME Research (n) </td> <td> 7 </td> <td> 12 </td> <td> < 0.05 </td> </tr> </table>	PMC2717068_table_4
	<table border="1" class="dataframe"> <tr> <th> Question </th> <th colspan="7"> Likert Scale </th> </tr> <tr> <th> How valuable has the student housing conditions survey, and discussion of findings, been for you? </th> <th> Extremely valuable </th> <th> 1 </th> <th> 2 </th> <th> 3 </th> <th> 4 </th> <th> 5 </th> <th> Not at all valuable </th> </tr> <tr> <td> </td> <td> No. </td> <td> 29 </td> <td> 60 </td> <td> 32 </td> <td> 12 </td> <td> 3 </td> <td> </td> </tr> <tr> <td> </td> <td> % </td> <td> 21% </td> <td> 44% </td> <td> 24% </td> <td> 9% </td> <td> 2% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your understanding of research methods? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 18 </td> <td> 52 </td> <td> 47 </td> <td> 13 </td> <td> 6 </td> <td> </td> </tr> <tr> <td> % </td> <td> 13% </td> <td> 38% </td> <td> 35% </td> <td> 10% </td> <td> 4% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your understanding of epidemiology? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 16 </td> <td> 41 </td> <td> 52 </td> <td> 20 </td> <td> 7 </td> <td> </td> </tr> <tr> <td> % </td> <td> 12% </td> <td> 30% </td> <td> 38% </td> <td> 15% </td> <td> 5% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your understanding of the environmental determinants of health? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 28 </td> <td> 69 </td> <td> 30 </td> <td> 7 </td> <td> 2 </td> <td> </td> </tr> <tr> <td> % </td> <td> 21% </td> <td> 51% </td> <td> 22% </td> <td> 5% </td> <td> 1% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your interest in public health? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 23 </td> <td> 58 </td> <td> 34 </td> <td> 12 </td> <td> 9 </td> <td> </td> </tr> <tr> <td> % </td> <td> 17% </td> <td> 43% </td> <td> 25% </td> <td> 9% </td> <td> 7% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your interest in health research? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 16 </td> <td> 48 </td> <td> 46 </td> <td> 15 </td> <td> 11 </td> <td> </td> </tr> <tr> <td> % </td> <td> 12% </td> <td> 35% </td> <td> 34% </td> <td> 11% </td> <td> 8% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey stimulate you to discuss housing and health issues with friends outside of class? </td> <td> Yes, often </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, never </td> </tr> <tr> <td> No. </td> <td> 30 </td> <td> 45 </td> <td> 43 </td> <td> 13 </td> <td> 5 </td> <td> </td> </tr> <tr> <td> % </td> <td> 22% </td> <td> 33% </td> <td> 32% </td> <td> 10% </td> <td> 4% </td> <td> </td> </tr> <tr> <td rowspan="3"> How much did this survey and seminar discussion challenge you to think? </td> <td> A great deal </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> Very Little </td> </tr> <tr> <td> No. </td> <td> 21 </td> <td> 63 </td> <td> 35 </td> <td> 11 </td> <td> 5 </td> <td> </td> </tr> <tr> <td> % </td> <td> 15% </td> <td> 46% </td> <td> 26% </td> <td> 8% </td> <td> 4% </td> <td> </td> </tr> <tr> <td rowspan="3"> Has this survey and seminar discussion made you more aware and concerned about societal problems? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 38 </td> <td> 57 </td> <td> 32 </td> <td> 4 </td> <td> 4 </td> <td> </td> </tr> <tr> <td> % </td> <td> 28% </td> <td> 42% </td> <td> 24% </td> <td> 3% </td> <td> 3% </td> <td> </td> </tr> <tr> <td rowspan="3"> Would you support use of this survey and seminar discussion for future 3rd year classes? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 56 </td> <td> 49 </td> <td> 23 </td> <td> 6 </td> <td> 2 </td> <td> </td> </tr> <tr> <td> % </td> <td> 41% </td> <td> 36% </td> <td> 17% </td> <td> 4% </td> <td> 1% </td> <td> </td> </tr> </table>	PMC2717069_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Groups </th> <th> </th> </tr> <tr> <th> </th> <th> Hypoglycemic (n = 436) </th> <th> Controls (n = 434) </th> <th> P-value </th> </tr> <tr> <td> Cervical ripening </td> <td> 36 (8%) </td> <td> 38 (9%) </td> <td> 0.792 </td> </tr> <tr> <td> Induction of labor </td> <td> 129 (30%) </td> <td> 87 (20%) </td> <td> <0.001 </td> </tr> <tr> <td> Delivery mode </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Spontaneous vaginal </td> <td> 314 (72%) </td> <td> 295 (68%) </td> <td> </td> </tr> <tr> <td> Assisted vaginal </td> <td> 15 (3%) </td> <td> 14 (3%) </td> <td> </td> </tr> <tr> <td> Cesarean section </td> <td> 107 (25%) </td> <td> 125 (29%) </td> <td> 0.364 </td> </tr> <tr> <td> Reason for cesarean section(1) </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Fetal distress </td> <td> 26 (24%) </td> <td> 23 (18%) </td> <td> </td> </tr> <tr> <td> Failure to progress </td> <td> 24 (22%) </td> <td> 36 (29%) </td> <td> </td> </tr> <tr> <td> Repeat cesarean section </td> <td> 35 (32%) </td> <td> 46 (37%) </td> <td> </td> </tr> <tr> <td> Breech/transverse lie </td> <td> 11 (10%) </td> <td> 9 (7%) </td> <td> </td> </tr> <tr> <td> Other </td> <td> 11 (10%) </td> <td> 11 (9%) </td> <td> 0.572 </td> </tr> <tr> <td> Reason for assisted vaginal delivery(1) </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Fetal distress </td> <td> 12 (80%) </td> <td> 10 (71%) </td> <td> </td> </tr> <tr> <td> Other </td> <td> 3 (20%) </td> <td> 4 (29%) </td> <td> 0.682 </td> </tr> <tr> <td> Fetal distress in labor </td> <td> 38 (9%) </td> <td> 33 (8%) </td> <td> 0.621 </td> </tr> <tr> <td> Cesarean delivery for fetal distress </td> <td> 26 (6%) </td> <td> 23 (5%) </td> <td> 0.769 </td> </tr> <tr> <td> Gestational age at delivery (med, min-max) </td> <td> 39 (23–41.5) </td> <td> 39 (28.6–41.6) </td> <td> 0.689 </td> </tr> <tr> <td> Gestational age distribution </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <37 </td> <td> 67 (15%) </td> <td> 43 (10%) </td> <td> </td> </tr> <tr> <td> 37–40 </td> <td> 242 (56%) </td> <td> 273 (63%) </td> <td> </td> </tr> <tr> <td> >40 </td> <td> 127 (29%) </td> <td> 118 (27%) </td> <td> 0.024 </td> </tr> <tr> <td> Gestational age at delivery <37 </td> <td> 67 (15%) </td> <td> 43 (10%) </td> <td> 0.015 </td> </tr> </table>	PMC2717071_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Group </th> <th> </th> </tr> <tr> <th> </th> <th> Hypoglycemic (n = 436) </th> <th> Controls (n = 434) </th> <th> P-value </th> </tr> <tr> <td> Birth weight (gm) (med, Q1-Q3) </td> <td> 3240 (2928–3550) </td> <td> 3313 (2980–3690) </td> <td> 0.008 </td> </tr> <tr> <td> Birth weight distribution </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <2500 </td> <td> 43 (10%) </td> <td> 22 (5%) </td> <td> </td> </tr> <tr> <td> 2500–4000 </td> <td> 370 (85%) </td> <td> 370 (85%) </td> <td> </td> </tr> <tr> <td> >4000 </td> <td> 23 (5%) </td> <td> 42 (10%) </td> <td> 0.002 </td> </tr> <tr> <td> IUGR </td> <td> 36 (12%) </td> <td> 29 (9%) </td> <td> 0.277 </td> </tr> <tr> <td> Umbilical artery pH<7.1 </td> <td> 14 (3%) </td> <td> 7 (2%) </td> <td> 0.130 </td> </tr> <tr> <td> 5 minutes Apgar score <7 </td> <td> 4 (1%) </td> <td> 1 (.2%) </td> <td> 0.374 </td> </tr> <tr> <td> Admission to NICU </td> <td> 36 (8%) </td> <td> 25 (6%) </td> <td> 0.149 </td> </tr> <tr> <td> Admission reasons(2) </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Prematurity </td> <td> 6 (17%) </td> <td> 4 (16%) </td> <td> </td> </tr> <tr> <td> RDS/TTN </td> <td> 26 (72%) </td> <td> 12 (48%) </td> <td> </td> </tr> <tr> <td> Other(2) </td> <td> 4 (11%) </td> <td> 9 (36%) </td> <td> 0.054 </td> </tr> </table>	PMC2717071_table_1
	<table border="1" class="dataframe"> <tr> <th> Outcome </th> <th> OR </th> <th> 95% CI </th> <th> RR </th> <th> 95% CI </th> <th> p-value </th> </tr> <tr> <td> Preeclampsia </td> <td> 3.13 </td> <td> 1.51–6.51 </td> <td> 2.98 </td> <td> 1.49–5.78 </td> <td> 0.002 </td> </tr> <tr> <td> Induction of labor </td> <td> 1.75 </td> <td> 0.83–1.66 </td> <td> 1.52 </td> <td> 0.86–1.47 </td> <td> 0.361 </td> </tr> <tr> <td> Preterm delivery </td> <td> 1.61 </td> <td> 0.92–2.82 </td> <td> 1.52 </td> <td> 0.93–2.39 </td> <td> 0.093 </td> </tr> <tr> <td> IUGR </td> <td> 1.24 </td> <td> 0.73–2.10 </td> <td> 1.21 </td> <td> 0.75–1.91 </td> <td> 0.425 </td> </tr> <tr> <td> Macrosomia </td> <td> 0.49 </td> <td> 0.28–0.85 </td> <td> 0.51 </td> <td> 0.30–0.86 </td> <td> 0.011 </td> </tr> <tr> <td> Umbilical artery pH<7.1 </td> <td> 2.00 </td> <td> 0.76–5.26 </td> <td> 1.97 </td> <td> 0.77–4.93 </td> <td> 0.159 </td> </tr> <tr> <td> 5 min Apgar score <7 </td> <td> 1.97 </td> <td> 0.20–19.91 </td> <td> 1.97 </td> <td> 0.20–19.19 </td> <td> 0.564 </td> </tr> <tr> <td> NICU admission </td> <td> 1.27 </td> <td> 0.62–2.05 </td> <td> 1.12 </td> <td> 0.63–1.94 </td> <td> 0.965 </td> </tr> </table>	PMC2717071_table_2
	<table border="1" class="dataframe"> <tr> <th> Code </th> <th> Clinician Comments </th> </tr> <tr> <td> Assessment of Severity </td> <td> "By how much the patient describes the itch. Like, if they say, it wakes me up at night, or it keeps me up at night, or it's relentless, or it drives me crazy, I know the itch is severe. Plus, you know, I might ask the patient to grade it on a scale of one to ten, how bad is your itch, with ten being the worst, one is being pretty mild or not present. (...) Oh, just the one to ten scale, that's the only systematic way I can grade itch numerically." "Well, I don't have a scale typically in the clinic. There is no numeric scale that I use, but I go by whether it keeps them up at night, or not. That's typically the threshold. The severity of itching really keeps a patient aware at night, and that's about it. I know that's very subjective, but I don't use anything more quantifiable than itch." </td> </tr> <tr> <td> Itch </td> <td> "In psoriasis it's less than it is for atopic dermatitis. It doesn't usually keep them up at night, but it is, in some people, a symptom that is annoying, rather than disabling." "If they're able to sleep at night, or it disables them during the daytime, if they've got to stop what they're doing to scratch. I also – well, I look at their skin to see if there are scratch marks, and if there's other accompanying signs of what we call excoriations, where they're digging at their skin, scratching and digging at their skin." "Itch is a very bothersome symptom for psoriasis and other skin conditions such as eczema. And itch can be more problematic than pain. Itch is constant. Itch is something patients are much more aware of, and they're always scratching themselves to the point where they start to bleed, and their skin gets infected. And it's usually worse at nighttime, because patients are more aware about their body, as opposed to daytime, where people are more – you know, they're more busy at work and things. That's when then get home, then they start to itch more. But I would say itch by far is the number one factor that drives patients crazy." </td> </tr> <tr> <td> Relevance of itch </td> <td> "I think it's highly relevant, because it's probably the most day in, day out thing that a lot of people face in that the itching is – comes to the top of forefront of symptomology, whether it's itching in your scalp, or itching on the patches of psoriasis. And it's again probably one of the single most bothersome things, other than the fact that it's there." </td> </tr> <tr> <td> Location </td> <td> "Scalp – wherever the plaques are, but scalp drives them crazy. Anywhere on the body." "Is the itch from lesions? Usually, yes." "Commonly hands, knees, ankles." "Their scalp and their lower legs. It can be where there's no lesions in the scalp, but in the lower legs there usually some evidence of dry, scaling skin with some scratch marks." </td> </tr> <tr> <td> Treatment/management challenges </td> <td> "Like if the treatment works, that's great, but if it doesn't work, then we've got to keep adding things to help control the itch, whether it be a pill for itch that they take at nighttime, like an antihistamine, or using various creams to keep applying to control the itch... I would probably say maybe 60% of the time the itch can be controlled with one treatment, whether it be the shots or light therapy. And then 40% of the time it's not adequate, it's got to add in something else, like a topical cream, to control the itch." "Particular challenges (related to the treatment or management of the itch)? Again, I think it's related to treating the underlying psoriasis itself." "Yes, there's no specific oral anti-itch medication. And some of the topical anti-itch medications are not always effective for long periods of time over large areas of the skin. Effective or feasible. If they have total body involvement, it's hard to – lotions, anti-itch lotions all over their body." </td> </tr> </table>	PMC2717072_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Focus Groups </th> </tr> <tr> <th> </th> <th> Patients with Mild Psoriasis (N = 8) </th> <th> Patients with Severe Psoriasis (N = 31) </th> </tr> <tr> <td> Female sex, n (%) </td> <td> 5 (63) </td> <td> 17 (55) </td> </tr> <tr> <td> Age, mean years (range) </td> <td> 36 (20 – 74) </td> <td> 45 (22 – 66) </td> </tr> <tr> <td> Race/Ethnicity, n (%) </td> <td> </td> <td> </td> </tr> <tr> <td> White </td> <td> 5 (63) </td> <td> 24 (77) </td> </tr> <tr> <td> Black/African American </td> <td> 0 </td> <td> 4 (13) </td> </tr> <tr> <td> Hispanic </td> <td> 1 (13) </td> <td> 1 (3) </td> </tr> <tr> <td> Mexican-American </td> <td> 1 (13) </td> <td> 0 </td> </tr> <tr> <td> Arabic </td> <td> 1 (13) </td> <td> 0 </td> </tr> <tr> <td> Spanish </td> <td> 0 </td> <td> 1 (3) </td> </tr> <tr> <td> Disease Diagnosis, n (%) </td> <td> </td> <td> </td> </tr> <tr> <td> Psoriasis </td> <td> 8 (100) </td> <td> 29 (94)b </td> </tr> <tr> <td> Co-existing Psoriatic arthritis </td> <td> 0 </td> <td> 1 (3) </td> </tr> <tr> <td> Heath Status, n (%) </td> <td> </td> <td> </td> </tr> <tr> <td> Excellent </td> <td> 1 (13) </td> <td> 3 (10) </td> </tr> <tr> <td> Very good </td> <td> 4 (50) </td> <td> 9 (29) </td> </tr> <tr> <td> Good </td> <td> 3 (38) </td> <td> 13 (42) </td> </tr> <tr> <td> Fair </td> <td> 0 </td> <td> 4 (13) </td> </tr> <tr> <td> Poor </td> <td> 0 </td> <td> 2 (7) </td> </tr> </table>	PMC2717072_table_1
	<table border="1" class="dataframe"> <tr> <th> Code/domain </th> <th> Patient Comment (Severity of Psoriasis) </th> </tr> <tr> <td> Symptoms/itch </td> <td> "You itch a lot. Scratch a lot, I mean." (Severe) "Scratch to relieve." (Severe) "It will spread over my whole body, the itching. I'll get scabs on my knees, on my elbows that (...) like yours (...) are very, very bad, and the more you scratch it, the worse it gets. (...) it just spreads." (Severe) "The worst is, for me, is just the itching. The itch and the dry." (Severe) "My itching, it gets inflamed. (...) It spreads – (...) And the more you scratch – you're scratching – (...) Mainly the itching." (Mild) "Because I'm scratching everywhere, people not knowing the reason why I'm scratching." (Mild) </td> </tr> <tr> <td> Change of psoriasis symptoms due to anxiety/worsen </td> <td> "So that's the worst, that's when I start to get really anxious. And it, like I said, it can change over the course of a day. When I know I got to start getting ready for work, that puts me in a whole other frame of mind and I will notice that I'm itching a little bit more and or maybe my hands are not as calm as they are on my days off." (Severe) </td> </tr> <tr> <td> Change of psoriasis symptoms due to stress/worsen </td> <td> "Mine only itches when I'm under stress." (Severe) "...I'll be thinking about it way too much, and then I'll start getting – affecting my skin, because the stress will make it outbreak, and then the outbreak, I'll want to itch, and just scratch..." (Severe) </td> </tr> <tr> <td> Change of psoriasis symptoms over day/varies </td> <td> "Yeah, for me it changes a lot too... Towards the end of the night is when it's usually more itchy for me." (Severe) </td> </tr> <tr> <td> Change of psoriasis symptoms over week/varies </td> <td> "...and then Sunday will hit, and then that's it. Then I'll start itching again, so it's like – and Mondays are so busy at work. And like towards Wednesday – that's – I don't know. It's like Monday and Wednesday. Those two days that – I don't know why those – hate those days. (Severe) "The itching to me varies. (...) Just sometimes I don't even think about it and other times it just, boom, it's just itching." (Severe) </td> </tr> <tr> <td> Impact on daily activities/difficulty concentrating </td> <td> "You lose concentration, because you want to scratch and (...) really want to itch this, but you don't want to itch it in front of somebody, and so you trail off to what you were originally helping somebody with, if you're working." (Mild) "Lack of concentration, or itchy – if you're really over-itchy, sometimes it's hard to concentrate on something else other than that whole-body itch." (Severe) </td> </tr> <tr> <td> Impact on daily activities/choice of clothing </td> <td> "For some reason whenever I have anything that's 100% cotton I tend to itch more. It gets irritated more, so everything is based on clothing or cotton. I try to buy a certain type of clothes. So and that's what I got to wear all the time." (Severe) </td> </tr> <tr> <td> Impact on emotions/embarrassed </td> <td> "I'm in front of people all day long, and it's incredibly embarrassing to start bleeding in front of someone, or scratching uncontrollably when you're not even thinking about it." (Severe) "Mine is just more of embarrassment. When you're scratching and people see things coming off of you or on your clothing..." (Mild) </td> </tr> <tr> <td> Impact on sleep/difficulty falling asleep </td> <td> "Before you go to sleep yeah. (...) Because your itches." (Mild) "It's itching instead of falling asleep." (Severe) "It's falling asleep, when it's itching, and you – and then the minute you start scratching, it only makes it worse. But it's hard...You tell yourself not to scratch, but you think you're going to stop it, you know? And then you scratch it, it only makes it worse, and you want to scratch more, and scratch more. It's bad." (Severe) </td> </tr> <tr> <td> Impact on sleep/difficulty staying asleep </td> <td> "Well, no. I'm going to wake up, I'm itchy. I'm going to put some cortisone on, I'm going grease myself down – then I'm going to try and go back to bed." (Severe) "Just, I want to rip my skin off, because it wakes me up. It's like it's never-ending." (Severe) </td> </tr> <tr> <td> Miss days of school or work because of psoriasis/itch </td> <td> "Yeah, you go every week and you get shots to stop you from itching." (Severe) "And I had it on my feet really bad, and I actually missed several days of work... Well, it's the itching." (Severe) "I can't just go out there (...) taking the train to work, being around a bunch of people, and coming back home – the whole time I just want to scratch and itch..." (Severe) </td> </tr> </table>	PMC2717072_table_2
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Patients with Mild Disease (N = 8) </th> <th> Patients with Severe Disease (N = 31) </th> <th> All Patients (N = 39) </th> </tr> <tr> <td> Patients rating itch as the most important symptoma </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No. of patients, n </td> <td> 8 </td> <td> 23 </td> <td> 31 </td> </tr> <tr> <td> Mean rating </td> <td> 9.1 </td> <td> 8.5 </td> <td> 8.7 </td> </tr> <tr> <td> Patients rating a 10, % </td> <td> 88% </td> <td> 70% </td> <td> 74% </td> </tr> <tr> <td> Patients rating itch as the most severe symptomb </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No. of patients, n </td> <td> 8 </td> <td> 23 </td> <td> 31 </td> </tr> <tr> <td> Mean rating </td> <td> 5.8 </td> <td> 8.1 </td> <td> 7.5 </td> </tr> <tr> <td> Patients rating a 10, % </td> <td> 0% </td> <td> 48% </td> <td> 35% </td> </tr> <tr> <td> Patients rating itch as the most troublesome symptomc </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No. of patients, n </td> <td> 8 </td> <td> 16 </td> <td> 24 </td> </tr> <tr> <td> Mean rating </td> <td> 9.0 </td> <td> 8.0 </td> <td> 8.3 </td> </tr> <tr> <td> Patients rating a 10, % </td> <td> 63% </td> <td> 50% </td> <td> 54% </td> </tr> </table>	PMC2717072_table_3
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Total Responses </th> <th> FG 1 vs FG 2 </th> <th> FG 1–2 vs FG 3 </th> <th> FG 1–3 vs FG 4 </th> <th> FG 1–4 vs FG 5 </th> </tr> <tr> <td> Symptoms </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Itch </td> <td> 19 </td> <td> 4 vs 4 </td> <td> 8 vs 3 </td> <td> 11 vs 5 </td> <td> 16 vs 3 </td> </tr> <tr> <td> Bleeding </td> <td> 13 </td> <td> 3 vs 5 </td> <td> 8 vs 1 </td> <td> 9 vs 3 </td> <td> 12 vs 1 </td> </tr> <tr> <td> Cracking </td> <td> 12 </td> <td> 0 vs 5 </td> <td> 5 vs 4 </td> <td> 9 vs 3 </td> <td> 12 vs 0 </td> </tr> <tr> <td> Scaling </td> <td> 12 </td> <td> 2 vs 4 </td> <td> 6 vs 4 </td> <td> 10 vs 1 </td> <td> 11 vs 1 </td> </tr> <tr> <td> Dry skin </td> <td> 6 </td> <td> 1 vs 1 </td> <td> 2 vs 1 </td> <td> 3 vs 3 </td> <td> 6 vs 0 </td> </tr> <tr> <td> Impact on daily activities </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Choice of clothing </td> <td> 17 </td> <td> 2 vs 6 </td> <td> 8 vs 2 </td> <td> 10 vs 4 </td> <td> 14 vs 3 </td> </tr> <tr> <td> Effects on work </td> <td> 9 </td> <td> 3 vs 2 </td> <td> 5 vs 0 </td> <td> 5 vs 2 </td> <td> 7 vs 2 </td> </tr> <tr> <td> More laundry/replacing clothes and linens </td> <td> 2 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> </tr> <tr> <td> Household duties </td> <td> 1 </td> <td> 0 vs 1 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> </tr> <tr> <td> Impact on social life </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Interaction with others </td> <td> 15 </td> <td> 3 vs 5 </td> <td> 8 vs 3 </td> <td> 11 vs 3 </td> <td> 14 vs 1 </td> </tr> <tr> <td> Attending social events </td> <td> 5 </td> <td> 0 vs 2 </td> <td> 2 vs 2 </td> <td> 4 vs 0 </td> <td> 4 vs 1 </td> </tr> <tr> <td> Leisure activities </td> <td> 4 </td> <td> 2 vs 1 </td> <td> 3 vs 0 </td> <td> 3 vs 1 </td> <td> 4 vs 0 </td> </tr> <tr> <td> Impact on sleep </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Sleeping less than usual </td> <td> 2 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> </tr> <tr> <td> Difficulty waking up and feeling well rested </td> <td> 1 </td> <td> 0 vs 1 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> </tr> <tr> <td> Impact on emotions </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Embarrassed </td> <td> 17 </td> <td> 5 vs 0 </td> <td> 5 vs 3 </td> <td> 8 vs 4 </td> <td> 12 vs 5 </td> </tr> <tr> <td> Annoyed </td> <td> 7 </td> <td> 2 vs 2 </td> <td> 4 vs 2 </td> <td> 6 vs 1 </td> <td> 7 vs 0 </td> </tr> <tr> <td> Frustrated </td> <td> 4 </td> <td> 0 vs 3 </td> <td> 3 vs 0 </td> <td> 3 vs 0 </td> <td> 3 vs 1 </td> </tr> <tr> <td> Anxious </td> <td> 2 </td> <td> 0 vs 0 </td> <td> 0 vs 0 </td> <td> 0 vs 1 </td> <td> 1 vs 1 </td> </tr> <tr> <td> Nervous </td> <td> 1 </td> <td> 0 vs 0 </td> <td> 0 vs 1 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> </tr> <tr> <td> Impact on sex </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Sexual activities </td> <td> 5 </td> <td> 2 vs 0 </td> <td> 2 vs 1 </td> <td> 3 vs 0 </td> <td> 3 vs 2 </td> </tr> <tr> <td> Decreased sexual desire </td> <td> 2 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> </tr> </table>	PMC2717072_table_4
	<table border="1" class="dataframe"> <tr> <th> </th> <th> </th> <th colspan="2"> Sinus rhythm at 12 +- 3 days </th> </tr> <tr> <th> </th> <th> All </th> <th> Yes </th> <th> No </th> </tr> <tr> <td> Patients, n </td> <td> 111 </td> <td> 56 </td> <td> 55 </td> </tr> <tr> <td> Age, years </td> <td> 67 ± 12 </td> <td> 66 ± 11 </td> <td> 67 ± 13 </td> </tr> <tr> <td> Weight, kg </td> <td> 86 ± 20 </td> <td> 85 ± 17 </td> <td> 86 ± 22 </td> </tr> <tr> <td> Length, cm </td> <td> 178 ± 9 </td> <td> 177 ± 9 </td> <td> 178 ± 10 </td> </tr> <tr> <td> BMI </td> <td> 27 ± 5 </td> <td> 27 ± 5 </td> <td> 27 ± 5 </td> </tr> <tr> <td> Male, n (%) </td> <td> 89 (80) </td> <td> 46 (82) </td> <td> 43 (78) </td> </tr> <tr> <td> AF episode duration, months </td> <td> 5.8 ± 8.1 </td> <td> 4.8 ± 5.4 </td> <td> 6.9 ± 10.1 </td> </tr> <tr> <td> First episode of AF, n </td> <td> 36 </td> <td> 20 </td> <td> 16 </td> </tr> <tr> <td> Hypothyreosis, n </td> <td> 2 (2) </td> <td> 1 (2) </td> <td> 1 (2) </td> </tr> <tr> <td> Hyperthyreosis, n </td> <td> 2 (2) </td> <td> 2 (4) </td> <td> 0 </td> </tr> <tr> <td> Hypertension, n </td> <td> 45 (41) </td> <td> 26 (46) </td> <td> 19 (35) </td> </tr> <tr> <td> Angina pectoris, n </td> <td> 18 (16) </td> <td> 10 (18) </td> <td> 8 (15) </td> </tr> <tr> <td> Previous myocardial infarction, n </td> <td> 17 (15) </td> <td> 7 (13) </td> <td> 10 (18) </td> </tr> <tr> <td> Previous CABG, n </td> <td> 12 (11) </td> <td> 7 (13) </td> <td> 5 (9) </td> </tr> <tr> <td> Previous PCI, n </td> <td> 9 (8) </td> <td> 3 (5) </td> <td> 6 (11) </td> </tr> <tr> <td> Diabetes mellitus, n </td> <td> 13 (12 </td> <td> 5 (9) </td> <td> 8 (15) </td> </tr> <tr> <td> Heart failure, n </td> <td> 25 (23) </td> <td> 13 (23) </td> <td> 12 (22) </td> </tr> <tr> <td> Dilated cardiomyopathy, n </td> <td> 11 (10) </td> <td> 6 (11) </td> <td> 5 (9) </td> </tr> <tr> <td> Hypertrophic cardiomyopathy, n </td> <td> 3 (3) </td> <td> 3 (5) </td> <td> 0 </td> </tr> <tr> <td> Stroke, n </td> <td> 6 (5) </td> <td> 3 (5) </td> <td> 3 (5) </td> </tr> <tr> <td> TIA, n </td> <td> 7 (6) </td> <td> 0 </td> <td> 7 (13) </td> </tr> <tr> <td> Venous thrombosis, n </td> <td> 1 (1) </td> <td> 1 (2) </td> <td> 0 </td> </tr> <tr> <td> Pulmonary embolism, n </td> <td> 1 (1) </td> <td> 1 (2) </td> <td> 0 </td> </tr> <tr> <td> Peripheral arterial embolism, n </td> <td> 1 (1) </td> <td> 1 (2) </td> <td> 0 </td> </tr> </table>	PMC2717073_table_0
	<table border="1" class="dataframe"> <tr> <th rowspan="2"> New symptoms scale </th> <th rowspan="2"> ICC (AF at 12 ± 3 days) </th> <th rowspan="2"> Lower 95% CI limit for ICC </th> </tr> <tr> </tr> <tr> <td> Dyspnoea at rest </td> <td> 0.82 </td> <td> 0.61 </td> </tr> <tr> <td> Dyspnoea on exertion </td> <td> 0.88 </td> <td> 0.72 </td> </tr> <tr> <td> Limitations in daily life due to AF </td> <td> 0.19 </td> <td> Neg </td> </tr> <tr> <td> Discomfort due to AF </td> <td> 0.04 </td> <td> Neg </td> </tr> <tr> <td> Fatigue due to AF </td> <td> 0.39 </td> <td> Neg </td> </tr> <tr> <td> Anxiety due to AF </td> <td> 0.93 </td> <td> 0.83 </td> </tr> <tr> <td> SF-36 domains </td> <td> </td> <td> </td> </tr> <tr> <td> Physical functioning </td> <td> 0.84 </td> <td> 0.64 </td> </tr> <tr> <td> Role – Physical </td> <td> 0.56 </td> <td> 0.17 </td> </tr> <tr> <td> Bodily pain </td> <td> 0.50 </td> <td> 0.09 </td> </tr> <tr> <td> General Health </td> <td> 0.75 </td> <td> 0.45 </td> </tr> <tr> <td> Vitality </td> <td> 0.77 </td> <td> 0.49 </td> </tr> <tr> <td> Social functioning </td> <td> 0.54 </td> <td> 0.14 </td> </tr> <tr> <td> Role – Emotional </td> <td> 0.57 </td> <td> 0.18 </td> </tr> <tr> <td> Mental Health </td> <td> 0.95 </td> <td> 0.10 </td> </tr> </table>	PMC2717073_table_1
	<table border="1" class="dataframe"> <tr> <th> Items </th> <th> Dyspnoea at rest </th> <th> Dyspnoea on exertion </th> <th> Limitations in working </th> <th> Limitations in daily life </th> <th> Discomfort due to AF </th> <th> Fatiguedue to AF </th> <th> Anxiety due to AF </th> </tr> <tr> <td> pf_tran </td> <td> -0.36437 </td> <td> -0.58810 </td> <td> -0.12466 </td> <td> -0.61232 </td> <td> -0.20312 </td> <td> -0.48616 </td> <td> -0.24267 </td> </tr> <tr> <td> Physical functioning </td> <td> < .0001 </td> <td> < .0001 </td> <td> 0.4315 </td> <td> < .0001 </td> <td> 0.0325 </td> <td> < .0001 </td> <td> 0.0106 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 111 </td> <td> 111 </td> <td> 111 </td> <td> 110 </td> </tr> <tr> <td> rp_tran </td> <td> -0.35569 </td> <td> -0.47634 </td> <td> -0.20069 </td> <td> -0.62755 </td> <td> -0.22794 </td> <td> -0.49356 </td> <td> -0.31813 </td> </tr> <tr> <td> Role – Physical </td> <td> 0.0001 </td> <td> < .0001 </td> <td> 0.2025 </td> <td> < .0001 </td> <td> 0.0171 </td> <td> < .0001 </td> <td> 0.0008 </td> </tr> <tr> <td> n </td> <td> 109 </td> <td> 109 </td> <td> 42 </td> <td> 108 </td> <td> 109 </td> <td> 109 </td> <td> 108 </td> </tr> <tr> <td> bp_tran </td> <td> -0.44545 </td> <td> -0.26582 </td> <td> -0.34962 </td> <td> -0.37650 </td> <td> -0.31149 </td> <td> -0.32431 </td> <td> -0.38909 </td> </tr> <tr> <td> Bodily Pain </td> <td> < .0001 </td> <td> 0.0048 </td> <td> 0.0232 </td> <td> < .0001 </td> <td> 0.0009 </td> <td> 0.0005 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 110 </td> <td> 111 </td> <td> 111 </td> <td> 109 </td> </tr> <tr> <td> gh_tran </td> <td> -0.29357 </td> <td> -0.27723 </td> <td> -0.29889 </td> <td> -0.51705 </td> <td> -0.31705 </td> <td> -0.40835 </td> <td> -0.38909 </td> </tr> <tr> <td> General Health </td> <td> 0.0019 </td> <td> 0.0034 </td> <td> 0.0545 </td> <td> < .0001 </td> <td> 0.0007 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 110 </td> <td> 110 </td> <td> 42 </td> <td> 109 </td> <td> 110 </td> <td> 110 </td> <td> 109 </td> </tr> <tr> <td> v_tran </td> <td> -0.25704 </td> <td> -0.40008 </td> <td> -0.40877 </td> <td> -0.66652 </td> <td> -0.40433 </td> <td> -0.66056 </td> <td> -0.36696 </td> </tr> <tr> <td> Vitality </td> <td> 0.0084 </td> <td> < .0001 </td> <td> 0.0120 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> <td> 0.0001 </td> </tr> <tr> <td> n </td> <td> 104 </td> <td> 104 </td> <td> 37 </td> <td> 103 </td> <td> 104 </td> <td> 104 </td> <td> 103 </td> </tr> <tr> <td> sf_tran </td> <td> -0.14190 </td> <td> -0.25434 </td> <td> -0.08276 </td> <td> -0.46915 </td> <td> -0.38437 </td> <td> -0.42230 </td> <td> -0.37927 </td> </tr> <tr> <td> Social Functioning </td> <td> 0.1374 </td> <td> 0.0071 </td> <td> 0.6023 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 110 </td> <td> 111 </td> <td> 111 </td> <td> 110 </td> </tr> <tr> <td> re-tran </td> <td> -0.32767 </td> <td> -0.37072 </td> <td> 0.11359 </td> <td> -0.52260 </td> <td> -0.21609 </td> <td> -0.48442 </td> <td> -0.42472 </td> </tr> <tr> <td> Role – Emotional </td> <td> 0.0004 </td> <td> < .0001 </td> <td> 0.4738 </td> <td> < .0001 </td> <td> 0.0227 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 110 </td> <td> 111 </td> <td> 111 </td> <td> 103 </td> </tr> <tr> <td> mh_tran </td> <td> -0.14611 </td> <td> -0.21271 </td> <td> -0.21615 </td> <td> -0.37553 </td> <td> -0.40701 </td> <td> -0.44899 </td> <td> -0.62826 </td> </tr> <tr> <td> Mental Health </td> <td> 0.1389 </td> <td> 0.0302 </td> <td> 0.1988 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 104 </td> <td> 104 </td> <td> 37 </td> <td> 103 </td> <td> 104 </td> <td> 104 </td> <td> 103 </td> </tr> </table>	PMC2717073_table_2
	<table border="1" class="dataframe"> <tr> <th> Item number </th> <th> Raw count </th> <th> Measure </th> <th> Realse </th> <th colspan="2"> Infit </th> <th colspan="2"> Outfit </th> <th> Score </th> </tr> <tr> <th> </th> <th> </th> <th> </th> <th> </th> <th> MNSQ </th> <th> ZSTD </th> <th> MNSQ </th> <th> ZSTD </th> <th> corr. </th> </tr> <tr> <td> AF1 </td> <td> 108 </td> <td> 0,41 </td> <td> 0,08 </td> <td> 0,98 </td> <td> -0,1 </td> <td> 0,99 </td> <td> 0 </td> <td> 0,51 </td> </tr> <tr> <td> AF3 </td> <td> 40 </td> <td> 0,22 </td> <td> 0,17 </td> <td> 0,89 </td> <td> -0,4 </td> <td> 1,28 </td> <td> 0,4 </td> <td> 0,39 </td> </tr> <tr> <td> AF7 </td> <td> 107 </td> <td> 0,15 </td> <td> 0,05 </td> <td> 1,04 </td> <td> 0,2 </td> <td> 1,01 </td> <td> 0 </td> <td> 0,65 </td> </tr> <tr> <td> AF5 </td> <td> 108 </td> <td> 0,12 </td> <td> 0,05 </td> <td> 1,06 </td> <td> 0,4 </td> <td> 1 </td> <td> 0 </td> <td> 0,66 </td> </tr> <tr> <td> AF4 </td> <td> 107 </td> <td> -0,06 </td> <td> 0,05 </td> <td> 0,84 </td> <td> -1,2 </td> <td> 0,79 </td> <td> -1,1 </td> <td> 0,76 </td> </tr> <tr> <td> AF2 </td> <td> 108 </td> <td> -0,4 </td> <td> 0,05 </td> <td> 1,24 </td> <td> 1,7 </td> <td> 1,2 </td> <td> 1,2 </td> <td> 0,69 </td> </tr> <tr> <td> AF6 </td> <td> 108 </td> <td> -0,43 </td> <td> 0,05 </td> <td> 0,87 </td> <td> -1 </td> <td> 0,84 </td> <td> -1,2 </td> <td> 0,78 </td> </tr> <tr> <td> Mean </td> <td> 98 </td> <td> 0 </td> <td> 0,07 </td> <td> 0,99 </td> <td> -0,1 </td> <td> 1,01 </td> <td> -0,1 </td> <td> </td> </tr> <tr> <td> SD </td> <td> 24 </td> <td> 0,29 </td> <td> 0,04 </td> <td> 0,13 </td> <td> 0,9 </td> <td> 0,16 </td> <td> 0,8 </td> <td> </td> </tr> </table>	PMC2717073_table_3
	<table border="1" class="dataframe"> <tr> <th> Score </th> <th> Description </th> </tr> <tr> <td> 0 </td> <td> No lesion </td> </tr> <tr> <td> 1 </td> <td> Hyperaemic area with erected pili </td> </tr> <tr> <td> 2 </td> <td> Moist, exudative and hyperaemic area with intact epidermis </td> </tr> <tr> <td> 3 </td> <td> Exudative area, exposed corium with no signs of healing </td> </tr> <tr> <td> 4 </td> <td> Exposed corium but in process of healing, dried-up lesion </td> </tr> <tr> <td> 5 </td> <td> Dark brown scab, completely or almost completely healed lesion </td> </tr> </table>	PMC2717074_table_0
	<table border="1" class="dataframe"><tr><td>N° of cases</td><td></td></tr><tr><td>Total of</td><td>68</td></tr><tr><td>Distribution of parity groups (%)</td><td></td></tr><tr><td>Primiparous</td><td>75.0</td></tr><tr><td rowspan="2">Multiparous a</td><td>25.0</td></tr><tr><td></td></tr><tr><td rowspan="2">DIM* 0–120 to</td><td>35.3</td></tr><tr><td>38.2</td></tr><tr><td>DIM > 240</td><td>26.5</td></tr></table>	PMC2717074_table_1
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Median duration </th> </tr> <tr> <td> No stratification </td> <td> 42 (36–48) </td> </tr> <tr> <td> Stratification </td> <td> </td> </tr> <tr> <td> Primiparous </td> <td> 39 (35–48) </td> </tr> <tr> <td> Multiparous </td> <td> 48 (42–48) </td> </tr> <tr> <td> Lactation stage at lesion onset </td> <td> </td> </tr> <tr> <td> DIM* 0–120 </td> <td> 42 (39–56) </td> </tr> <tr> <td> DIM 121–240 </td> <td> 42 (35–48) </td> </tr> <tr> <td> DIM > 240 </td> <td> 41 (35–48) </td> </tr> </table>	PMC2717074_table_2
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Pre-contrast </th> <th> Post-contrast </th> <th> CER* </th> </tr> <tr> <td> Triolein Group (n = 12) </td> <td> 504 (56.5) </td> <td> 1793 (229.9) </td> <td> 2.61 (0.73) </td> </tr> <tr> <td> Saline Group (n = 18) </td> <td> 582 (519.1) </td> <td> 712 (704.0) </td> <td> 0.22 (0.37) </td> </tr> </table>	PMC2717075_table_0
	<table border="1" class="dataframe"> <tr> <th> HPVgenotype </th> <th> Primer sequences </th> <th> Amplicon (pb)* </th> </tr> <tr> <td> 6/11 </td> <td> TGC AAG AAT GCA CTG ACC AC TGC ATG TTG TCC AGC AGT GT </td> <td> 334 </td> </tr> <tr> <td> 16 </td> <td> CAC AGT TAT GCA CAG AGC TGC CAT ATA TTC ATG CAA TGT AGG TGT A </td> <td> 457 </td> </tr> <tr> <td> 18 </td> <td> CAC TTC ACT GCA AGA CAT AGA GTT GTG AAA TCG TCG TTT TTC A </td> <td> 332 </td> </tr> <tr> <td> 31 </td> <td> GAA ATT GCA TGA ACT AAG CTC G CAC ATA TAC CTT TGT TTG TCA A </td> <td> 263 </td> </tr> <tr> <td> 33 </td> <td> ACT ATA CAC AAC ATT GAA CTA GTT TTT ACA CGT CAC AGT GCA </td> <td> 398 </td> </tr> <tr> <td> 42 </td> <td> CCC AAA GTA GTG GTC CCA GTT A GAT CTT TCG TAG TGT CGC AGT G </td> <td> 277 </td> </tr> <tr> <td> 52 </td> <td> TAA GGC TGC AGT GTG TGC AG CTA ATA GTT ATT TCA CTT AAT GGT </td> <td> 229 </td> </tr> <tr> <td> 58 </td> <td> GTA AAG TGT GCT TAC GAT TGC GTT GTT ACA GGT TAC ACT TGT </td> <td> 274 </td> </tr> </table>	PMC2717078_table_0
	<table border="1" class="dataframe"> <tr> <th colspan="4"> HPV-DNA </th> </tr> <tr> <th> Type n = 18 </th> <th> Carcinogenic risk </th> <th> Frequency n = 82 </th> <th> % </th> </tr> <tr> <td> 6/11 </td> <td> LR </td> <td> 17 </td> <td> 20.7 </td> </tr> <tr> <td> 42 </td> <td> LR </td> <td> 13 </td> <td> 15.9 </td> </tr> <tr> <td> 16 </td> <td> HR </td> <td> 13 </td> <td> 15.9 </td> </tr> <tr> <td> 18 </td> <td> HR </td> <td> 9 </td> <td> 11 </td> </tr> <tr> <td> 58 </td> <td> HR </td> <td> 5 </td> <td> 6.1 </td> </tr> <tr> <td> 31 </td> <td> HR </td> <td> 3 </td> <td> 3.7 </td> </tr> <tr> <td> 35 </td> <td> HR </td> <td> 3 </td> <td> 3.7 </td> </tr> <tr> <td> 52 </td> <td> HR </td> <td> 3 </td> <td> 3.7 </td> </tr> <tr> <td> 51 </td> <td> HR </td> <td> 2 </td> <td> 2.4 </td> </tr> <tr> <td> 54 </td> <td> LR </td> <td> 2 </td> <td> 2.4 </td> </tr> <tr> <td> 59 </td> <td> HR </td> <td> 2 </td> <td> 2.4 </td> </tr> <tr> <td> 26 </td> <td> PHR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 33 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 34 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 45 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 68 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 70 </td> <td> LR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 73 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> NC* </td> <td> - </td> <td> 3 </td> <td> 3.7 </td> </tr> </table>	PMC2717078_table_1
	<table border="1" class="dataframe"> <tr> <th> Cohort (n = 223) </th> <th> Characteristic </th> <th> aSer/Ser (n = 170) </th> <th> aSer/Leu (n = 43) </th> <th> aLeu/Leu (n = 10) </th> </tr> <tr> <td> No (%) of patients </td> <td> Co-existing diseases </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 103 (46.2) </td> <td> Arterial hypertension </td> <td> 77 (74.8) </td> <td> 22 (21.4) </td> <td> 4 (3.9) </td> </tr> <tr> <td> 82 (36.8) </td> <td> Myocardial disease </td> <td> 67 (81.7) </td> <td> 14 (17.0) </td> <td> 1 (1.2) </td> </tr> <tr> <td> 53 (23.8) </td> <td> Diabetes </td> <td> 35 (66.0) </td> <td> 14 (26.0) </td> <td> 4 (7.5) </td> </tr> <tr> <td> 52 (23.3) </td> <td> Lung pathology </td> <td> 44 (84.6) </td> <td> 6 (11.5) </td> <td> 2 (3.8) </td> </tr> <tr> <td> 16 (7.2) </td> <td> Renal pathology </td> <td> 11 (68.8) </td> <td> 4 (25.0) </td> <td> 1 (6.3) </td> </tr> <tr> <td> No (%) of patients </td> <td> Type of surgery </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 76 (34.1) </td> <td> Upper-GI resection </td> <td> 58 (76.3) </td> <td> 16 (21.1) </td> <td> 2 (2.6) </td> </tr> <tr> <td> 62 (27.8) </td> <td> Colorectal resection </td> <td> 46 (74.2) </td> <td> 12 (19.4) </td> <td> 4 (6.5) </td> </tr> <tr> <td> 50 (22.4) </td> <td> bOther abdominal </td> <td> 37 (74.0) </td> <td> 10 (20.0) </td> <td> 3 (6.0) </td> </tr> <tr> <td> 15 (6.7) </td> <td> Thoracic </td> <td> 11 (73.4) </td> <td> 3 (20.0) </td> <td> 1 (6.7) </td> </tr> <tr> <td> 20 (9.0) </td> <td> Limb and others </td> <td> 18 (90.0) </td> <td> 2 (10.0) </td> <td> - - </td> </tr> <tr> <td> No (%) of infections </td> <td> Type of Infection </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 92 (41.3) </td> <td> Pneumonia </td> <td> 68 (73.9) </td> <td> 20 (21.7) </td> <td> 4 (4.3) </td> </tr> <tr> <td> 38 (17.0) </td> <td> Peritonitis </td> <td> 27 (71.1) </td> <td> 9 (23.7) </td> <td> 2 (5.3) </td> </tr> <tr> <td> 65 (29.2) </td> <td> Abscess </td> <td> 52 (80.0) </td> <td> 10 (15.4) </td> <td> 3 (4.6) </td> </tr> <tr> <td> 4 (1.8) </td> <td> Urinary tract infections </td> <td> 3 (75.0) </td> <td> 1 (25.0) </td> <td> - - </td> </tr> <tr> <td> 24 (10.8) </td> <td> Other </td> <td> 20 (83.3) </td> <td> 3 (12.5) </td> <td> 1 (4.2) </td> </tr> <tr> <td> No (%) of infectionsc </td> <td> Microorganisms </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 129 (57.9) </td> <td> Gram-negative </td> <td> 97 (75.2) </td> <td> 25 (19.4) </td> <td> 7 (5.4) </td> </tr> <tr> <td> 83 (37.2) </td> <td> Gram-positive </td> <td> 60 (72.3) </td> <td> 18 (21.7) </td> <td> 5 (6.0) </td> </tr> <tr> <td> 15 (6.7) </td> <td> Fungi </td> <td> 13 (86.7) </td> <td> 2 (13.3) </td> <td> - - </td> </tr> <tr> <td> 31 (13.9) </td> <td> Polymicrobial </td> <td> 19 (61.3) </td> <td> 9 (29.0) </td> <td> 3 (9.8) </td> </tr> <tr> <td> 24 (10.8) </td> <td> Clinically diagnosed </td> <td> 15 (62.5) </td> <td> 8 (33.3) </td> <td> 1 (4.2) </td> </tr> <tr> <td> No (%) of patients </td> <td> Morbidity and Mortality </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 114 (51.1) </td> <td> Sepsis without organ dysfunction </td> <td> 90 (78.9) </td> <td> 22 (19.3) </td> <td> 2 (1.8) </td> </tr> <tr> <td> 109 (48.9) </td> <td> Severe sepsis and septic shock </td> <td> 80 (73.4) </td> <td> 21 (19.3) </td> <td> 8 (7.3)d </td> </tr> <tr> <td> 28 (12.6) </td> <td> Mortality ICU </td> <td> 21 (75.0) </td> <td> 6 (21.4) </td> <td> 1 (3.6) </td> </tr> <tr> <td> 34 (15.3) </td> <td> Mortality hospital </td> <td> 26 (76.5) </td> <td> 7 (20.6) </td> <td> 1 (2.9) </td> </tr> </table>	PMC2717080_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th> </th> <th> </th> <th colspan="3"> No. of individuals with genotype (%) </th> <th> </th> </tr> <tr> <th> Population and disease </th> <th> No. </th> <th> Variant Allele Frequency (%) </th> <th> Ser/Ser </th> <th> Ser/Leu </th> <th> Leu/Leu </th> <th> P valuea </th> </tr> <tr> <td> Ghana, delivering women </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> P. falciparum positive </td> <td> 541 </td> <td> 0.1 </td> <td> 540 (99.8) </td> <td> 1 (0.2) </td> <td> 0 (0) </td> <td> 0.49 </td> </tr> <tr> <td> P. falciparum negative </td> <td> 554 </td> <td> 0 </td> <td> 554 (100) </td> <td> 0 (0) </td> <td> 0 (0) </td> <td> </td> </tr> <tr> <td> Germany </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Sepsis patients </td> <td> 223 </td> <td> 18.1 </td> <td> 170 (76.2) </td> <td> 43 (19.3) </td> <td> 10 (4.5) </td> <td> 0.19 </td> </tr> <tr> <td> Controls </td> <td> 188 </td> <td> 19.2 </td> <td> 138 (74.4) </td> <td> 48 (25.5) </td> <td> 2 (1.1)b </td> <td> </td> </tr> <tr> <td> Bangladesh </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Leprosy patients </td> <td> 263 </td> <td> 16.3 </td> <td> 186 (70.7) </td> <td> 68 (25.9) </td> <td> 9 (3.4) </td> <td> 0.22 </td> </tr> <tr> <td> Controls </td> <td> 280 </td> <td> 17.2 </td> <td> 188 (67.1) </td> <td> 88 (31.5) </td> <td> 4 (1.4) </td> <td> </td> </tr> <tr> <td> Turkey </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> 0.11 </td> </tr> <tr> <td> Leprosy patients </td> <td> 60 </td> <td> 10.8 </td> <td> 47 (78) </td> <td> 13 (21) </td> <td> 0 (0) </td> <td> </td> </tr> <tr> <td> Controls </td> <td> 100 </td> <td> 6.5 </td> <td> 88 (88) </td> <td> 11 (11) </td> <td> 1 (1) </td> <td> </td> </tr> </table>	PMC2717080_table_1
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="6"> Particle size (nm) (± SD) </th> </tr> <tr> <th> Samples </th> <th> N/P = 1 </th> <th> N/P = 3 </th> <th> N/P = 5 </th> <th> N/P = 7 </th> <th> N/P = 10 </th> <th> N/P = 15 </th> </tr> <tr> <td> PCFC-g-PEI/pDNA complexes </td> <td> 208.05 ± 15.55 </td> <td> 211.85 ± 11.95 </td> <td> 215.3 ± 12.2 </td> <td> 195.35 ± 6.95 </td> <td> 161.4 ± 23.2 </td> <td> 234.85 ± 10.25 </td> </tr> <tr> <td> PEI/pDNA complexes </td> <td> 118.5 ± 2.5 </td> <td> 88.89 ± 0.83 </td> <td> 99.115 ± 3.885 </td> <td> 136.35 ± 4.45 </td> <td> 159.1 ± 5.7 </td> <td> 98.59 ± 9.81 </td> </tr> </table>	PMC2717081_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="6"> Zeta potential (mV) (± SD) </th> </tr> <tr> <th> Samples </th> <th> N/P = 1 </th> <th> N/P = 3 </th> <th> N/P = 5 </th> <th> N/P = 7 </th> <th> N/P = 10 </th> <th> N/P = 15 </th> </tr> <tr> <td> PCFC-g-PEI/pDNA complexes </td> <td> 31.2 ± 2.1 </td> <td> 16.75 ± 0.85 </td> <td> 1.5125 ± 0.6575 </td> <td> 1.38 ± 0.02 </td> <td> 0.325 ± 0.19 </td> <td> 7.835 ± 1.675 </td> </tr> <tr> <td> PEI/pDNA complexes </td> <td> 25.15 ± 0.75 </td> <td> 21.25 ± 0.25 </td> <td> 13 ± 0.7 </td> <td> 14.8 ± 1.5 </td> <td> 1.855 ± 0.235 </td> <td> 0.651 ± 0.062 </td> </tr> </table>	PMC2717081_table_1
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Mean </th> <th> Minimum </th> <th> Maximum </th> <th> SD </th> </tr> <tr> <td> Age (year) </td> <td> 27.12 </td> <td> 19 </td> <td> 40 </td> <td> 4.84 </td> </tr> <tr> <td> Gestational age (week) </td> <td> 33.70 </td> <td> 5 </td> <td> 42 </td> <td> 9.50 </td> </tr> <tr> <td> HCHB1 (g/l) </td> <td> 126.35 </td> <td> 55 </td> <td> 163 </td> <td> 18.02 </td> </tr> <tr> <td> LAHB2 (g/l) </td> <td> 128.45 </td> <td> 78 </td> <td> 162 </td> <td> 14.84 </td> </tr> </table>	PMC2717084_table_0
	<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> % </th> </tr> <tr> <td> Age group </td> <td> </td> </tr> <tr> <td> 15–19 </td> <td> 35.8 </td> </tr> <tr> <td> 20–24 </td> <td> 49.2 </td> </tr> <tr> <td> 25–29 </td> <td> 12.7 </td> </tr> <tr> <td> 30 and above </td> <td> 2.3 </td> </tr> <tr> <td> Median age </td> <td> 21.0 </td> </tr> <tr> <td> Marital status </td> <td> </td> </tr> <tr> <td> Unmarried </td> <td> 88.3 </td> </tr> <tr> <td> Currently married </td> <td> 11.7 </td> </tr> <tr> <td> Districts </td> <td> </td> </tr> <tr> <td> Kathmandu valley (3 districts) </td> <td> 9.2 </td> </tr> <tr> <td> Outside Kathmandu valley (64 districts) </td> <td> 90.8 </td> </tr> <tr> <td> Level of education </td> <td> </td> </tr> <tr> <td> Intermediate </td> <td> 27.7 </td> </tr> <tr> <td> Undergraduate </td> <td> 53.9 </td> </tr> <tr> <td> Graduate degree </td> <td> 18.3 </td> </tr> <tr> <td> Type of accommodation </td> <td> </td> </tr> <tr> <td> With family </td> <td> 41.0 </td> </tr> <tr> <td> Alone </td> <td> 19.0 </td> </tr> <tr> <td> With friends </td> <td> 40.0 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 573 </td> </tr> </table>	PMC2717085_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th> % </th> </tr> <tr> <td> Experience of kissing a girl </td> <td> 57.4 </td> </tr> <tr> <td> Experience of dating </td> <td> 44.5 </td> </tr> <tr> <td> Experience of placing hand on a girl's breast </td> <td> 60.2 </td> </tr> <tr> <td> Experience of placing hand on a girl's sex organ </td> <td> 34.9 </td> </tr> <tr> <td> Experience of sexual intercourse </td> <td> 46.9 </td> </tr> <tr> <td> Experience of premarital sex </td> <td> 39.1 </td> </tr> <tr> <td> Having close unmarried friend with experience of premarital sex </td> <td> 53.0 </td> </tr> <tr> <td> N </td> <td> 573 </td> </tr> </table>	PMC2717085_table_1
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Premarital sex </th> <th colspan="2"> Total </th> </tr> <tr> <th> </th> <th> Yes </th> <th> No </th> <th> % </th> <th> Number </th> </tr> <tr> <td> Age group </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 15–19 </td> <td> 34.6 </td> <td> 65.4 </td> <td> 100.0 </td> <td> 205 </td> </tr> <tr> <td> 20 and above </td> <td> 41.6 </td> <td> 58.4 </td> <td> 100.0 </td> <td> 368 </td> </tr> <tr> <td> Level of education </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Intermediate </td> <td> 35.2 </td> <td> 64.8 </td> <td> 100.0 </td> <td> 159 </td> </tr> <tr> <td> Undergraduate </td> <td> 39.8 </td> <td> 60.2 </td> <td> 100.0 </td> <td> 309 </td> </tr> <tr> <td> Graduate degree </td> <td> 42.9 </td> <td> 57.1 </td> <td> 100.0 </td> <td> 105 </td> </tr> <tr> <td> Marital status </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Married </td> <td> 32.8 </td> <td> 67.2 </td> <td> 100.0 </td> <td> 67 </td> </tr> <tr> <td> Unmarried </td> <td> 39.9 </td> <td> 60.1 </td> <td> 100.0 </td> <td> 506 </td> </tr> <tr> <td> District </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Outside Kathmandu valley </td> <td> 39.8 </td> <td> 60.2 </td> <td> 100.0 </td> <td> 520 </td> </tr> <tr> <td> Kathmandu valley </td> <td> 32.1 </td> <td> 67.9 </td> <td> 100.0 </td> <td> 53 </td> </tr> <tr> <td> Living arrangement </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> With family </td> <td> 36.6 </td> <td> 63.4 </td> <td> 100.0 </td> <td> 232 </td> </tr> <tr> <td> Alone </td> <td> 43.4 </td> <td> 56.6 </td> <td> 100.0 </td> <td> 106 </td> </tr> <tr> <td> With friends </td> <td> 39.6 </td> <td> 60.4 </td> <td> 100.0 </td> <td> 235 </td> </tr> <tr> <td> Attitude towards female virginity* </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Conservative </td> <td> 33.4 </td> <td> 66.6 </td> <td> 100.0 </td> <td> 305 </td> </tr> <tr> <td> Liberal </td> <td> 45.5 </td> <td> 54.5 </td> <td> 100.0 </td> <td> 268 </td> </tr> <tr> <td> Attitude towards male virginity* </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Conservative </td> <td> 30.0 </td> <td> 70.0 </td> <td> 100.0 </td> <td> 290 </td> </tr> <tr> <td> Liberal </td> <td> 48.4 </td> <td> 51.6 </td> <td> 100.0 </td> <td> 283 </td> </tr> <tr> <td> Family structure </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Joint family </td> <td> 39.6 </td> <td> 60.4 </td> <td> 100.0 </td> <td> 139 </td> </tr> <tr> <td> Nuclear family </td> <td> 38.9 </td> <td> 61.1 </td> <td> 100.0 </td> <td> 434 </td> </tr> <tr> <td> Religion* </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Non-Hindu </td> <td> 20.0 </td> <td> 80.0 </td> <td> 100.0 </td> <td> 35 </td> </tr> <tr> <td> Hindu </td> <td> 40.3 </td> <td> 59.7 </td> <td> 100.0 </td> <td> 538 </td> </tr> <tr> <td> Has a friend who has experienced premarital sex*** </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No </td> <td> 14.9 </td> <td> 85.1 </td> <td> 100.0 </td> <td> 268 </td> </tr> <tr> <td> Yes </td> <td> 60.3 </td> <td> 39.7 </td> <td> 100.0 </td> <td> 305 </td> </tr> <tr> <td> Total </td> <td> 39.1 </td> <td> 60.9 </td> <td> 100.0 </td> <td> 573 </td> </tr> </table>	PMC2717085_table_2
	<table border="1" class="dataframe"> <tr> <th rowspan="2"> In </th> <th> % </th> </tr> <tr> <td> 6.7 </td> </tr> <tr> <td rowspan="2"> 15–16 had </td> <td> 25.0 </td> </tr> <tr> <td> 32.0 </td> </tr> <tr> <td> 19 or more </td> <td> 36.3 </td> </tr> <tr> <td> Total (age range 10–25 years) </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 224 </td> </tr> </table>	PMC2717085_table_3
	<table border="1" class="dataframe"> <tr> <th> How many sex partners did you have (total)? </th> <th> % </th> </tr> <tr> <td> One </td> <td> 45.1 </td> </tr> <tr> <td> Two </td> <td> 23.7 </td> </tr> <tr> <td> Three and more </td> <td> 31.3 </td> </tr> <tr> <td> Average number of sex partners </td> <td> 2.4 </td> </tr> <tr> <td> SD </td> <td> 2.1 </td> </tr> <tr> <td> Ranges </td> <td> 1–15 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 224 </td> </tr> </table>	PMC2717085_table_4
	<table border="1" class="dataframe"> <tr> <th> </th> <th> % </th> </tr> <tr> <td> Have you ever had sex with CSW? </td> <td> </td> </tr> <tr> <td rowspan="2"> Yes was </td> <td> 22.8 </td> </tr> <tr> <td> 77.2 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 224 </td> </tr> <tr> <td> How often did you use condom with CSW? </td> <td> </td> </tr> <tr> <td> Every act of sexual intercourse </td> <td> 49.0 </td> </tr> <tr> <td rowspan="2"> Sometimes they </td> <td> 45.1 </td> </tr> <tr> <td> 5.9 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 51 </td> </tr> </table>	PMC2717085_table_5
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Model I </th> <th> Model II </th> <th> Model III </th> </tr> <tr> <td> Individual characteristics </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Age group </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 15–19 </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> 20 and above </td> <td> 1.34 </td> <td> 1.39 </td> <td> 1.69* </td> </tr> <tr> <td> Level of education </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Intermediate </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Undergraduate </td> <td> 0.93 </td> <td> 0.89 </td> <td> 0.52* </td> </tr> <tr> <td> Graduate degree </td> <td> 0.88 </td> <td> 0.79 </td> <td> 0.48* </td> </tr> <tr> <td> Marital status </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Married </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Unmarried </td> <td> 1.30 </td> <td> 1.29 </td> <td> 1.73 </td> </tr> <tr> <td> District </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Outside Kathmandu valley </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Kathmandu valley </td> <td> 0.82 </td> <td> 0.84 </td> <td> 0.97 </td> </tr> <tr> <td> Living arrangement </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> With family </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Alone </td> <td> 1.32 </td> <td> 1.39 </td> <td> 1.28 </td> </tr> <tr> <td> With friends </td> <td> 1.05 </td> <td> 1.07 </td> <td> 1.07 </td> </tr> <tr> <td> Attitude towards male virginity </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Conservative (ref) </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Liberal </td> <td> 2.16* </td> <td> 2.15* </td> <td> 1.91** </td> </tr> <tr> <td> Family characteristics </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Family structure </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Joint family </td> <td> </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Nuclear family </td> <td> </td> <td> 0.91 </td> <td> 0.81 </td> </tr> <tr> <td> Religion </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Non-Hindu (ref) </td> <td> </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Hindu </td> <td> </td> <td> 2.63* </td> <td> 2.99* </td> </tr> <tr> <td> Peer characteristics </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Has close unmarried friend who has experienced premarital sex </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No (ref) </td> <td> </td> <td> </td> <td> 1.0 </td> </tr> <tr> <td> Yes </td> <td> </td> <td> </td> <td> 9.2*** </td> </tr> <tr> <td> Intercept </td> <td> 0.28 </td> <td> 0.124 </td> <td> 0.033 </td> </tr> <tr> <td> -2 log likelihood </td> <td> 741.7 </td> <td> 736.1 </td> <td> 611.1 </td> </tr> <tr> <td> Cox & Snell R square </td> <td> 0.043 </td> <td> 0.052 </td> <td> 0.238 </td> </tr> </table>	PMC2717085_table_6
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Method </th> <th> Threshold </th> <th> Clusters </th> <th> Singletons </th> <th> Max. cluster size </th> </tr> <tr> <td> Rice </td> <td> sHYB </td> <td> N/A </td> <td> 305 </td> <td> 0 </td> <td> 2,533 </td> </tr> <tr> <td rowspan="6"> Rice </td> <td> HYB </td> <td> 1.1 </td> <td> 2 </td> <td> 21 </td> <td> 22,459 </td> </tr> <tr> <td> </td> <td> 1.2 </td> <td> 50 </td> <td> 36 </td> <td> 22,078 </td> </tr> <tr> <td> </td> <td> 1.35 </td> <td> 853 </td> <td> 286 </td> <td> 10,773 </td> </tr> <tr> <td> </td> <td> 1.4 </td> <td> 1,361 </td> <td> 528 </td> <td> 4,052 </td> </tr> <tr> <td> </td> <td> 1.45 </td> <td> 1,863 </td> <td> 880 </td> <td> 359 </td> </tr> <tr> <td> </td> <td> 1.5 </td> <td> 2,341 </td> <td> 1,405 </td> <td> 143 </td> </tr> <tr> <td rowspan="8"> Rice </td> <td> RESTR </td> <td> 1e-8 </td> <td> 128 </td> <td> 125 </td> <td> 21,663 </td> </tr> <tr> <td> </td> <td> 1e-10 </td> <td> 1,247 </td> <td> 357 </td> <td> 258 </td> </tr> <tr> <td> </td> <td> 1e-12 </td> <td> 1,929 </td> <td> 855 </td> <td> 122 </td> </tr> <tr> <td> </td> <td> 1e-15 </td> <td> 2,959 </td> <td> 3,007 </td> <td> 79 </td> </tr> <tr> <td> </td> <td> 1e-17 </td> <td> 3,421 </td> <td> 5,799 </td> <td> 67 </td> </tr> <tr> <td> </td> <td> 1e-20 </td> <td> 3,085 </td> <td> 12,399 </td> <td> 59 </td> </tr> <tr> <td> </td> <td> 1e-25 </td> <td> 680 </td> <td> 20,925 </td> <td> 12 </td> </tr> <tr> <td> </td> <td> 1e-30 </td> <td> 8 </td> <td> 22,470 </td> <td> 2 </td> </tr> <tr> <td> Rice </td> <td> RAND </td> <td> N/A </td> <td> 1,901 </td> <td> 0 </td> <td> 113 </td> </tr> <tr> <td> Barley </td> <td> sHYB </td> <td> N/A </td> <td> 70 </td> <td> 0 </td> <td> 1,413 </td> </tr> <tr> <td rowspan="3"> Barley </td> <td> HYB </td> <td> 1.5 </td> <td> 311 </td> <td> 141 </td> <td> 14,471 </td> </tr> <tr> <td> </td> <td> 1.6 </td> <td> 318 </td> <td> 211 </td> <td> 14,375 </td> </tr> <tr> <td> </td> <td> 1.7 </td> <td> 2,124 </td> <td> 988 </td> <td> 2,880 </td> </tr> </table>	PMC2717093_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Clones </th> <th> Contigs </th> <th> Singl. </th> <th> Q-contigs </th> </tr> <tr> <td> Rice FPC Standard </td> <td> 22,486 </td> <td> 1,918 </td> <td> 860 </td> <td> 8 </td> </tr> <tr> <td> Rice Comp. sHYB </td> <td> 22,486 </td> <td> 2,032 </td> <td> 1,156 </td> <td> 6 </td> </tr> <tr> <td> Rice Comp. HYB </td> <td> 22,486 </td> <td> 2,070 </td> <td> 2,593 </td> <td> 3 </td> </tr> <tr> <td> Rice Comp. RESTR </td> <td> 22,486 </td> <td> 1,918 </td> <td> 860 </td> <td> 8 </td> </tr> <tr> <td> Rice Comp. RAND </td> <td> 22,486 </td> <td> 1,994 </td> <td> 862 </td> <td> 6 </td> </tr> <tr> <td> Barley FPC Standard </td> <td> 61,647 </td> <td> 8,852 </td> <td> 8,821 </td> <td> 869 </td> </tr> <tr> <td> Barley Comp. sHYB </td> <td> 61,647 </td> <td> 9,316 </td> <td> 10,866 </td> <td> 601 </td> </tr> <tr> <td> Barley Comp. HYB </td> <td> 61,647 </td> <td> 9,376 </td> <td> 13,024 </td> <td> 489 </td> </tr> </table>	PMC2717093_table_1
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Assembly score (%) </th> <th> Misplaced clones </th> <th> Misass. contigs </th> <th> Global ordering </th> </tr> <tr> <td> FPC Standard </td> <td> 96.43 </td> <td> 675 </td> <td> 493 </td> <td> 0.8252 </td> </tr> <tr> <td> Comp. sHYB </td> <td> 97.67 </td> <td> 343 </td> <td> 290 </td> <td> 0.8496 </td> </tr> <tr> <td> Comp. HYB </td> <td> 99.75 </td> <td> 10 </td> <td> 7 </td> <td> 0.8575 </td> </tr> <tr> <td> Comp. RESTR </td> <td> 96.43 </td> <td> 675 </td> <td> 473 </td> <td> 0.8254 </td> </tr> <tr> <td> Comp. RAND </td> <td> 96.48 </td> <td> 668 </td> <td> 492 </td> <td> 0.8252 </td> </tr> </table>	PMC2717093_table_2
	<table border="1" class="dataframe"> <tr> <th> cor- </th> <th> MTP clones </th> <th> Coverage (%) </th> <th> Overlaps (%) </th> </tr> <tr> <td> FPC Standard </td> <td> 2,791 </td> <td> 84.89 </td> <td> 84.31 </td> </tr> <tr> <td> Comp. sHYB </td> <td> 2,874 </td> <td> 85.66 </td> <td> 86.94 </td> </tr> <tr> <td rowspan="2"> Comp. HYB a </td> <td> 2,810 </td> <td> 85.89 </td> <td> 94.05 </td> </tr> <tr> <td> 2,792 </td> <td> 84.85 </td> <td> 84.33 </td> </tr> <tr> <td> Comp. RAND </td> <td> 2,856 </td> <td> 85.08 </td> <td> 83.75 </td> </tr> </table>	PMC2717093_table_3
	<table border="1" class="dataframe"> <tr> <th> </th> <th> TP (%) </th> <th> FN (%) </th> <th> Singl. (%) </th> </tr> <tr> <td> Rice FPC Standard </td> <td> 88.91 </td> <td> 8.53 </td> <td> 2.56 </td> </tr> <tr> <td> Rice Comp. sHYB </td> <td> 87.90 </td> <td> 7.05 </td> <td> 5.05 </td> </tr> <tr> <td> Rice Comp. HYB </td> <td> 83.87 </td> <td> 1.90 </td> <td> 14.23 </td> </tr> <tr> <td> Rice Comp. RESTR </td> <td> 88.91 </td> <td> 8.53 </td> <td> 2.56 </td> </tr> <tr> <td> Rice Comp. RAND </td> <td> 87.80 </td> <td> 9.64 </td> <td> 2.56 </td> </tr> <tr> <td> Rice Manual </td> <td> 92.09 </td> <td> 7.26 </td> <td> 0.65 </td> </tr> <tr> <td> Barley Standard </td> <td> 82.27 </td> <td> 9.63 </td> <td> 8.10 </td> </tr> <tr> <td> Barley Comp. sHYB </td> <td> 82.55 </td> <td> 9.25 </td> <td> 8.20 </td> </tr> <tr> <td> Barley Comp. HYB </td> <td> 72.55 </td> <td> 9.06 </td> <td> 18.40 </td> </tr> </table>	PMC2717093_table_4
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="3"> Day care attendees (N = 61) </th> <th colspan="3"> All participants (N = 213) </th> </tr> <tr> <th> Serotype </th> <th> DCC1 </th> <th> DCC2 </th> <th> DCC3 </th> <th> DCC1 </th> <th> DCC2 </th> <th> DCC3 </th> </tr> <tr> <td> 9V </td> <td> 15 </td> <td> 0 </td> <td> 0 </td> <td> 21 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 18C </td> <td> 0 </td> <td> 0 </td> <td> 13 </td> <td> 0 </td> <td> 0 </td> <td> 20 </td> </tr> <tr> <td> 3 </td> <td> 9 </td> <td> 2 </td> <td> 6 </td> <td> 11 </td> <td> 2 </td> <td> 6 </td> </tr> <tr> <td> 19F </td> <td> 0 </td> <td> 8 </td> <td> 0 </td> <td> 1 </td> <td> 14 </td> <td> 1 </td> </tr> <tr> <td> 15B/C </td> <td> 2 </td> <td> 4 </td> <td> 5 </td> <td> 3 </td> <td> 6 </td> <td> 6 </td> </tr> <tr> <td> 11A </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 1 </td> <td> 4 </td> <td> 7 </td> </tr> <tr> <td> 19A </td> <td> 7 </td> <td> 0 </td> <td> 0 </td> <td> 8 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 35F </td> <td> 3 </td> <td> 2 </td> <td> 0 </td> <td> 3 </td> <td> 4 </td> <td> 1 </td> </tr> <tr> <td> 14 </td> <td> 0 </td> <td> 2 </td> <td> 2 </td> <td> 0 </td> <td> 4 </td> <td> 3 </td> </tr> <tr> <td> 6B </td> <td> 1 </td> <td> 1 </td> <td> 0 </td> <td> 1 </td> <td> 4 </td> <td> 1 </td> </tr> <tr> <td> 22 </td> <td> 0 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> <td> 4 </td> <td> 0 </td> </tr> <tr> <td> 33 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> <td> 3 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 38 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 6A </td> <td> 1 </td> <td> 1 </td> <td> 0 </td> <td> 1 </td> <td> 1 </td> <td> 0 </td> </tr> <tr> <td> 9N </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 1 </td> <td> 1 </td> </tr> <tr> <td> 10 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 16 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 18B </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> </tr> <tr> <td> 35B </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> </tr> <tr> <td> 7 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> </tr> <tr> <td> Non-typables </td> <td> 0 </td> <td> 0 </td> <td> 0 </td> <td> 0 </td> <td> 3 </td> <td> 3 </td> </tr> <tr> <td> Total </td> <td> 45 </td> <td> 23 </td> <td> 30 </td> <td> 57 </td> <td> 48 </td> <td> 51 </td> </tr> </table>	PMC2717096_table_0
	<table border="1" class="dataframe"> <tr> <th> Model parameter </th> <th> Posterior mean </th> <th> 5% quantile </th> <th> 95% quantile </th> </tr> <tr> <td> κ Community acquisition rate (per month) </td> <td> 0.0059 </td> <td> 0.0043 </td> <td> 0.0077 </td> </tr> <tr> <td> βfam Family transmission rate (per month) </td> <td> 0.36 </td> <td> 0.23 </td> <td> 0.52 </td> </tr> <tr> <td> βdcc DCC transmission rate (per month) </td> <td> 0.53 </td> <td> 0.38 </td> <td> 0.71 </td> </tr> <tr> <td> μ Clearance rate (per month) </td> <td> 0.69 </td> <td> 0.64 </td> <td> 0.75 </td> </tr> <tr> <td> θ Competition parameter </td> <td> 0.68 </td> <td> 0.35 </td> <td> 1.10 </td> </tr> <tr> <td> η Relative susceptibility (adults vs. children) </td> <td> 0.41 </td> <td> 0.28 </td> <td> 0.58 </td> </tr> <tr> <td> δ Relative clearance rate (adults vs. children) </td> <td> 1.23 </td> <td> 1.06 </td> <td> 1.41 </td> </tr> </table>	PMC2717096_table_1
	<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Vaginal (V19I, V12I, V11I) </th> <th colspan="2"> Ectocervical (3ECI) </th> <th colspan="2"> Endocervical (sA2EN) </th> </tr> <tr> <th> </th> <th> MOI 10 </th> <th> PBS </th> <th> MOI 10 </th> <th> PBS </th> <th> MOI 10 </th> <th> PBS </th> </tr> <tr> <td> IL-6 </td> <td> 127 ± 13.1* </td> <td> 69 ± 1.7 </td> <td> 63.7 ± 1.8* </td> <td> 21.3 ± 2.4 </td> <td> 348 ± 13* </td> <td> 196 ± 15 </td> </tr> <tr> <td> IL-8 </td> <td> 1458 ± 117* </td> <td> 785 ± 11.3 </td> <td> 3304 ± 300* </td> <td> 722 ± 98 </td> <td> 5e7 ± 1347* </td> <td> 6e4 ± 367 </td> </tr> <tr> <td> G-CSF </td> <td> 261 ± 46 </td> <td> 227 ± 37 </td> <td> 548 ± 143 </td> <td> 779 ± 122 </td> <td> 155 ± 6.2* </td> <td> 93 ± 21 </td> </tr> <tr> <td> GM-CSF </td> <td> 24 ± 1.8* </td> <td> 8 ± 3.1 </td> <td> 16 ± 2.6 </td> <td> 10 ± 1.0 </td> <td> 160 ± 9.4* </td> <td> 45 ± 12 </td> </tr> <tr> <td> MCP-1 </td> <td> 5.8 ± 1.4 </td> <td> 7 ± 2.1 </td> <td> 11.4 ± 1.3 </td> <td> 10 ± 3.1 </td> <td> 7.2 ± 1.1* </td> <td> 0.46 ± 0.02 </td> </tr> </table>	PMC2717097_table_0
	<table border="1" class="dataframe"> <tr> <th> </th> <th> Primer combinations used </th> <th> Size of the expected PCR product [bp] </th> <th> PCR product obtained </th> </tr> <tr> <td> GI1 </td> <td> GI1–1/GI1–2 </td> <td> 1,331 </td> <td> - </td> </tr> <tr> <td> GI1* </td> <td> GI1–2/GI1–3 </td> <td> 677 </td> <td> + </td> </tr> <tr> <td> GI2 </td> <td> GI2-1/GI2–2 </td> <td> 624 </td> <td> + </td> </tr> <tr> <td> GI2* </td> <td> GI2–3/GI2–4 </td> <td> 902 </td> <td> - </td> </tr> <tr> <td> GI3 </td> <td> GI3–1/GI3–2 </td> <td> 967 </td> <td> + </td> </tr> <tr> <td> GI1+GI2 </td> <td> GI2–3/GI1–2 </td> <td> 1,175 </td> <td> - </td> </tr> <tr> <td> GI2+GI3 </td> <td> GI3-2/GI2-2 </td> <td> 578 </td> <td> + </td> </tr> <tr> <td> GI2*+GI3 </td> <td> GI3-3/GI2–4 </td> <td> 494 </td> <td> - </td> </tr> <tr> <td> GI1–GI3 </td> <td> GI3-2/GI1–2 </td> <td> 720 </td> <td> + </td> </tr> <tr> <td> GI4 </td> <td> GI4-1/GI4-2 </td> <td> 384 </td> <td> + </td> </tr> <tr> <td> GI5 </td> <td> GI5-1/GI5-2 </td> <td> 571 </td> <td> - </td> </tr> <tr> <td> GI6 </td> <td> GI6-1/GI6-2 </td> <td> 850 </td> <td> + </td> </tr> <tr> <td> GI7 </td> <td> GI7-1/GI7-2 </td> <td> 384 </td> <td> + </td> </tr> </table>	PMC2717098_table_0
	<table border="1" class="dataframe"> <tr> <th> Designation </th> <th> DNA-Sequence </th> </tr> <tr> <td> GI1-1 </td> <td> 5'-TAC GGA CCT TCT CGG CGG-3' </td> </tr> <tr> <td> GI1–2 </td> <td> 5'-GAC CCA AGG CAA GAC GCT G-3' </td> </tr> <tr> <td> GI1–3 </td> <td> 5'-ATT ACC CGC ATT CCC TTG TTG-3' </td> </tr> <tr> <td> GI2-1 </td> <td> 5'-TCG TTG ACC TCG CTC CTC CA-3' </td> </tr> <tr> <td> GI2-2 </td> <td> 5'-TAC GAC AGT TGA CCA CAG TTG-3' </td> </tr> <tr> <td> GI2–3 </td> <td> 5'-CTC TGC CGT CCC TCC TTG-3' </td> </tr> <tr> <td> GI2–4 </td> <td> 5'-TCA AGA CCA TCG TAT AGC GG-3' </td> </tr> <tr> <td> GI3-1 </td> <td> 5'-AGG TCT AGG AAA ACT GGG CGA ATC-3' </td> </tr> <tr> <td> GI3-2 </td> <td> 5'-GTA TTC CTG TGC CTA GAT TGG-3' </td> </tr> <tr> <td> GI3–3 </td> <td> 5'-TCA GCC CCA GCA ACT ATC C-3' </td> </tr> <tr> <td> GI4-1 </td> <td> 5'-ATG AAC ACC CGG CGA CCC-3' </td> </tr> <tr> <td> GI4-2 </td> <td> 5'-GAG CTA ACC TAC TGT CCC AT-3' </td> </tr> <tr> <td> GI5-1 </td> <td> 5'-GTT TTG GGA TGT TTT GAA GCG TG-3' </td> </tr> <tr> <td> GI5-2 </td> <td> 5'-CGG TCG AAG AAG CCA GCA GT-3' </td> </tr> <tr> <td> GI6-2 </td> <td> 5'-GAT AGG GTT CGC TCA CAC GGC-3' </td> </tr> <tr> <td> GI6-1 </td> <td> 5'-CTC CTC CAG CAA CAA TAC GG-3' </td> </tr> <tr> <td> GI7-1 </td> <td> 5'-TTG AGA CGA CTA TGA ACC CAG-3' </td> </tr> <tr> <td> GI7-2 </td> <td> 5'-CGC CCA TTG CCA CGA CCG-3' </td> </tr> <tr> <td> Tet1 </td> <td> 5'-GAC GGC GGC CGC ATC TGG CAA AGC-3' </td> </tr> <tr> <td> Tet2 </td> <td> 5'-ATA CTA GTC ATC GCG TGA TCC TCG CGA A-3' </td> </tr> <tr> <td> Tet3 </td> <td> 5'-ATG AAT TCA ATA CGC CCG AGA CCC GCG-3' </td> </tr> <tr> <td> Tet4 </td> <td> 5'-CAT CTC GAG AAA ACG GTG AAG GCC AGC-3' </td> </tr> <tr> <td> tRNA45-1 </td> <td> 5'-CCG TCT CCA ATC CCA AGG C-3' </td> </tr> <tr> <td> tRNA45-2 </td> <td> 5'-CTG GAA CAA GAA GGC CG C-3' </td> </tr> </table>	PMC2717098_table_1
	<table border="1" class="dataframe"> <tr> <th> MIC Mutant </th> <th> Design Score </th> <th> SEC Binding </th> </tr> <tr> <td> N69Q_Q108L_Q120I_K154S_T155D </td> <td> -8.1 </td> <td> + </td> </tr> <tr> <td> N69Q_Q120I_K154S_T155D_Y157L </td> <td> -7.1 </td> <td> - </td> </tr> <tr> <td> N69Q_D72F_K154S_T155D </td> <td> -7.1 </td> <td> + </td> </tr> <tr> <td> N69Q_Q120I_K154S_T155D </td> <td> -6 </td> <td> + </td> </tr> <tr> <td> N69Q_D72F_Q108L_K152V_Y157L </td> <td> -5.9 </td> <td> + </td> </tr> <tr> <td> K152V_K154S_T155D_Y157L </td> <td> -5.8 </td> <td> + </td> </tr> <tr> <td> N69Q_K154D </td> <td> -4.3 </td> <td> + </td> </tr> <tr> <td> K154S_T155D </td> <td> -4 </td> <td> - </td> </tr> <tr> <td> K152V_K154S_T155D </td> <td> -3.9 </td> <td> - </td> </tr> <tr> <td> N69Q_D72F_Q108L </td> <td> -3.9 </td> <td> + </td> </tr> <tr> <td> N69Q_D72F </td> <td> -3.6 </td> <td> + </td> </tr> <tr> <td> N69Q </td> <td> -2.8 </td> <td> + </td> </tr> <tr> <td> K152V_Y157L </td> <td> -2.2 </td> <td> + </td> </tr> <tr> <td> K154D </td> <td> -1.5 </td> <td> + </td> </tr> <tr> <td> Q108L </td> <td> -0.5 </td> <td> + </td> </tr> <tr> <td> Wild-type </td> <td> 0 </td> <td> + </td> </tr> <tr> <td> D72W </td> <td> 0.3 </td> <td> - </td> </tr> <tr> <td> Q120I </td> <td> 0.7 </td> <td> + </td> </tr> <tr> <td> Q120I_K154M </td> <td> 0.8 </td> <td> n/a </td> </tr> <tr> <td> N69W </td> <td> 1.8 </td> <td> ++ </td> </tr> <tr> <td> N69W_K152E_K154S </td> <td> 4.2 </td> <td> ++ </td> </tr> <tr> <td> N69W_K152E_K154D </td> <td> 4.3 </td> <td> ++ </td> </tr> <tr> <td> K152E_K154M </td> <td> 4.4 </td> <td> + </td> </tr> <tr> <td> N69W_D72F_K152E </td> <td> 4.5 </td> <td> ++ </td> </tr> <tr> <td> N69W_D72W_K152E </td> <td> 5.1 </td> <td> + </td> </tr> <tr> <td> N69W_K152E </td> <td> 5.5 </td> <td> ++ </td> </tr> </table>	PMC2717102_table_0
	<table border="1" class="dataframe"> <tr> <th> Origin </th> <th> Sequence </th> <th> Reference </th> </tr> <tr> <td> Plasma proteins </td> <td> </td> <td> </td> </tr> <tr> <td> Complement factor C3 </td> <td> LGEACKKVFLDCCNYITELRRQHARAS </td> <td> [13,14] </td> </tr> <tr> <td> High molecular weight kininogen </td> <td> HKHGHGHGKHKNKGKKNGKH </td> <td> [15] </td> </tr> <tr> <td> Fibronectin </td> <td> QPPRARITGYIIKYEKPG </td> <td> [17] </td> </tr> <tr> <td> Protein C Inhibitor </td> <td> SEKTLRKWLKMFKKRQLELY </td> <td> [11] </td> </tr> <tr> <td> Histidine-rich glycoprotein </td> <td> GHHPHGHHPHGHHPHGHHPH </td> <td> [18,19] </td> </tr> <tr> <td> Extracellular proteins </td> <td> </td> <td> </td> </tr> <tr> <td> Amphiregulin </td> <td> LKKNGSCKRGPRTHYGQKAIL </td> <td> [17] </td> </tr> <tr> <td> Heparin-binding EGF-like growth factor </td> <td> GKRKKKGKGLGKKRDPCLRKYK </td> <td> [17] </td> </tr> <tr> <td> Fibroblast growth factor </td> <td> </td> <td> </td> </tr> <tr> <td> Hepatocyte growth factor </td> <td> LKIKTKKVNTADQCANRCTRNKGL </td> <td> </td> </tr> <tr> <td> Vitronectin </td> <td> AKKQRFRHRNRKGYR </td> <td> [11] </td> </tr> <tr> <td> PRELP </td> <td> QPTRRPRPGTGPGRRPRPRPRP </td> <td> [17] </td> </tr> <tr> <td> Laminin chains </td> <td> SRNLSEIKLLISQARK KDFLSIELFRGRVKV LGTRLRAQSRQRSRPGRWHKVSVRW RLRAQSRQRSRPGRWHKVSVRW </td> <td> [11] </td> </tr> </table>	PMC2717103_table_0
	<table border="1" class="dataframe"> <tr> <th> Causes </th> <th> number </th> <th> % </th> </tr> <tr> <td> ≥ BMI** 30 kg/m2 </td> <td> 3 </td> <td> 6.8 </td> </tr> <tr> <td> PEGs suture-free technique </td> <td> 6 </td> <td> 13.6 </td> </tr> <tr> <td> PEGs could not be performed </td> <td> </td> <td> </td> </tr> <tr> <td> Non dilatable stenosis </td> <td> 26 </td> <td> 59.1 </td> </tr> <tr> <td> Neoplasias affecting stomach </td> <td> 3 </td> <td> 6.8 </td> </tr> <tr> <td> Gastric ulcer perforation </td> <td> 2 </td> <td> 4.5 </td> </tr> <tr> <td> Patients with ascites </td> <td> 2 </td> <td> 4.5 </td> </tr> <tr> <td> Partial gastrectomy </td> <td> 1 </td> <td> 2.3 </td> </tr> <tr> <td> Respiratory failure associated to supine position </td> <td> 1 </td> <td> 2.3 </td> </tr> </table>	PMC2717113_table_0

<table border="1" class="dataframe"> <tr> <th> Name </th> <th> Description </th> </tr> <tr> <td> C2 </td> <td> complement component 2 </td> </tr> <tr> <td> PMP22 </td> <td> peripheral myelin protein 22 </td> </tr> <tr> <td> SDC1 </td> <td> syndecan 1 </td> </tr> <tr> <td> COL11A1 </td> <td> collagen, type XI, alpha 1 </td> </tr> <tr> <td> ITGB4 </td> <td> integrin, beta 4 </td> </tr> <tr> <td> DCN </td> <td> decorin </td> </tr> <tr> <td> THBS4 </td> <td> thrombospondin 4 </td> </tr> <tr> <td> COL1A1 </td> <td> collagen, type I, alpha 1 </td> </tr> <tr> <td> IFIT1 </td> <td> interferon-induced protein with tetratricopeptide repeats 1 </td> </tr> <tr> <td> LUM </td> <td> lumican </td> </tr> <tr> <td> MMP9 </td> <td> matrix metalloproteinase 9 </td> </tr> <tr> <td> COL3A1 </td> <td> collagen, type III, alpha 1 </td> </tr> <tr> <td> COL1A2 </td> <td> collagen, type I, alpha 2 </td> </tr> <tr> <td> JAK1 </td> <td> Janus kinase 1 </td> </tr> <tr> <td> MMP12 </td> <td> matrix metalloproteinase 12 </td> </tr> <tr> <td> TNFSF10 </td> <td> tumour necrosis factor (ligand) superfamily, member 10 </td> </tr> <tr> <td> HSPA4 </td> <td> heat shock 70 kDa protein 4 </td> </tr> <tr> <td> FBLN2 </td> <td> ﬁ bulin 2 </td> </tr> <tr> <td> SFRP2 </td> <td> secreted frizzled-related protein 2 </td> </tr> <tr> <td> COL15A1 </td> <td> collagen, type XV, alpha 1 </td> </tr> <tr> <td> FBLN1 </td> <td> ﬁ bulin-1 </td> </tr> <tr> <td> GEM </td> <td> GTP binding protein </td> </tr> <tr> <td> MATN2 </td> <td> matrilin 2 </td> </tr> <tr> <td> CCL21 </td> <td> chemokine (C-C motif) ligand 21 </td> </tr> <tr> <td> CCL19 </td> <td> chemokine (C-C motif) ligand 19 </td> </tr> <tr> <td> SLCO2A1 </td> <td> solute carrier organic anion transporter family, member 2A1 </td> </tr> <tr> <td> MFAP5 </td> <td> microﬁ brillar-associated protein 5 </td> </tr> <tr> <td> CXCL14 </td> <td> chemokine (C-X-C motif) ligand 14 </td> </tr> <tr> <td> PRG4 </td> <td> proteoglycan 4 </td> </tr> <tr> <td> CCL13 </td> <td> chemokine (C-C motif) ligand 13 </td> </tr> <tr> <td> CCL14 </td> <td> chemokine (C-C motif) ligand 14 </td> </tr> <tr> <td> CCL15 </td> <td> chemokine (C-C motif) ligand 15 </td> </tr> </table>

PMC2716678_table_3

<table border="1" class="dataframe"> <tr> <th> </th> <th> True normal tissues </th> <th> True tumor tissues </th> </tr> <tr> <td> Predicted as normal tissues </td> <td> 1 </td> <td> 1 </td> </tr> <tr> <td> Predicted as tumor tissues </td> <td> 5 </td> <td> 41 </td> </tr> </table>

PMC2716681_table_0

<table border="1" class="dataframe"><tr><td></td><td></td><td>Batch I Analysis</td><td></td><td></td></tr><tr><td></td><td>Organ donor (N)</td><td>Adjacent to tumor (A)</td><td>Tumor (T)</td><td>Total</td></tr><tr><td>Liver</td><td>21</td><td>30</td><td>43</td><td>94</td></tr><tr><td>Prostate</td><td>23</td><td>59</td><td>66</td><td>148</td></tr><tr><td></td><td></td><td>Batch II Analysis</td><td></td><td></td></tr><tr><td></td><td>Organ donor (N)</td><td>Tumor (T)</td><td></td><td>Total</td></tr><tr><td>Liver</td><td>21</td><td>43</td><td></td><td>64</td></tr><tr><td>Prostate</td><td>23</td><td>66</td><td></td><td>89</td></tr><tr><td>Lung</td><td>17</td><td>134</td><td></td><td>151</td></tr><tr><td>Bladder</td><td>5</td><td>57</td><td></td><td>62</td></tr></table>

PMC2716681_table_1

<table border="1" class="dataframe"><tr><td></td><td colspan="2">Liver vs. Prostate</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>pro→liv</td><td>pro→pro</td><td>liv→pro</td></tr><tr><td>All genes</td><td>96.5%</td><td>66.3%</td><td>93.9%</td><td>47.4%</td></tr><tr><td>Common signature</td><td>96.5%</td><td>93.0%</td><td>98.8%</td><td>96.3%</td></tr><tr><td></td><td colspan="2">Liver vs. Prostate</td><td></td><td></td></tr><tr><td>All genes</td><td>92.6%</td><td>77.9%</td><td>96.6%</td><td>54.6%</td></tr><tr><td>Common signature</td><td>98.2%</td><td>96.0%</td><td>98.3%</td><td>96.6%</td></tr><tr><td></td><td colspan="2">Liver vs. Prostate</td><td></td><td></td></tr><tr><td>All genes</td><td>79.9%</td><td>51.9%</td><td>71.4%</td><td>55.7%</td></tr><tr><td>Common signature</td><td>75.6%</td><td>74.7%</td><td>66.7%</td><td>65.1%</td></tr></table>

PMC2716681_table_2

<table border="1" class="dataframe"><tr><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>pro→liv</td><td>pro→pro</td><td>liv→pro</td></tr><tr><td>All genes</td><td>96.51%</td><td>66.28%</td><td>93.94%</td><td>47.36%</td></tr><tr><td>Common signature</td><td>97.67%</td><td>97.67%</td><td>95.55%</td><td>94.14%</td></tr><tr><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>lun→liv</td><td>lun→lun</td><td>liv→lun</td></tr><tr><td>All genes</td><td>96.51%</td><td>56.98%</td><td>90.72%</td><td>45.32%</td></tr><tr><td>Common signature</td><td>95.23%</td><td>93.02%</td><td>95.94%</td><td>94.72%</td></tr><tr><td></td><td colspan="2">Lung</td><td></td><td></td></tr><tr><td></td><td>lun→lun</td><td>pro→lun</td><td>pro→pro</td><td>lun→pro</td></tr><tr><td>All genes</td><td>90.72%</td><td>69.03%</td><td>93.94%</td><td>62.88%</td></tr><tr><td>Common signature</td><td>94.82%</td><td>94.45%</td><td>79.61%</td><td>72.76%</td></tr><tr><td></td><td colspan="2">Liver</td><td></td><td></td></tr><tr><td></td><td>liv→liv</td><td>bla→liv</td><td>bla→bla</td><td>liv→bla</td></tr><tr><td>All genes</td><td>96.51%</td><td>62.79%</td><td>88.60%</td><td>49.65%</td></tr><tr><td>Common signature</td><td>91.74%</td><td>91.86%</td><td>98.25%</td><td>98.25%</td></tr><tr><td></td><td colspan="2">Prostate</td><td></td><td></td></tr><tr><td></td><td>pro→pro</td><td>bla→pro</td><td>bla→bla</td><td>pro→bla</td></tr><tr><td>All genes</td><td>93.94%</td><td>36.30%</td><td>88.60%</td><td>42.63%</td></tr><tr><td>Common signature</td><td>92.92%</td><td>86.86%</td><td>97.81%</td><td>88.25%</td></tr><tr><td></td><td colspan="2">Lung</td><td></td><td></td></tr><tr><td></td><td>lun→lun</td><td>bla→lun</td><td>bla→bla</td><td>lun→bla</td></tr><tr><td>All genes</td><td>90.72%</td><td>51.87%</td><td>88.60%</td><td>50.88%</td></tr><tr><td>Common signature</td><td>89.38%</td><td>85.91%</td><td>97.37%</td><td>85.61%</td></tr></table>

PMC2716681_table_3

<table border="1" class="dataframe"> <tr> <th> </th> <th> </th> <th colspan="4"> Test data </th> </tr> <tr> <th> </th> <th> </th> <th> Liver </th> <th> Prostate </th> <th> Lung </th> <th> Bladder </th> </tr> <tr> <td rowspan="4"> Training data </td> <td> Liver </td> <td> 96.5% (69)* </td> <td> (225)+ 94.1% </td> <td> (119)+ 94.7% </td> <td> (53)+ 98.3% </td> </tr> <tr> <td> Prostate </td> <td> (225)+ 97.7% </td> <td> 93.9% (55)* </td> <td> (288)+ 94.5% </td> <td> (10)+ 88.3% </td> </tr> <tr> <td> Lung </td> <td> (119)+ 93.0% </td> <td> (288)+ 72.8% </td> <td> 90.7% (57)* </td> <td> (19)+ 85.6% </td> </tr> <tr> <td> Bladder </td> <td> (53)+ 91.9% </td> <td> (10)+ 86.9% </td> <td> (19)+ 85.9% </td> <td> 88.6% (135)* </td> </tr> </table>

PMC2716681_table_4

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> A2780 </th> <th colspan="2"> A2780/CDDP </th> <th colspan="2"> SKOV3 </th> </tr> <tr> <th> </th> <th> control </th> <th> BRCA1 si </th> <th> control </th> <th> BRCA1 si </th> <th> control </th> <th> BRCA1 si </th> </tr> <tr> <td> G1 </td> <td> 52.57±5.11% </td> <td> 50.03±4.88% </td> <td> 48.87±4.76% </td> <td> 44.77±5.71% </td> <td> 45.07±4.1% </td> <td> 43.03±2.71% </td> </tr> <tr> <td> S </td> <td> 16.43±3.18% </td> <td> 19.33±2.81% </td> <td> 10.89±2.18% </td> <td> 10.40±3.23% </td> <td> 9.43±5.18% </td> <td> 9.39±1.86% </td> </tr> <tr> <td> G2/M </td> <td> 19.73±2.50% </td> <td> 21.37±2.76% </td> <td> 28.83±2.44% </td> <td> 29.39±3.50% </td> <td> 23.03±1.50% </td> <td> 23.99±2.90% </td> </tr> </table>

PMC2716781_table_0

<table border="1" class="dataframe"> <tr> <th> Group </th> <th> Site </th> <th> n </th> <th> Women/Men </th> <th> Age (years) </th> <th> BMI (kg/m2) </th> </tr> <tr> <td rowspan="4"> Control </td> <td> UK </td> <td> 21 </td> <td> 20/1 </td> <td> 40.5 ± 11.0 </td> <td> 25.4 ± 3.8 </td> </tr> <tr> <td> Australia </td> <td> 16 </td> <td> 12/4 </td> <td> 44.5 ± 12.1 </td> <td> 24.3 ± 5.1 </td> </tr> <tr> <td> Spain </td> <td> 23 </td> <td> 17/6 </td> <td> 38.5 ± 11.1 </td> <td> 23.0 ± 2.6 </td> </tr> <tr> <td> Total </td> <td> 60 </td> <td> 49/11 </td> <td> 40.8 ± 11.4 </td> <td> 24.2 ± 3.8 </td> </tr> <tr> <td rowspan="4"> Routes </td> <td> UK </td> <td> 21 </td> <td> 19/2 </td> <td> 43.8 ± 10.2 </td> <td> 25.2 ± 4.1 </td> </tr> <tr> <td> Australia </td> <td> 19 </td> <td> 13/6 </td> <td> 43.3 ± 10.0 </td> <td> 26.7 ± 4.4 </td> </tr> <tr> <td> Spain </td> <td> 20 </td> <td> 13/7 </td> <td> 39.4 ± 7.0 </td> <td> 23.5 ± 2.8 </td> </tr> <tr> <td> Total </td> <td> 60 </td> <td> 45/15 </td> <td> 42.1 ± 9.2 </td> <td> 25.1 ± 4.0 </td> </tr> <tr> <td rowspan="4"> Incidental </td> <td> UK </td> <td> 21 </td> <td> 18/3 </td> <td> 39.8 ± 10.4 </td> <td> 25.1 ± 3.4 </td> </tr> <tr> <td> Australia </td> <td> 14 </td> <td> 11/3 </td> <td> 43.2 ± 10.3 </td> <td> 28.1 ± 6.0 </td> </tr> <tr> <td> Spain </td> <td> 24 </td> <td> 18/6 </td> <td> 40.8 ± 8.9 </td> <td> 24.0 ± 3.1 </td> </tr> <tr> <td> Total </td> <td> 59 </td> <td> 4712 </td> <td> 41.0 ± 9.7 </td> <td> 25.4 ± 4.3 </td> </tr> </table>

PMC2717045_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="5"> Risk groups </th> <th> </th> </tr> <tr> <th> Country </th> <th> MSM </th> <th> IDUs </th> <th> Heterosexuals </th> <th> Others </th> <th> Unknown </th> <th> Sum </th> </tr> <tr> <td> United Kingdom (GBR) </td> <td> 59 (66%) </td> <td> 0 (0%) </td> <td> 6 (7%) </td> <td> 0 (0%) </td> <td> 25 (28%) </td> <td> 90 </td> </tr> <tr> <td> Austria (AUT) </td> <td> 18 (20%) </td> <td> 5(6%) </td> <td> 7 (8%) </td> <td> 0 (0%) </td> <td> 60 (67%) </td> <td> 90 </td> </tr> <tr> <td> Belgium (BEL) </td> <td> 56 (65%) </td> <td> 3 (3%) </td> <td> 11 (13%) </td> <td> 4 (5%) </td> <td> 12 (14%) </td> <td> 86 </td> </tr> <tr> <td> Denmark (DNK) </td> <td> 15 (17%) </td> <td> 4 (4%) </td> <td> 7 (8%) </td> <td> 0 (0%) </td> <td> 64 (71%) </td> <td> 90 </td> </tr> <tr> <td> Spain (ESP) </td> <td> 46 (51%) </td> <td> 21 (23%) </td> <td> 17 (19%) </td> <td> 0 (0%) </td> <td> 6 (7%) </td> <td> 90 </td> </tr> <tr> <td> Germany (DEU) </td> <td> 85 (94%) </td> <td> 0 (0%) </td> <td> (0%) </td> <td> 0 (0%) </td> <td> 5 (6%) </td> <td> 90 </td> </tr> <tr> <td> Greece (GRC) </td> <td> 39 (53%) </td> <td> 3 (4%) </td> <td> 8 (11%) </td> <td> 1 (1%) </td> <td> 22 (30%) </td> <td> 73 </td> </tr> <tr> <td> Israel (ISR) </td> <td> 15 (44%) </td> <td> 8 (24%) </td> <td> 7 (21%) </td> <td> 1 (3%) </td> <td> 3 (9%) </td> <td> 34 </td> </tr> <tr> <td> Italy (ITA) </td> <td> 31 (34%) </td> <td> 15 (17%) </td> <td> 32 (36%) </td> <td> 0 (0%) </td> <td> 12 (13%) </td> <td> 90 </td> </tr> <tr> <td> Luxembourg (LUX) </td> <td> 50 (56%) </td> <td> 15 (17%) </td> <td> 19 (21%) </td> <td> 0 (0%) </td> <td> 6 (7%) </td> <td> 90 </td> </tr> <tr> <td> Netherlands (NLD) </td> <td> 57 (68%) </td> <td> 7 (8%) </td> <td> 15 (18%) </td> <td> 0 (0%) </td> <td> 5 (6%) </td> <td> 84 </td> </tr> <tr> <td> Norway (NOR) </td> <td> 19 (73%) </td> <td> 1 (4%) </td> <td> 5 (19%) </td> <td> 0 (0%) </td> <td> 1 (4%) </td> <td> 26 </td> </tr> <tr> <td> Poland (POL) </td> <td> 12 (13%) </td> <td> 42 (47%) </td> <td> 19 (21%) </td> <td> 0 (0%) </td> <td> 17 (19%) </td> <td> 90 </td> </tr> <tr> <td> Portugal (PRT) </td> <td> 27 (30%) </td> <td> 16 (18%) </td> <td> 35 (39%) </td> <td> 0 (0%) </td> <td> 12 (13%) </td> <td> 90 </td> </tr> <tr> <td> Serbia </td> <td> 22 (50%) </td> <td> 6 (14% </td> <td> 16 (36%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 44 </td> </tr> <tr> <td> Sweden (SWE) </td> <td> 44 (49%) </td> <td> 3 (3%) </td> <td> 10 (11%) </td> <td> 0 (0%) </td> <td> 33 (37%) </td> <td> 90 </td> </tr> <tr> <td> Switzerland (CHE) </td> <td> 48 (53%) </td> <td> 10 (11%) </td> <td> 28 (31%) </td> <td> 0 (0%) </td> <td> 4 (4%) </td> <td> 90 </td> </tr> <tr> <td> Sum </td> <td> 643 (48%) </td> <td> 159 (12%) </td> <td> 242 (18%) </td> <td> 6 (0.5%) </td> <td> 287 (21%) </td> <td> 1337 </td> </tr> </table>

PMC2717046_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th> White (291) </th> <th> Hispanic (22) </th> <th> Black (12) </th> <th> Asian (5) </th> <th> Other (15) </th> </tr> <tr> <td> SNAP </td> <td> 0.709 </td> <td> 0.750 </td> <td> 1.240 </td> <td> 0.818 </td> <td> 0.659 </td> </tr> <tr> <td> PAML </td> <td> 0.839 </td> <td> 0.826 </td> <td> 1.411 </td> <td> 1.346 </td> <td> 0.751 </td> </tr> <tr> <td> HYPHY </td> <td> 0.949 </td> <td> 0.729 </td> <td> 1.453 </td> <td> 0.720 </td> <td> 1.202 </td> </tr> </table>

PMC2717047_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Race </th> <th colspan="2"> Race by treatment </th> </tr> <tr> <th> Method </th> <th> ANOVA </th> <th> Corrected pairwise t-tests </th> <th> ANOVA </th> <th> lm coefficient </th> </tr> <tr> <td> SNAP </td> <td> (0.011) </td> <td> black vs hispanic (0.020) black vs other (0.013) black vs white (0.004) </td> <td> (0.025) </td> <td> black placebo (0.001) </td> </tr> <tr> <td> PAML </td> <td> (0.019) </td> <td> black vs hispanic (0.047) black vs other (0.047) black vs white (0.033) </td> <td> </td> <td> black placebo (0.016) </td> </tr> <tr> <td> HYPHY </td> <td> </td> <td> </td> <td> </td> <td> black placebo (0.015) </td> </tr> </table>

PMC2717047_table_1

<table border="1" class="dataframe"> <tr> <th> Analyte </th> <th> Collision energy (eV) </th> <th> Collision exit potential (V) </th> <th> Declustering potential (V) </th> <th> Entrance potential (V) </th> </tr> <tr> <td> myo-inositol </td> <td> -10.0 </td> <td> -5.0 </td> <td> -70.0 </td> <td> -10.0 </td> </tr> <tr> <td> [2H6]-myo-inositol </td> <td> -18.0 </td> <td> -9.0 </td> <td> -70.0 </td> <td> -10.0 </td> </tr> </table>

PMC2717050_table_0

PMC2717051_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th rowspan="2"> Time 1 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 2 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 3 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> </tr> <tr> <th> </th> </tr> <tr> <td> Total Difficulties </td> <td> 20.15 </td> <td> 5.19 </td> <td> 46 </td> <td> 17.41 </td> <td> 6.31 </td> <td> 32 </td> <td> 15.06 </td> <td> 8.36 </td> <td> 17 </td> </tr> <tr> <td> Pro-Social Behaviour </td> <td> 6.09 </td> <td> 2.3 </td> <td> 46 </td> <td> 6.38 </td> <td> 2.67 </td> <td> 32 </td> <td> 6.2 </td> <td> 3.22 </td> <td> 17 </td> </tr> <tr> <td> Hyperactivity </td> <td> 5.8 </td> <td> 2.19 </td> <td> 46 </td> <td> 5.44 </td> <td> 2.42 </td> <td> 32 </td> <td> 4.71 </td> <td> 2.73 </td> <td> 17 </td> </tr> <tr> <td> Conduct Problems </td> <td> 4 </td> <td> 2.07 </td> <td> 46 </td> <td> 3.69 </td> <td> 2.15 </td> <td> 32 </td> <td> 2.76 </td> <td> 2.44 </td> <td> 17 </td> </tr> <tr> <td> Emotional Difficulties </td> <td> 6.93 </td> <td> 1.89 </td> <td> 46 </td> <td> 5.63 </td> <td> 2.86 </td> <td> 32 </td> <td> 4.88 </td> <td> 2.96 </td> <td> 17 </td> </tr> <tr> <td> Peer Problems </td> <td> 3.41 </td> <td> 2.15 </td> <td> 46 </td> <td> 2.66 </td> <td> 2.35 </td> <td> 32 </td> <td> 2.53 </td> <td> 2.24 </td> <td> 17 </td> </tr> </table>

PMC2717051_table_1

PMC2717051_table_2

<table border="1" class="dataframe"> <tr> <th> </th> <th rowspan="2"> Time 1 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 2 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> <th rowspan="2"> Time 3 Mean </th> <th rowspan="2"> SD </th> <th rowspan="2"> N </th> </tr> <tr> <th> </th> </tr> <tr> <td> Challenges </td> <td> 12.76 </td> <td> 3.84 </td> <td> 46 </td> <td> 8.88 </td> <td> 3.95 </td> <td> 24 </td> <td> 6.65 </td> <td> 3.82 </td> <td> 13 </td> </tr> <tr> <td> Goals </td> <td> 6.14 </td> <td> 2.93 </td> <td> 46 </td> <td> 10.66 </td> <td> 4.18 </td> <td> 22 </td> <td> 11.35 </td> <td> 4.65 </td> <td> 13 </td> </tr> </table>

PMC2717051_table_3

<table border="1" class="dataframe"> <tr> <th> Parameters </th> <th> Oromo folksongs </th> <th> Remark </th> </tr> <tr> <td> Lyrics </td> <td> More than one issue is addressed </td> <td> With the exception to some of the folksongs, most of them describe various and more than one issues </td> </tr> <tr> <td> Vocal style </td> <td> Less ornamental to ornamental </td> <td> Sometimes melismatic or strophic forms exist </td> </tr> <tr> <td> Timber </td> <td> Soft to less harsh </td> <td> Occasionally strident and forced singing </td> </tr> <tr> <td> Performer arrangement </td> <td> Responsorial-leader chorus alternation is the dominant one </td> <td> At times chorus-chorus alternation style. Responsorial- leader chorus alternation of male songs is less often followed by acclamation of women group. Few Solo songs exist. </td> </tr> <tr> <td> Melody </td> <td> Have a narrow range up to a fifth interval; melodies are patterned in descending and ascending order; 2 or three melodies are used </td> <td> The melodic form of the folksong is strophic consisting of two to eight lines. The relationships among the lines do vary or are similar. Some of the folksongs have similar or different content. Most of the folk songs are monophonic and some are polyphonic (more than one melodic line). Most of the songs listed here for describing the bioecocultural heritages are sung without accompaniment of instruments and hence are predominantly vocal folksongs. </td> </tr> <tr> <td> Scale </td> <td> Major; natural minor; pentatonic major </td> <td> Most of the folksongs collected here are diatonic or pentatonic or prepentatonic </td> </tr> <tr> <td> Rhythm </td> <td> Hard to identify; not a major element; 3/4 or 6/8 </td> <td> The rhythm and metre are not similar throughout the folksongs described. Mostly they are non-metric as they are mostly vocal. The music has been described as primarily melodic with simple rhythmic accompaniments that can be similar or different. </td> </tr> <tr> <td> Song type </td> <td> Both secular and sacred </td> <td> Folksongs are impulsive creations which are not developed by artists in organized ways hence can have various foci. </td> </tr> <tr> <td> Qñt* </td> <td> Tzta and Bati </td> <td> Most of the folksongs are composed without notations. It might be the same composer or different who created both the words and the music. One of the major classes of the folksongs, the ballads are narrative songs for describing varieties which are identified by their texts. The instrumental folksongs commonly accompanied by drums in the region are used for dances. </td> </tr> </table>

PMC2717052_table_0

<table border="1" class="dataframe"> <tr> <th> Patient characteristics 16 </th> <th> Number of patients </th> <th> HER 2 +(%) </th> </tr> <tr> <td> Total Patients </td> <td> 73 </td> <td> 21 (28.8) </td> </tr> <tr> <td> Sex </td> <td> </td> <td> </td> </tr> <tr> <td rowspan="2"> Male The </td> <td> 69 </td> <td> 19 (27.5) </td> </tr> <tr> <td> 4 </td> <td> 2 (50) </td> </tr> <tr> <td> Stage </td> <td> </td> <td> </td> </tr> <tr> <td> Stage IIIB </td> <td> 30 </td> <td> 9 (30) </td> </tr> <tr> <td> Stage IV </td> <td> 43 </td> <td> 12 (27.9) </td> </tr> <tr> <td> Histopathology </td> <td> </td> <td> </td> </tr> <tr> <td> Adenocarcinoma </td> <td> 27 </td> <td> 11 (40.7) </td> </tr> <tr> <td> Squamous cell (Epidermoid) </td> <td> 34 </td> <td> 5 (14.7) </td> </tr> <tr> <td> Not otherwise specified (NOS) </td> <td> 12 </td> <td> 5 (41.6) </td> </tr> </table>

PMC2717055_table_0

PMC2717055_table_1

<table border="1" class="dataframe"> <tr> <th> Patient characteristics </th> <th> Number of patients </th> <th> CR+PR+SD </th> <th> PD </th> </tr> <tr> <td> Total Patients </td> <td> 73 </td> <td> 61(83.6%) </td> <td> 12 (16.4%) </td> </tr> <tr> <td> Sex </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Male </td> <td> 69 </td> <td> 58 (84%) </td> <td> 11 (16%) </td> </tr> <tr> <td> Female </td> <td> 4 </td> <td> 3(75%) </td> <td> 1 (25%) </td> </tr> <tr> <td> Stage </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Stage IIIB </td> <td> 30 </td> <td> 29(96.6%) </td> <td> 1(3.4%) </td> </tr> <tr> <td> Stage IV </td> <td> 43 </td> <td> 32 (74.4%) </td> <td> 11 (25.6%) </td> </tr> <tr> <td> Histopathology </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Adenocarcinoma </td> <td> 27 </td> <td> 21(78%) </td> <td> 6(22%) </td> </tr> <tr> <td> Squamous cell (Epidermoid) </td> <td> 34 </td> <td> 31(91.2%) </td> <td> 3 (8.8%) </td> </tr> <tr> <td> Not otherwise specified (NOS) </td> <td> 12 </td> <td> 9 (75%) </td> <td> 3 (25%) </td> </tr> </table>

PMC2717055_table_2

<table border="1" class="dataframe"> <tr> <th> GO term </th> <th> Level1 </th> <th> Genes2 </th> <th> ORFs3 </th> <th> Prot. DIP4 </th> <th> Prot.DIP/ ORFs (%) </th> <th> Prot. GOLD5 </th> <th> Prot.GOLD/ ORFs (%) </th> </tr> <tr> <td> Developmental process (BP) </td> <td> 1 </td> <td> 768 </td> <td> 757 </td> <td> 632 </td> <td> 83.5% </td> <td> 257 </td> <td> 34.0% </td> </tr> <tr> <td> Reproduction (BP) </td> <td> 1 </td> <td> 299 </td> <td> 298 </td> <td> 245 </td> <td> 82.2% </td> <td> 111 </td> <td> 37.3% </td> </tr> <tr> <td> Establishment of cellular localization (BP) </td> <td> 1 </td> <td> 573 </td> <td> 568 </td> <td> 452 </td> <td> 79.6% </td> <td> 188 </td> <td> 33.1% </td> </tr> <tr> <td> Response to stimulus (BP) </td> <td> 1 </td> <td> 670 </td> <td> 657 </td> <td> 514 </td> <td> 78.2% </td> <td> 207 </td> <td> 31.5% </td> </tr> <tr> <td> Ribonucleoprotein complex (CC) </td> <td> 2 </td> <td> 556 </td> <td> 459 </td> <td> 318 </td> <td> 69.3% </td> <td> 96 </td> <td> 20.9% </td> </tr> <tr> <td> Organelle envelope (CC) </td> <td> 2 </td> <td> 346 </td> <td> 345 </td> <td> 230 </td> <td> 66.7% </td> <td> 69 </td> <td> 20.0% </td> </tr> <tr> <td> Transcription regulator activity (MF) </td> <td> 1 </td> <td> 307 </td> <td> 303 </td> <td> 276 </td> <td> 91.1% </td> <td> 107 </td> <td> 35.3% </td> </tr> <tr> <td> Structural molecule activity (MF) </td> <td> 1 </td> <td> 307 </td> <td> 286 </td> <td> 231 </td> <td> 80.8% </td> <td> 75 </td> <td> 26.2% </td> </tr> <tr> <td rowspan="2"> Transporter activity (MF) </td> <td> 1 </td> <td> 380 </td> <td> 377 </td> <td> 297 </td> <td> 78.8% </td> <td> 63 </td> <td> 16.7% </td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> Average: 78.9% </td> <td> </td> <td> Average: 28.3% </td> </tr> </table>

PMC2717056_table_0

<table border="1" class="dataframe"><tr><td>GO term</td><td>N (P) DIP</td><td>N (P) GOLD</td><td>GO term</td><td>N (P) DIP</td><td>N (P) GOLD</td></tr><tr><td>Developmental process (32502)</td><td>632 (16)</td><td>257 (8)</td><td>Organelle envelope (31967)</td><td>230 (12)</td><td>69 (2)</td></tr><tr><td>Reproductive developmental process (3006)</td><td>26 (0)</td><td>13 (0)</td><td>Organelle inner membrane (19866)</td><td>105 (8)</td><td>27 (2)</td></tr><tr><td>Anatomical structure development (48856)</td><td>186 (15)</td><td>94 (8)</td><td>Organelle outer membrane (31968)</td><td>24 (0)</td><td>---</td></tr><tr><td>Cellular developmental process (48869)</td><td>450 (1)</td><td>169 (0)</td><td>Organelle envelope lumen (31970)</td><td>25 (0)</td><td>---</td></tr><tr><td rowspan="2">Aging (7568)</td><td>40 (0)</td><td>22 (0)</td><td>Nuclear envelope (5635)</td><td>86 (3)</td><td>35 (0)</td></tr><tr><td></td><td></td><td>Mitochondrial envelope (5740)</td><td>148 (9)</td><td>34 (2)</td></tr><tr><td>Reproduction (3)</td><td>245 (7)</td><td>111 (4)</td><td></td><td></td><td></td></tr><tr><td>Sexual reproduction (19953)</td><td>95 (0)</td><td>41 (0)</td><td>Transcription regulator activity (30528)</td><td>276 (14)</td><td>107 (5)</td></tr><tr><td>Asexual reproduction (19954)</td><td>74 (6)</td><td>44 (4)</td><td>Transcriptional activator activity (16563)</td><td>50 (0)</td><td>24 (0)</td></tr><tr><td>Reproductive process (22414)</td><td>207 (7)</td><td>88 (4)</td><td>Transcriptional repressor activity (16564)</td><td>35 (2)</td><td>13 (1)</td></tr><tr><td rowspan="2">Rep. of a single-celled organism (32505)</td><td>220 (7)</td><td>99 (4)</td><td>Transcription factor activity (3700)</td><td>45 (2)</td><td>13 (1)</td></tr><tr><td></td><td></td><td>RNA polymerase II transcription factor activity (3702)</td><td>112 (4)</td><td>44 (1)</td></tr><tr><td>Establishment of cellular localization (51649)</td><td>452 (21)</td><td>188 (10)</td><td>Transcriptional elongation regulator activity (3711)</td><td>14 (6)</td><td>---</td></tr><tr><td>Secretion by cell (32940)</td><td>206 (9)</td><td>84 (3)</td><td>Transcription cofactor activity (3712)</td><td>36 (1)</td><td>16 (0)</td></tr><tr><td>Establishment of nucleus localization (40023)</td><td>17 (0)</td><td>---</td><td></td><td></td><td></td></tr><tr><td rowspan="2">Intracellular transport (46907)</td><td>409 (21)</td><td>175 (10)</td><td>Structural molecule activity (5198)</td><td>231 (29)</td><td>75 (18)</td></tr><tr><td></td><td></td><td>Structural constituent of ribosome (3735)</td><td>115 (0)</td><td>21 (0)</td></tr><tr><td>Response to stimulus (50896)</td><td>514 (3)</td><td>207 (0)</td><td>Structural constituent of cytoskeleton (5200)</td><td>50 (29)</td><td>31 (18)</td></tr><tr><td>Response to endogenous stimulus (9719)</td><td>197 (3)</td><td>101 (0)</td><td></td><td></td><td></td></tr><tr><td>Cellular response to stimulus (51716)</td><td>13 (0)</td><td>---</td><td>Transporter Activity (5215)</td><td>297 (8)</td><td>63 (1)</td></tr><tr><td>Response to abiotic stimulus (9628)</td><td>83 (0)</td><td>32 (0)</td><td>Ion transport activity (15075)</td><td>111 (5)</td><td>16 (0)</td></tr><tr><td>Response to external stimulus (9605)</td><td>27 (0)</td><td>13 (0)</td><td>Carbohydrate transporter activity (15144)</td><td>26 (0)</td><td>---</td></tr><tr><td>Response to biotic stimulus (6907)</td><td>19 (0)</td><td>---</td><td>ATPase activity, coupled to movement of substances (43492)</td><td>41 (2)</td><td>---</td></tr><tr><td>Response to chemical stimulus (42221)</td><td>212 (0)</td><td>65 (0)</td><td>Amine transporter activity (5275)</td><td>27 (0)</td><td>---</td></tr><tr><td rowspan="2">Response to stress (6950)</td><td>370 (3)</td><td>159 (0)</td><td>Organic acid transporter activity (5342)</td><td>32 (0)</td><td>---</td></tr><tr><td></td><td></td><td>Carrier activity (5386)</td><td>67 (0)</td><td>13 (0)</td></tr><tr><td>Ribonucleoprotein complex (30529)</td><td>318 (64)</td><td>96 (12)</td><td>Intracellular transporter activity (5478)</td><td>28 (0)</td><td>17 (0)</td></tr><tr><td>Small nuclear ribonucleoprotein complex (30532)</td><td>58 (2)</td><td>24 (0)</td><td>Protein transporter activity (8565)</td><td>48 (1)</td><td>29 (1)</td></tr><tr><td>Preribosome (30684)</td><td>12 (4)</td><td>---</td><td>Lipid transporter activity (5319)</td><td>11(2)</td><td>---</td></tr><tr><td>Spliceosome (5681)</td><td>74 (12)</td><td>33 (2)</td><td></td><td></td><td></td></tr><tr><td>Small nucleolar ribonucleoprotein complex (5732)</td><td>49 (43)</td><td>10 (9)</td><td></td><td></td><td></td></tr><tr><td>Ribosome (5840)</td><td>156 (5)</td><td>45 (1)</td><td></td><td></td><td></td></tr><tr><td>Polysome (5844)</td><td>11 (0)</td><td>---</td><td></td><td></td><td></td></tr></table>

PMC2717056_table_1

<table border="1" class="dataframe"> <tr> <th> GO TERMS </th> <th> Coverage </th> <th> Purity (Average) </th> <th> Ambiguity </th> <th> Φ(average ± s.e.m.) </th> </tr> <tr> <td> Developmental process (32502) </td> <td> 63.6% (402/632) </td> <td> 62.2% </td> <td> 13.0% (74/570) </td> <td> 0.46 ± 0.02 </td> </tr> <tr> <td> Reproduction (3) </td> <td> 58.4% (142/245) </td> <td> 94.1% </td> <td> 0% (0/25) </td> <td> 0.38 ± 0.11 </td> </tr> <tr> <td> Establishment of cellular localization (51649) </td> <td> 66.8% (302/452) </td> <td> 88.4% </td> <td> 1.1% (3/264) </td> <td> 0.43 ± 0.10 </td> </tr> <tr> <td> Response to stimulus (50896) </td> <td> 56.4% (290/514) </td> <td> 77.5% </td> <td> 19.5% (32/164) </td> <td> 0.46 ± 0.05 </td> </tr> <tr> <td> Ribonucleoprotein complex (30529) </td> <td> 59.7% (190/318) </td> <td> 77.8% </td> <td> 12.8% (31/242) </td> <td> 0.64 ± 0.06 </td> </tr> <tr> <td> Organelle envelope (31967) </td> <td> 39.6% (91/230) </td> <td> 84.9% </td> <td> 1.2% (1/83) </td> <td> 0.47 ± 0.09 </td> </tr> <tr> <td> Transcription regulator activity (30528) </td> <td> 43.5% (120/276) </td> <td> 67.6% </td> <td> 15.0% (30/200) </td> <td> 0.40 ± 0.08 </td> </tr> <tr> <td> Structural molecule activity (5198) </td> <td> 39.8% (92/231) </td> <td> 95.6% </td> <td> 0% (0/165) </td> <td> 0.53 </td> </tr> <tr> <td> Transporter Activity (5215) </td> <td> 33.7% (100/297) </td> <td> 72.5% </td> <td> 6.4% (12/186) </td> <td> 0.43 ± 0.06 </td> </tr> </table>

PMC2717056_table_2

<table border="1" class="dataframe"> <tr> <th> GO TERMS </th> <th> Coverage </th> <th> Purity (Average) </th> <th> Ambiguity </th> <th> Φ(average ± s.e.m.) </th> </tr> <tr> <td> Developmental process (32502) </td> <td> 83.3% (214/257) </td> <td> 82.0% </td> <td> 7.2% (16/222) </td> <td> 0.51 ± 0.06 </td> </tr> <tr> <td> Reproduction (3) </td> <td> 96.4% (107/111) </td> <td> 82.5% </td> <td> 8.3% (1/12) </td> <td> 0.45 ± 0.03 </td> </tr> <tr> <td> Establishment of cellular localization (51649) </td> <td> 86.7% (163/188) </td> <td> 76.8% </td> <td> 46.2% (49/106) </td> <td> 0.37 ± 0.02 </td> </tr> <tr> <td> Response to stimulus (50896) </td> <td> 78.3% (162/207) </td> <td> 73.2% </td> <td> 32.1% (18/56) </td> <td> 0.48 ± 0.07 </td> </tr> <tr> <td> Ribonucleoprotein complex (30529) </td> <td> 82.3% (79/96) </td> <td> 70.7% </td> <td> 56.2% (41/73) </td> <td> 0.72 ± 0.03 </td> </tr> <tr> <td> Organelle envelope (31967) </td> <td> 87.0% (60/69) </td> <td> 79.5% </td> <td> 26.5% (9/34) </td> <td> 0.70 ± 0.05 </td> </tr> <tr> <td> Transcription regulator activity (30528) </td> <td> 39.3% (42/107) </td> <td> 64.7% </td> <td> 33.8% (26/77) </td> <td> 0.42 ± 0.03 </td> </tr> <tr> <td> Structural molecule activity (5198) </td> <td> 69.3% (52/75) </td> <td> 68.8% </td> <td> 42.3% (22/52) </td> <td> 0.91 </td> </tr> <tr> <td> Transporter Activity (5215) </td> <td> 87.3% (55/63) </td> <td> 93.6% </td> <td> 0.0% (0/50) </td> <td> 0.63 ± 0.13 </td> </tr> </table>

PMC2717056_table_3

<table border="1" class="dataframe"> <tr> <th> </th> <th> A priori Genetic Group </th> <th> Geneclass </th> <th> </th> <th> </th> <th> Structure </th> <th> </th> <th> </th> </tr> <tr> <td> </td> <td> </td> <td> RFLP </td> <td> SSR </td> <td> RFLP </td> <td> </td> <td> SSR </td> <td> </td> </tr> <tr> <td> Individuals </td> <td> </td> <td> </td> <td> </td> <td> Ancestry (%) </td> <td> CI </td> <td> Ancestry (%) </td> <td> CI </td> </tr> <tr> <td> AC663 </td> <td> A </td> <td> E 1.445 </td> <td> </td> <td> E 43.5 A 39 B 14.2 </td> <td> 0–100 0–100 0–61 </td> <td> </td> <td> </td> </tr> <tr> <td> CC604 </td> <td> C </td> <td> - </td> <td> E 3.224 </td> <td> </td> <td> - </td> <td> E 49.1 C 47.4 </td> <td> 23.3–76.2 18.4–73.5 </td> </tr> <tr> <td> CC658 </td> <td> C </td> <td> - </td> <td> D 5.010 </td> <td> </td> <td> - </td> <td> D 56.3 A 21.2 </td> <td> 24.8–83.6 0–71.9 </td> </tr> <tr> <td> DC186 </td> <td> D </td> <td> - </td> <td> - </td> <td> D 64 E 16 A 16 </td> <td> 36.1–86.5 0–52.8 0–54.2 </td> <td> D 57.9 A 33.5 </td> <td> 29.6–84 0–68.3 </td> </tr> <tr> <td> DC194 </td> <td> D </td> <td> - </td> <td> - </td> <td> D 37.5 E 29.6 A 31.6 </td> <td> 0–66.1 0–85.8 0–94.2 </td> <td> D 72.6 E 25.3 </td> <td> 48.3–94.4 0–50.3 </td> </tr> <tr> <td> DC345 </td> <td> D </td> <td> A 0.579 </td> <td> E 0.526 </td> <td> D 33.7 E 30 A 34.3 </td> <td> 0–65.2 0–97.3 0–997 </td> <td> D 51.5 E 38.7 </td> <td> 26.7–74.7 12.9–65.2 </td> </tr> <tr> <td> DC350 </td> <td> D </td> <td> - </td> <td> E 1.553 </td> <td> D 54.5 E 20.7 A 21.7 </td> <td> 0–87.1 0–75.5 0–91.7 </td> <td> D 42.4 E 51.6 </td> <td> 19.8–65.5 14.2–76.9 </td> </tr> <tr> <td> DC358 </td> <td> D </td> <td> - </td> <td> - </td> <td> D 49.9 E 21 A 21.5 </td> <td> 12.1–77.9 0–66.6 0–68.5 </td> <td> D 64.3 E 21.2 </td> <td> 42.6–83.7 0–51.2 </td> </tr> </table>

PMC2717059_table_0

PMC2717059_table_1

<table border="1" class="dataframe"> <tr> <th> Variable, % unless otherwise indicated </th> <th> EuroSCORE > 20, n = 237 </th> <th> EuroSCORE ≤ 20, n = 1,184 </th> </tr> <tr> <td> Critical preoperative state* </td> <td> 24.5 </td> <td> 1.0 </td> </tr> <tr> <td> Emergency surgery </td> <td> 10.1 </td> <td> 0.9 </td> </tr> <tr> <td> Concomitant thoracic aortic surgery </td> <td> 16.5 </td> <td> 5.7 </td> </tr> <tr> <td> Concomitant CABG </td> <td> 58.7 </td> <td> 42.2 </td> </tr> <tr> <td> Type of prosthesis </td> <td> </td> <td> </td> </tr> <tr> <td> Bioprosthesis (tissue valve) Mechanical valve Homograft </td> <td> 84.0 13.5 2.5 </td> <td> 81.7 17.6 0.8 </td> </tr> <tr> <td> Cardiopulmonary bypass time, mean min ± SD </td> <td> 178.5 ± 64.4 </td> <td> 148.8 ± 51.8 </td> </tr> <tr> <td> Aortic clamp time, mean min ± SD </td> <td> 122.8 ± 47.0 </td> <td> 106.7 ± 37.8 </td> </tr> <tr> <td> Prosthetic valve indexed EOA§<0.75 cm2/m2 </td> <td> 4.7 </td> <td> 10.4 </td> </tr> </table>

PMC2717063_table_0

<table border="1" class="dataframe"> <tr> <th> Outcome, % </th> <th> EuroSCORE > 20, n = 237 </th> <th> ≤ EuroSCORE 20, n = 1,184 </th> <th> P </th> </tr> <tr> <td> Mortality (in-hospital or within 30 days of surgery) </td> <td> 11.4 </td> <td> 3.2 </td> <td> <0.0001 </td> </tr> <tr> <td> In-hospital events </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Ventilation > 24 hours </td> <td> 27.9 </td> <td> 9.3 </td> <td> <0.0001 </td> </tr> <tr> <td> Length of stay > 9 days </td> <td> 59.1 </td> <td> 28.1 </td> <td> <0.0001 </td> </tr> <tr> <td> Stroke </td> <td> 5.1 </td> <td> 2.3 </td> <td> 0.02 </td> </tr> <tr> <td> Atrial fibrillation (new onset) </td> <td> 31.7 </td> <td> 28.4 </td> <td> 0.31 </td> </tr> <tr> <td> Erythrocyte transfusion </td> <td> 73.0 </td> <td> 34.5 </td> <td> <0.0001 </td> </tr> <tr> <td> Permanent pacemaker implantation </td> <td> 10.1 </td> <td> 5.4 </td> <td> 0.01 </td> </tr> </table>

PMC2717063_table_1

<table border="1" class="dataframe"> <tr> <th> WHO </th> <th> n </th> <th> Age (yr) </th> <th> MGb(%) </th> <th> Weight (g) </th> <th> Masaoka I </th> <th> Masaoka II </th> <th> Masaoka III </th> <th> Masaoka IV </th> </tr> <tr> <td> A </td> <td> 15 </td> <td> 64.0 ± 9.8 </td> <td> 26.6 </td> <td> 164.0 ± 293.0 </td> <td> 10 </td> <td> 4 </td> <td> 1 </td> <td> 0 </td> </tr> <tr> <td> AB </td> <td> 21 </td> <td> 58.5 ± 10.6 </td> <td> 14.2 </td> <td> 114.0 ± 131.4 </td> <td> 15 </td> <td> 2 </td> <td> 4 </td> <td> 0 </td> </tr> <tr> <td> B1 </td> <td> 13 </td> <td> 58.6 ± 6.3 </td> <td> 23.0 </td> <td> 103.0 ± 99.5 </td> <td> 9 </td> <td> 2 </td> <td> 1 </td> <td> 1 </td> </tr> <tr> <td> B2 </td> <td> 13 </td> <td> 51.8 ± 20.3 </td> <td> 53.0 </td> <td> 125.0 ± 108.6 </td> <td> 5 </td> <td> 6 </td> <td> 0 </td> <td> 2 </td> </tr> <tr> <td> B3 </td> <td> 3 </td> <td> 67.8 ± 23.4 </td> <td> 66.6 </td> <td> 166.0 ± 83.5 </td> <td> 1 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> C </td> <td> 19 </td> <td> 54.1 ± 13.4 </td> <td> 0 </td> <td> 139.0 ± 403.4 </td> <td> 2 </td> <td> 3 </td> <td> 3 </td> <td> 11 </td> </tr> <tr> <td> Total </td> <td> 84 </td> <td> - </td> <td> 22.6 </td> <td> - </td> <td> 42 </td> <td> 19 </td> <td> 9 </td> <td> 14 </td> </tr> </table>

PMC2717064_table_0

<table border="1" class="dataframe"> <tr> <th> Masaoka </th> <th> n </th> <th> R0-status </th> <th> N1 </th> <th> M1 </th> <th> Recurrence </th> <th> 5-year survival (%) </th> </tr> <tr> <td> I </td> <td> 42 </td> <td> 42 (100%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 97.6 </td> </tr> <tr> <td> II </td> <td> 19 </td> <td> 18 (94.7%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 1 (5.3%) </td> <td> 94.7 </td> </tr> <tr> <td> III </td> <td> 9 </td> <td> 6 (66.7%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 0 (0%) </td> <td> 66.7 </td> </tr> <tr> <td> IV </td> <td> 14 </td> <td> 5 (35.7%) </td> <td> 6 (42.8%) </td> <td> 8 (57.1) </td> <td> 1 (7%) </td> <td> 64.3 </td> </tr> </table>

PMC2717064_table_1

<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> n </th> <th> Pseudocapsula complete </th> <th> Pseudocapsula incomplete </th> <th> Pseudocapsula no capsula </th> <th> p-valueb </th> </tr> <tr> <td> Masaoka I </td> <td> 42 </td> <td> 38 </td> <td> 4 </td> <td> 0 </td> <td> 0.001 </td> </tr> <tr> <td> II </td> <td> 19 </td> <td> 1 </td> <td> 16 </td> <td> 2 </td> <td> </td> </tr> <tr> <td> III </td> <td> 9 </td> <td> 1 </td> <td> 3 </td> <td> 5 </td> <td> </td> </tr> <tr> <td> IV </td> <td> 14 </td> <td> 0 </td> <td> 3 </td> <td> 11 </td> <td> </td> </tr> <tr> <td> N-status N0 </td> <td> 79 </td> <td> 40 </td> <td> 24 </td> <td> 15 </td> <td> 0.042 </td> </tr> <tr> <td> N1 </td> <td> 5 </td> <td> 0 </td> <td> 2 </td> <td> 3 </td> <td> </td> </tr> <tr> <td> M-status M0 </td> <td> 76 </td> <td> 40 </td> <td> 25 </td> <td> 11 </td> <td> 0.001 </td> </tr> <tr> <td> M1 </td> <td> 8 </td> <td> </td> <td> 1 </td> <td> 7 </td> <td> </td> </tr> <tr> <td> Vessel infiltration </td> <td> 13 </td> <td> 0 </td> <td> 3 </td> <td> 9 </td> <td> 0.001 </td> </tr> <tr> <td> Pericard infiltration </td> <td> 14 </td> <td> 1 </td> <td> 1 </td> <td> 12 </td> <td> 0.001 </td> </tr> <tr> <td> Recurrence </td> <td> 2 </td> <td> 0 </td> <td> 1 </td> <td> 1 </td> <td> 0.047 </td> </tr> <tr> <td> Age (yr)c </td> <td> 84 </td> <td> 40 </td> <td> 26 </td> <td> 18 </td> <td> 0.44 </td> </tr> <tr> <td> Sex Male </td> <td> 45 </td> <td> 14 </td> <td> 17 </td> <td> 14 </td> <td> 0.004 </td> </tr> <tr> <td> Female </td> <td> 39 </td> <td> 26 </td> <td> 9 </td> <td> 4 </td> <td> </td> </tr> <tr> <td> MGd </td> <td> 19 </td> <td> 10 </td> <td> 6 </td> <td> 3 </td> <td> 0.86 </td> </tr> </table>

PMC2717064_table_2

<table border="1" class="dataframe"> <tr> <th> Risk factor </th> <th> Univariate analysis </th> <th colspan="3"> Multivariate analysisc </th> </tr> <tr> <th> </th> <th> p valueb </th> <th> Relative risk </th> <th> 95% Confidence interval </th> <th> p value </th> </tr> <tr> <td> R-status </td> <td> 0.0001 </td> <td> 3.9 </td> <td> 2.0 – 7.6 </td> <td> 0.001 </td> </tr> <tr> <td> Masaoka stagingd </td> <td> 0.0001 </td> <td> 2.0 </td> <td> 1.0 – 4.1 </td> <td> 0.020 </td> </tr> <tr> <td> Presence of a pseudocapsula </td> <td> 0.0002 </td> <td> - </td> <td> - </td> <td> 0.179 </td> </tr> <tr> <td> WHOd classificatione </td> <td> 0.0001 </td> <td> - </td> <td> - </td> <td> 0.181 </td> </tr> <tr> <td> Sex </td> <td> 0.562 </td> <td> - </td> <td> - </td> <td> 0.849 </td> </tr> <tr> <td> Age </td> <td> 0.360 </td> <td> - </td> <td> - </td> <td> 0.206 </td> </tr> </table>

PMC2717064_table_3

<table border="1" class="dataframe"> <tr> <th> Examination subject </th> <th> Date </th> <th> Format </th> <th> Reliability (KR20) </th> </tr> <tr> <td rowspan="2"> Generic clinical knowledge </td> <td> March </td> <td> EMQ </td> <td> 0.758 </td> </tr> <tr> <td> August </td> <td> EMQ </td> <td> 0.730 </td> </tr> <tr> <td> Care of the Elderly and </td> <td> March </td> <td> SBA </td> <td> 0.760 </td> </tr> <tr> <td> General Medical Specialties </td> <td> August </td> <td> SBA </td> <td> 0.757 </td> </tr> <tr> <td rowspan="2"> General Medicine, Medicine in the Community and Surgery </td> <td> March </td> <td> SBA </td> <td> 0.760 </td> </tr> <tr> <td> August </td> <td> SBA </td> <td> 0.705 </td> </tr> </table>

PMC2717066_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th> Intervention group n = (%) </th> <th> Control group n = (%) </th> <th> Total n = (%) </th> <th> Group differences </th> <th> p value </th> </tr> <tr> <td> </td> <td colspan="2"> Total n = (%)Tutor </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Total </td> <td> 6 </td> <td> 6 </td> <td> 12 </td> <td> n/a </td> <td> n/a </td> </tr> <tr> <td> male </td> <td> 1 (16.7) </td> <td> 2 (33.3) </td> <td> 3 (25.0) </td> <td> n/a </td> <td> n/a </td> </tr> <tr> <td> white </td> <td> 6 (100.0) </td> <td> 5 (83.3) </td> <td> 11 (91.7) </td> <td> n/a </td> <td> n/a </td> </tr> <tr> <td> </td> <td colspan="2"> Student factors </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Total </td> <td> 177/348 (50.9) </td> <td> 171/348 (49.1) </td> <td> 348 (100.0) </td> <td> </td> <td> </td> </tr> <tr> <td> Mean age </td> <td> 22 yrs 4 months </td> <td> 22 yrs 4 months </td> <td> 22 yrs 4 months </td> <td> t(346) = 0.8 </td> <td> 0.94 </td> </tr> <tr> <td> white* </td> <td> 80/175 (45.7) </td> <td> 87/166 (52.5) </td> <td> 167/341 (49.0) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> Asian Indian, Pakistani, Bangladeshi </td> <td> 47/175 (26.9) </td> <td> 37/166 (22.3) </td> <td> 84/341 (34.0) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> Chinese </td> <td> 16/175 (9.1) </td> <td> 12/166 (7.2) </td> <td> 28/341 (8.2) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> All Other </td> <td> 32/175 (18.3) </td> <td> 30/166 (18.1) </td> <td> 62/341 (18.2) </td> <td> χ2 = 1.9; df = 3 </td> <td> 0.60 </td> </tr> <tr> <td> Male** </td> <td> 69/176 (39.2) </td> <td> 59/171 (34.5) </td> <td> 128/347 (36.9) </td> <td> χ2 = 0.8; df = 1 </td> <td> 0.36 </td> </tr> <tr> <td> Graduate entry*** </td> <td> 23/176 (13.1) </td> <td> 20/166 (12.1) </td> <td> 43/342 (12.6) </td> <td> χ2 = 0.1; df = 1 </td> <td> 0.75 </td> </tr> <tr> <td> With iBSC*** </td> <td> 107/176 (60.8) </td> <td> 101/166 (60.8) </td> <td> 208/342 (60.8) </td> <td> χ2 = 0.2; df = 1 </td> <td> 0.89 </td> </tr> <tr> <td> Oxford or Cambridge transfer </td> <td> 21/177 (11.9) </td> <td> 30/171 (17.5) </td> <td> 51/348 (14.7) </td> <td> χ2 = 2.2; df = 1 </td> <td> 0.13 </td> </tr> <tr> <td> Mean pre-intervention written z score </td> <td> 0.05 (SD = 1.0) </td> <td> -0.05 (SD = 1.0) </td> <td> 0.00 (SD = 1.0) </td> <td> t(343) = -0.9 </td> <td> 0.36 </td> </tr> <tr> <td> Mean Neuroticism score </td> <td> 8.1 (SD = 2.3) </td> <td> 7.8 (SD = 2.3) </td> <td> 8.0 (SD = 2.3) </td> <td> t(270) = -0.8 </td> <td> 0.45 </td> </tr> <tr> <td> Mean Conscientiousness score </td> <td> 11.3 (SD = 2.6) </td> <td> 11.3 (SD = 2.0) </td> <td> 11.3 (SD = 2.3) </td> <td> t(272) = 0.2 </td> <td> 0.86 </td> </tr> <tr> <td> Mean Openness score </td> <td> 11.1 (SD = 2.2) </td> <td> 10.9 (SD = 2.4) </td> <td> 11.0 (SD = 2.3) </td> <td> t(272) = -0.9 </td> <td> 0.39 </td> </tr> <tr> <td> Mean Agreeableness score </td> <td> 13.3 (SD = 1.6) </td> <td> 13.0 (SD = 1.6) </td> <td> 13.2 (SD = 1.6) </td> <td> t(268) = -1.8 </td> <td> 0.07 </td> </tr> <tr> <td> Mean Extraversion score </td> <td> 11.6 (SD = 2.1) </td> <td> 11.6 (SD = 1.8) </td> <td> 11.6 (SD = 1.9) </td> <td> t(271) = -0.13 </td> <td> 0.90 </td> </tr> <tr> <td> Mean Surface study score </td> <td> 14.9 (SD = 3.9) </td> <td> 14.7 (SD = 3.4) </td> <td> 14.8 (SD = 3.6) </td> <td> t(265) = -0.5 </td> <td> 0.61 </td> </tr> <tr> <td> Mean Strategic study score </td> <td> 18.5 (SD = 5.4) </td> <td> 17.7 (SD = 4.7) </td> <td> 18.1 (SD = 5.1) </td> <td> t(266) = -0.8 </td> <td> 0.45 </td> </tr> <tr> <td> Mean Deep study score </td> <td> 19.4 (SD = 4.1) </td> <td> 19.3 (SD = 3.9) </td> <td> 19.3 (SD = 4.0) </td> <td> t(267) = -0.3 </td> <td> 0.79 </td> </tr> <tr> <td> Mean GHQ (stress) score </td> <td> 11.4 (SD = 5.3) </td> <td> 10.2 (SD = 4.4) </td> <td> 10.8 (SD = 4.9) </td> <td> t(262) = -1.9 </td> <td> 0.06 </td> </tr> </table>

PMC2717066_table_1

<table border="1" class="dataframe"> <tr> <th> Ethnic group </th> <th> Condition </th> <th> Mean written z-score (SD) </th> <th> Mean OSCE z-score (SD) </th> <th> N </th> </tr> <tr> <td rowspan="2"> W </td> <td> Intervention </td> <td> 0.063 (0.90) </td> <td> 0.271 (0.96) </td> <td> 79 </td> </tr> <tr> <td> Control </td> <td> 0.244 (1.00) </td> <td> -0.002 (0.96) </td> <td> 84 </td> </tr> <tr> <td rowspan="2"> EM </td> <td> Intervention </td> <td> -0.098 (1.09) </td> <td> 0.001 (1.00) </td> <td> 95 </td> </tr> <tr> <td> Control </td> <td> -0.175 (0.96) </td> <td> -0.286 (0.97) </td> <td> 77 </td> </tr> </table>

PMC2717066_table_2

<table border="1" class="dataframe"> <tr> <th> Dimensions </th> <th> Word categories </th> <th> Type of word </th> <th> Group with highest frequency </th> <th> t </th> <th> Mean use by all students </th> <th> Mean Difference between groups </th> <th> p value </th> </tr> <tr> <td rowspan="2"> Standard linguistic dimensions </td> <td> % of dictionary words </td> <td> </td> <td> EM </td> <td> -2.0 </td> <td> 75.5 </td> <td> -1.2 </td> <td> 0.04 </td> </tr> <tr> <td> Total pronouns </td> <td> Pronoun </td> <td> EM </td> <td> -2.8 </td> <td> 10.9 </td> <td> -0.9 </td> <td> 0.01 </td> </tr> <tr> <td rowspan="4"> Psychologi-cal processes </td> <td> Affective or emotional processes </td> <td> Optimism and energy (certainty, pride, win) </td> <td> W </td> <td> 2.0 </td> <td> 0.9 </td> <td> 0.2 </td> <td> 0.05 </td> </tr> <tr> <td> Cognitive processes </td> <td> Cognitive processes </td> <td> EM </td> <td> -2.2 </td> <td> 0.1 </td> <td> -0.5 </td> <td> 0.03 </td> </tr> <tr> <td> Sensory and perceptual processes </td> <td> Hear (heard, listen, sound) </td> <td> EM </td> <td> -3.5 </td> <td> 0.9 </td> <td> -0.3 </td> <td> <0.001 </td> </tr> <tr> <td> Social Processes </td> <td> Communication (talk, share converse) </td> <td> EM </td> <td> -2.4 </td> <td> 2.2 </td> <td> -0.4 </td> <td> 0.02 </td> </tr> <tr> <td> Relativity </td> <td> Motion </td> <td> Motion (walk, move, go) </td> <td> EM </td> <td> -2.5 </td> <td> 0.9 </td> <td> -0.2 </td> <td> 0.01 </td> </tr> <tr> <td rowspan="2"> Personal Concerns </td> <td> Occupation </td> <td> Job or work (employ, boss, career) </td> <td> W </td> <td> 2.2 </td> <td> 1.1 </td> <td> 0.2 </td> <td> 0.03 </td> </tr> <tr> <td> Metaphysical issues </td> <td> Religion (God, church, rabbi) </td> <td> EM </td> <td> -2.1 </td> <td> 0.2 </td> <td> -0.2 </td> <td> 0.04 </td> </tr> </table>

PMC2717066_table_3

<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> Study aggregate </th> </tr> <tr> <td> Age (year), Median (IQR*) </td> <td> 35 (33–37) </td> </tr> <tr> <td> Gender (W:M) </td> <td> 43%/57% </td> </tr> <tr> <td> Married </td> <td> 65% </td> </tr> <tr> <td> Time from medical school to residency training (years), Median (IQR*) </td> <td> 5 (4–7) </td> </tr> <tr> <td> Visa status (J1/H1/Employment authorization) </td> <td> 88% </td> </tr> <tr> <td> Asian origin </td> <td> 59% </td> </tr> <tr> <td> USMLE Step 1, Median (IQR*) </td> <td> 85 (80–88) </td> </tr> <tr> <td> USMLE Step 2 Clinical skills, Median (IQR*) </td> <td> 82 (79–87) </td> </tr> <tr> <td> Pre-GME Clinical experience, n (%) </td> <td> 43/51 (84) </td> </tr> <tr> <td> Pre-GME Research Experience, n (%) </td> <td> 34/51 (66.7) </td> </tr> <tr> <td> US Externship, n (%) </td> <td> 14/51 (27.5) </td> </tr> <tr> <td> Pre-GME Awards, n (%) </td> <td> 26/51(50.1) </td> </tr> <tr> <td> ABIM examination pass, n (%) </td> <td> 49/51(96) </td> </tr> <tr> <td> Fellowship aspirants, n (%) </td> <td> 12/51 (23.5) </td> </tr> <tr> <td> Fellowship within 3 years after graduation, n (%) </td> <td> 8/51 (16) </td> </tr> </table>

PMC2717068_table_0

<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> Above PG level median (n = 18) </th> <th> Below PG level median (n = 33) </th> <th> *P value </th> </tr> <tr> <td> Age, median (range) in years </td> <td> 33 (31–40) </td> <td> 36 (31–47) </td> <td> < 0.05 </td> </tr> <tr> <td> Male:Female (ratio) </td> <td> 9:9 </td> <td> 20:13 </td> <td> NS </td> </tr> <tr> <td> Marital Status (unmarried: married) </td> <td> 5:13 </td> <td> 13:20 </td> <td> NS </td> </tr> <tr> <td> Asian/Others </td> <td> 3/5 </td> <td> 16/17 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 86 (76–97) </td> <td> 83 (75–96) </td> <td> NS </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 86 (77–93) </td> <td> 80 (75–92) </td> <td> < 0.05 </td> </tr> <tr> <td> Time from medical school to residency, median (range) in years </td> <td> 4 (1 – 14) </td> <td> 5 (1–17) </td> <td> NS </td> </tr> <tr> <td> Temporary Visa status (n) </td> <td> 16 </td> <td> 29 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Clinical Experience (n) </td> <td> 15 </td> <td> 28 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Research Experience (n) </td> <td> 12 </td> <td> 22 </td> <td> NS </td> </tr> <tr> <td> US Externship </td> <td> 7 </td> <td> 7 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Awards </td> <td> 9 </td> <td> 17 </td> <td> NS </td> </tr> </table>

PMC2717068_table_1

<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> Above US Median (n = 13) </th> <th> Below US Median (n = 38) </th> <th> *P value </th> </tr> <tr> <td> Age, median (range) in years </td> <td> 35 (32–42) </td> <td> 35.5 (31–47) </td> <td> NS </td> </tr> <tr> <td> **Male/Female (ratio) </td> <td> 11:2 </td> <td> 18: 20 </td> <td> < 0.05 </td> </tr> <tr> <td> Marital Status (unmarried/married) </td> <td> 8: 5 </td> <td> 25: 13 </td> <td> NS </td> </tr> <tr> <td> Asian/Others </td> <td> 9/4 </td> <td> 21/17 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 86 (76–97) </td> <td> 83 (75–96) </td> <td> < 0.05 </td> </tr> <tr> <td> USMLE step II Clinical Skills median (range) </td> <td> 86 (77–93) </td> <td> 80 (75–92) </td> <td> < 0.05 </td> </tr> <tr> <td> Time from medical school to residency, median (range) in years </td> <td> 4 (1 – 14) </td> <td> 5 (1–17) </td> <td> NS </td> </tr> <tr> <td> Temporary Visa status (n) </td> <td> 11 </td> <td> 34 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Clinical Experience (n) </td> <td> 15 </td> <td> 28 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Research Experience (n) </td> <td> 12 </td> <td> 22 </td> <td> NS </td> </tr> <tr> <td> US Externship </td> <td> 7 </td> <td> 7 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Awards </td> <td> 9 </td> <td> 17 </td> <td> NS </td> </tr> </table>

PMC2717068_table_2

<table border="1" class="dataframe"> <tr> <th> #Characteristics </th> <th> Above US Median </th> <th> Below US Median </th> <th> P value </th> </tr> <tr> <td colspan="2"> (Above median </td> <td> </td> <td> </td> </tr> <tr> <td> Male/Female (ratio) (unadjusted analysis) </td> <td> 22:10 </td> <td> 7: 12 </td> <td> < 0.05 </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 85 (77–97) </td> <td> 82 (75–96) </td> <td> NS </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 85.5 (75–93) </td> <td> 81 (76–87) </td> <td> NS </td> </tr> <tr> <td colspan="2"> (Above median </td> <td> </td> <td> </td> </tr> <tr> <td> Male/Female (ratio) (unadjusted analysis) </td> <td> 11: 3 </td> <td> 18: 19 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 86.5 (76–97) </td> <td> 82.5 (75–90) </td> <td> < 0.05 </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 85.5 (75–93) </td> <td> 81 (76–87) </td> <td> < 0.05 </td> </tr> </table>

PMC2717068_table_3

<table border="1" class="dataframe"> <tr> <th> Characteristics (units) </th> <th> Fellowship pursuing residents (n = 8) </th> <th> Others (n = 43) </th> <th> P value </th> </tr> <tr> <td> Age, median (range) in years </td> <td> 33 (31 – 39) </td> <td> 35 (31–47) </td> <td> NS </td> </tr> <tr> <td> Male/Female (ratio) </td> <td> 4:4 </td> <td> 25: 18 </td> <td> NS </td> </tr> <tr> <td> Marital status (unmarried/married) </td> <td> 6: 2 </td> <td> 27:16 </td> <td> NS </td> </tr> <tr> <td> Asian/Others </td> <td> 4/4 </td> <td> 26/17 </td> <td> NS </td> </tr> <tr> <td> #USMLE step I median (range) </td> <td> 85 (76–97) </td> <td> 85 (75–96) </td> <td> NS </td> </tr> <tr> <td> USMLE step II Clinical skills median (range) </td> <td> 82.5 (80–92) </td> <td> 82 (75–93) </td> <td> NS </td> </tr> <tr> <td> Time from medical school to residency, median (range) in years </td> <td> 5 (3 – 14) </td> <td> 5 (1–17) </td> <td> NS </td> </tr> <tr> <td> Visa status </td> <td> 7 </td> <td> 38 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Clinical Experience (n) </td> <td> 7 </td> <td> 36 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Research Experience (n) </td> <td> 5 </td> <td> 29 </td> <td> NS </td> </tr> <tr> <td> US Externship (n) </td> <td> 1 </td> <td> 13 </td> <td> NS </td> </tr> <tr> <td> Pre-GME Awards (n) </td> <td> 5 </td> <td> 21 </td> <td> NS </td> </tr> <tr> <td> Fellowship aspirants (n) </td> <td> 7 </td> <td> 5 </td> <td> < 0.05 </td> </tr> <tr> <td> GME Research (n) </td> <td> 7 </td> <td> 12 </td> <td> < 0.05 </td> </tr> </table>

PMC2717068_table_4

<table border="1" class="dataframe"> <tr> <th> Question </th> <th colspan="7"> Likert Scale </th> </tr> <tr> <th> How valuable has the student housing conditions survey, and discussion of findings, been for you? </th> <th> Extremely valuable </th> <th> 1 </th> <th> 2 </th> <th> 3 </th> <th> 4 </th> <th> 5 </th> <th> Not at all valuable </th> </tr> <tr> <td> </td> <td> No. </td> <td> 29 </td> <td> 60 </td> <td> 32 </td> <td> 12 </td> <td> 3 </td> <td> </td> </tr> <tr> <td> </td> <td> % </td> <td> 21% </td> <td> 44% </td> <td> 24% </td> <td> 9% </td> <td> 2% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your understanding of research methods? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 18 </td> <td> 52 </td> <td> 47 </td> <td> 13 </td> <td> 6 </td> <td> </td> </tr> <tr> <td> % </td> <td> 13% </td> <td> 38% </td> <td> 35% </td> <td> 10% </td> <td> 4% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your understanding of epidemiology? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 16 </td> <td> 41 </td> <td> 52 </td> <td> 20 </td> <td> 7 </td> <td> </td> </tr> <tr> <td> % </td> <td> 12% </td> <td> 30% </td> <td> 38% </td> <td> 15% </td> <td> 5% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your understanding of the environmental determinants of health? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 28 </td> <td> 69 </td> <td> 30 </td> <td> 7 </td> <td> 2 </td> <td> </td> </tr> <tr> <td> % </td> <td> 21% </td> <td> 51% </td> <td> 22% </td> <td> 5% </td> <td> 1% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your interest in public health? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 23 </td> <td> 58 </td> <td> 34 </td> <td> 12 </td> <td> 9 </td> <td> </td> </tr> <tr> <td> % </td> <td> 17% </td> <td> 43% </td> <td> 25% </td> <td> 9% </td> <td> 7% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey and seminar discussion improve your interest in health research? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 16 </td> <td> 48 </td> <td> 46 </td> <td> 15 </td> <td> 11 </td> <td> </td> </tr> <tr> <td> % </td> <td> 12% </td> <td> 35% </td> <td> 34% </td> <td> 11% </td> <td> 8% </td> <td> </td> </tr> <tr> <td rowspan="3"> Did this survey stimulate you to discuss housing and health issues with friends outside of class? </td> <td> Yes, often </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, never </td> </tr> <tr> <td> No. </td> <td> 30 </td> <td> 45 </td> <td> 43 </td> <td> 13 </td> <td> 5 </td> <td> </td> </tr> <tr> <td> % </td> <td> 22% </td> <td> 33% </td> <td> 32% </td> <td> 10% </td> <td> 4% </td> <td> </td> </tr> <tr> <td rowspan="3"> How much did this survey and seminar discussion challenge you to think? </td> <td> A great deal </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> Very Little </td> </tr> <tr> <td> No. </td> <td> 21 </td> <td> 63 </td> <td> 35 </td> <td> 11 </td> <td> 5 </td> <td> </td> </tr> <tr> <td> % </td> <td> 15% </td> <td> 46% </td> <td> 26% </td> <td> 8% </td> <td> 4% </td> <td> </td> </tr> <tr> <td rowspan="3"> Has this survey and seminar discussion made you more aware and concerned about societal problems? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 38 </td> <td> 57 </td> <td> 32 </td> <td> 4 </td> <td> 4 </td> <td> </td> </tr> <tr> <td> % </td> <td> 28% </td> <td> 42% </td> <td> 24% </td> <td> 3% </td> <td> 3% </td> <td> </td> </tr> <tr> <td rowspan="3"> Would you support use of this survey and seminar discussion for future 3rd year classes? </td> <td> Yes, greatly </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 4 </td> <td> 5 </td> <td> No, not at all </td> </tr> <tr> <td> No. </td> <td> 56 </td> <td> 49 </td> <td> 23 </td> <td> 6 </td> <td> 2 </td> <td> </td> </tr> <tr> <td> % </td> <td> 41% </td> <td> 36% </td> <td> 17% </td> <td> 4% </td> <td> 1% </td> <td> </td> </tr> </table>

PMC2717069_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Groups </th> <th> </th> </tr> <tr> <th> </th> <th> Hypoglycemic (n = 436) </th> <th> Controls (n = 434) </th> <th> P-value </th> </tr> <tr> <td> Cervical ripening </td> <td> 36 (8%) </td> <td> 38 (9%) </td> <td> 0.792 </td> </tr> <tr> <td> Induction of labor </td> <td> 129 (30%) </td> <td> 87 (20%) </td> <td> <0.001 </td> </tr> <tr> <td> Delivery mode </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Spontaneous vaginal </td> <td> 314 (72%) </td> <td> 295 (68%) </td> <td> </td> </tr> <tr> <td> Assisted vaginal </td> <td> 15 (3%) </td> <td> 14 (3%) </td> <td> </td> </tr> <tr> <td> Cesarean section </td> <td> 107 (25%) </td> <td> 125 (29%) </td> <td> 0.364 </td> </tr> <tr> <td> Reason for cesarean section(1) </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Fetal distress </td> <td> 26 (24%) </td> <td> 23 (18%) </td> <td> </td> </tr> <tr> <td> Failure to progress </td> <td> 24 (22%) </td> <td> 36 (29%) </td> <td> </td> </tr> <tr> <td> Repeat cesarean section </td> <td> 35 (32%) </td> <td> 46 (37%) </td> <td> </td> </tr> <tr> <td> Breech/transverse lie </td> <td> 11 (10%) </td> <td> 9 (7%) </td> <td> </td> </tr> <tr> <td> Other </td> <td> 11 (10%) </td> <td> 11 (9%) </td> <td> 0.572 </td> </tr> <tr> <td> Reason for assisted vaginal delivery(1) </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Fetal distress </td> <td> 12 (80%) </td> <td> 10 (71%) </td> <td> </td> </tr> <tr> <td> Other </td> <td> 3 (20%) </td> <td> 4 (29%) </td> <td> 0.682 </td> </tr> <tr> <td> Fetal distress in labor </td> <td> 38 (9%) </td> <td> 33 (8%) </td> <td> 0.621 </td> </tr> <tr> <td> Cesarean delivery for fetal distress </td> <td> 26 (6%) </td> <td> 23 (5%) </td> <td> 0.769 </td> </tr> <tr> <td> Gestational age at delivery (med, min-max) </td> <td> 39 (23–41.5) </td> <td> 39 (28.6–41.6) </td> <td> 0.689 </td> </tr> <tr> <td> Gestational age distribution </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <37 </td> <td> 67 (15%) </td> <td> 43 (10%) </td> <td> </td> </tr> <tr> <td> 37–40 </td> <td> 242 (56%) </td> <td> 273 (63%) </td> <td> </td> </tr> <tr> <td> >40 </td> <td> 127 (29%) </td> <td> 118 (27%) </td> <td> 0.024 </td> </tr> <tr> <td> Gestational age at delivery <37 </td> <td> 67 (15%) </td> <td> 43 (10%) </td> <td> 0.015 </td> </tr> </table>

PMC2717071_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Group </th> <th> </th> </tr> <tr> <th> </th> <th> Hypoglycemic (n = 436) </th> <th> Controls (n = 434) </th> <th> P-value </th> </tr> <tr> <td> Birth weight (gm) (med, Q1-Q3) </td> <td> 3240 (2928–3550) </td> <td> 3313 (2980–3690) </td> <td> 0.008 </td> </tr> <tr> <td> Birth weight distribution </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> <2500 </td> <td> 43 (10%) </td> <td> 22 (5%) </td> <td> </td> </tr> <tr> <td> 2500–4000 </td> <td> 370 (85%) </td> <td> 370 (85%) </td> <td> </td> </tr> <tr> <td> >4000 </td> <td> 23 (5%) </td> <td> 42 (10%) </td> <td> 0.002 </td> </tr> <tr> <td> IUGR </td> <td> 36 (12%) </td> <td> 29 (9%) </td> <td> 0.277 </td> </tr> <tr> <td> Umbilical artery pH<7.1 </td> <td> 14 (3%) </td> <td> 7 (2%) </td> <td> 0.130 </td> </tr> <tr> <td> 5 minutes Apgar score <7 </td> <td> 4 (1%) </td> <td> 1 (.2%) </td> <td> 0.374 </td> </tr> <tr> <td> Admission to NICU </td> <td> 36 (8%) </td> <td> 25 (6%) </td> <td> 0.149 </td> </tr> <tr> <td> Admission reasons(2) </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Prematurity </td> <td> 6 (17%) </td> <td> 4 (16%) </td> <td> </td> </tr> <tr> <td> RDS/TTN </td> <td> 26 (72%) </td> <td> 12 (48%) </td> <td> </td> </tr> <tr> <td> Other(2) </td> <td> 4 (11%) </td> <td> 9 (36%) </td> <td> 0.054 </td> </tr> </table>

PMC2717071_table_1

<table border="1" class="dataframe"> <tr> <th> Outcome </th> <th> OR </th> <th> 95% CI </th> <th> RR </th> <th> 95% CI </th> <th> p-value </th> </tr> <tr> <td> Preeclampsia </td> <td> 3.13 </td> <td> 1.51–6.51 </td> <td> 2.98 </td> <td> 1.49–5.78 </td> <td> 0.002 </td> </tr> <tr> <td> Induction of labor </td> <td> 1.75 </td> <td> 0.83–1.66 </td> <td> 1.52 </td> <td> 0.86–1.47 </td> <td> 0.361 </td> </tr> <tr> <td> Preterm delivery </td> <td> 1.61 </td> <td> 0.92–2.82 </td> <td> 1.52 </td> <td> 0.93–2.39 </td> <td> 0.093 </td> </tr> <tr> <td> IUGR </td> <td> 1.24 </td> <td> 0.73–2.10 </td> <td> 1.21 </td> <td> 0.75–1.91 </td> <td> 0.425 </td> </tr> <tr> <td> Macrosomia </td> <td> 0.49 </td> <td> 0.28–0.85 </td> <td> 0.51 </td> <td> 0.30–0.86 </td> <td> 0.011 </td> </tr> <tr> <td> Umbilical artery pH<7.1 </td> <td> 2.00 </td> <td> 0.76–5.26 </td> <td> 1.97 </td> <td> 0.77–4.93 </td> <td> 0.159 </td> </tr> <tr> <td> 5 min Apgar score <7 </td> <td> 1.97 </td> <td> 0.20–19.91 </td> <td> 1.97 </td> <td> 0.20–19.19 </td> <td> 0.564 </td> </tr> <tr> <td> NICU admission </td> <td> 1.27 </td> <td> 0.62–2.05 </td> <td> 1.12 </td> <td> 0.63–1.94 </td> <td> 0.965 </td> </tr> </table>

PMC2717071_table_2

<table border="1" class="dataframe"> <tr> <th> Code </th> <th> Clinician Comments </th> </tr> <tr> <td> Assessment of Severity </td> <td> "By how much the patient describes the itch. Like, if they say, it wakes me up at night, or it keeps me up at night, or it's relentless, or it drives me crazy, I know the itch is severe. Plus, you know, I might ask the patient to grade it on a scale of one to ten, how bad is your itch, with ten being the worst, one is being pretty mild or not present. (...) Oh, just the one to ten scale, that's the only systematic way I can grade itch numerically." "Well, I don't have a scale typically in the clinic. There is no numeric scale that I use, but I go by whether it keeps them up at night, or not. That's typically the threshold. The severity of itching really keeps a patient aware at night, and that's about it. I know that's very subjective, but I don't use anything more quantifiable than itch." </td> </tr> <tr> <td> Itch </td> <td> "In psoriasis it's less than it is for atopic dermatitis. It doesn't usually keep them up at night, but it is, in some people, a symptom that is annoying, rather than disabling." "If they're able to sleep at night, or it disables them during the daytime, if they've got to stop what they're doing to scratch. I also – well, I look at their skin to see if there are scratch marks, and if there's other accompanying signs of what we call excoriations, where they're digging at their skin, scratching and digging at their skin." "Itch is a very bothersome symptom for psoriasis and other skin conditions such as eczema. And itch can be more problematic than pain. Itch is constant. Itch is something patients are much more aware of, and they're always scratching themselves to the point where they start to bleed, and their skin gets infected. And it's usually worse at nighttime, because patients are more aware about their body, as opposed to daytime, where people are more – you know, they're more busy at work and things. That's when then get home, then they start to itch more. But I would say itch by far is the number one factor that drives patients crazy." </td> </tr> <tr> <td> Relevance of itch </td> <td> "I think it's highly relevant, because it's probably the most day in, day out thing that a lot of people face in that the itching is – comes to the top of forefront of symptomology, whether it's itching in your scalp, or itching on the patches of psoriasis. And it's again probably one of the single most bothersome things, other than the fact that it's there." </td> </tr> <tr> <td> Location </td> <td> "Scalp – wherever the plaques are, but scalp drives them crazy. Anywhere on the body." "Is the itch from lesions? Usually, yes." "Commonly hands, knees, ankles." "Their scalp and their lower legs. It can be where there's no lesions in the scalp, but in the lower legs there usually some evidence of dry, scaling skin with some scratch marks." </td> </tr> <tr> <td> Treatment/management challenges </td> <td> "Like if the treatment works, that's great, but if it doesn't work, then we've got to keep adding things to help control the itch, whether it be a pill for itch that they take at nighttime, like an antihistamine, or using various creams to keep applying to control the itch... I would probably say maybe 60% of the time the itch can be controlled with one treatment, whether it be the shots or light therapy. And then 40% of the time it's not adequate, it's got to add in something else, like a topical cream, to control the itch." "Particular challenges (related to the treatment or management of the itch)? Again, I think it's related to treating the underlying psoriasis itself." "Yes, there's no specific oral anti-itch medication. And some of the topical anti-itch medications are not always effective for long periods of time over large areas of the skin. Effective or feasible. If they have total body involvement, it's hard to – lotions, anti-itch lotions all over their body." </td> </tr> </table>

PMC2717072_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Focus Groups </th> </tr> <tr> <th> </th> <th> Patients with Mild Psoriasis (N = 8) </th> <th> Patients with Severe Psoriasis (N = 31) </th> </tr> <tr> <td> Female sex, n (%) </td> <td> 5 (63) </td> <td> 17 (55) </td> </tr> <tr> <td> Age, mean years (range) </td> <td> 36 (20 – 74) </td> <td> 45 (22 – 66) </td> </tr> <tr> <td> Race/Ethnicity, n (%) </td> <td> </td> <td> </td> </tr> <tr> <td> White </td> <td> 5 (63) </td> <td> 24 (77) </td> </tr> <tr> <td> Black/African American </td> <td> 0 </td> <td> 4 (13) </td> </tr> <tr> <td> Hispanic </td> <td> 1 (13) </td> <td> 1 (3) </td> </tr> <tr> <td> Mexican-American </td> <td> 1 (13) </td> <td> 0 </td> </tr> <tr> <td> Arabic </td> <td> 1 (13) </td> <td> 0 </td> </tr> <tr> <td> Spanish </td> <td> 0 </td> <td> 1 (3) </td> </tr> <tr> <td> Disease Diagnosis, n (%) </td> <td> </td> <td> </td> </tr> <tr> <td> Psoriasis </td> <td> 8 (100) </td> <td> 29 (94)b </td> </tr> <tr> <td> Co-existing Psoriatic arthritis </td> <td> 0 </td> <td> 1 (3) </td> </tr> <tr> <td> Heath Status, n (%) </td> <td> </td> <td> </td> </tr> <tr> <td> Excellent </td> <td> 1 (13) </td> <td> 3 (10) </td> </tr> <tr> <td> Very good </td> <td> 4 (50) </td> <td> 9 (29) </td> </tr> <tr> <td> Good </td> <td> 3 (38) </td> <td> 13 (42) </td> </tr> <tr> <td> Fair </td> <td> 0 </td> <td> 4 (13) </td> </tr> <tr> <td> Poor </td> <td> 0 </td> <td> 2 (7) </td> </tr> </table>

PMC2717072_table_1

<table border="1" class="dataframe"> <tr> <th> Code/domain </th> <th> Patient Comment (Severity of Psoriasis) </th> </tr> <tr> <td> Symptoms/itch </td> <td> "You itch a lot. Scratch a lot, I mean." (Severe) "Scratch to relieve." (Severe) "It will spread over my whole body, the itching. I'll get scabs on my knees, on my elbows that (...) like yours (...) are very, very bad, and the more you scratch it, the worse it gets. (...) it just spreads." (Severe) "The worst is, for me, is just the itching. The itch and the dry." (Severe) "My itching, it gets inflamed. (...) It spreads – (...) And the more you scratch – you're scratching – (...) Mainly the itching." (Mild) "Because I'm scratching everywhere, people not knowing the reason why I'm scratching." (Mild) </td> </tr> <tr> <td> Change of psoriasis symptoms due to anxiety/worsen </td> <td> "So that's the worst, that's when I start to get really anxious. And it, like I said, it can change over the course of a day. When I know I got to start getting ready for work, that puts me in a whole other frame of mind and I will notice that I'm itching a little bit more and or maybe my hands are not as calm as they are on my days off." (Severe) </td> </tr> <tr> <td> Change of psoriasis symptoms due to stress/worsen </td> <td> "Mine only itches when I'm under stress." (Severe) "...I'll be thinking about it way too much, and then I'll start getting – affecting my skin, because the stress will make it outbreak, and then the outbreak, I'll want to itch, and just scratch..." (Severe) </td> </tr> <tr> <td> Change of psoriasis symptoms over day/varies </td> <td> "Yeah, for me it changes a lot too... Towards the end of the night is when it's usually more itchy for me." (Severe) </td> </tr> <tr> <td> Change of psoriasis symptoms over week/varies </td> <td> "...and then Sunday will hit, and then that's it. Then I'll start itching again, so it's like – and Mondays are so busy at work. And like towards Wednesday – that's – I don't know. It's like Monday and Wednesday. Those two days that – I don't know why those – hate those days. (Severe) "The itching to me varies. (...) Just sometimes I don't even think about it and other times it just, boom, it's just itching." (Severe) </td> </tr> <tr> <td> Impact on daily activities/difficulty concentrating </td> <td> "You lose concentration, because you want to scratch and (...) really want to itch this, but you don't want to itch it in front of somebody, and so you trail off to what you were originally helping somebody with, if you're working." (Mild) "Lack of concentration, or itchy – if you're really over-itchy, sometimes it's hard to concentrate on something else other than that whole-body itch." (Severe) </td> </tr> <tr> <td> Impact on daily activities/choice of clothing </td> <td> "For some reason whenever I have anything that's 100% cotton I tend to itch more. It gets irritated more, so everything is based on clothing or cotton. I try to buy a certain type of clothes. So and that's what I got to wear all the time." (Severe) </td> </tr> <tr> <td> Impact on emotions/embarrassed </td> <td> "I'm in front of people all day long, and it's incredibly embarrassing to start bleeding in front of someone, or scratching uncontrollably when you're not even thinking about it." (Severe) "Mine is just more of embarrassment. When you're scratching and people see things coming off of you or on your clothing..." (Mild) </td> </tr> <tr> <td> Impact on sleep/difficulty falling asleep </td> <td> "Before you go to sleep yeah. (...) Because your itches." (Mild) "It's itching instead of falling asleep." (Severe) "It's falling asleep, when it's itching, and you – and then the minute you start scratching, it only makes it worse. But it's hard...You tell yourself not to scratch, but you think you're going to stop it, you know? And then you scratch it, it only makes it worse, and you want to scratch more, and scratch more. It's bad." (Severe) </td> </tr> <tr> <td> Impact on sleep/difficulty staying asleep </td> <td> "Well, no. I'm going to wake up, I'm itchy. I'm going to put some cortisone on, I'm going grease myself down – then I'm going to try and go back to bed." (Severe) "Just, I want to rip my skin off, because it wakes me up. It's like it's never-ending." (Severe) </td> </tr> <tr> <td> Miss days of school or work because of psoriasis/itch </td> <td> "Yeah, you go every week and you get shots to stop you from itching." (Severe) "And I had it on my feet really bad, and I actually missed several days of work... Well, it's the itching." (Severe) "I can't just go out there (...) taking the train to work, being around a bunch of people, and coming back home – the whole time I just want to scratch and itch..." (Severe) </td> </tr> </table>

PMC2717072_table_2

<table border="1" class="dataframe"> <tr> <th> </th> <th> Patients with Mild Disease (N = 8) </th> <th> Patients with Severe Disease (N = 31) </th> <th> All Patients (N = 39) </th> </tr> <tr> <td> Patients rating itch as the most important symptoma </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No. of patients, n </td> <td> 8 </td> <td> 23 </td> <td> 31 </td> </tr> <tr> <td> Mean rating </td> <td> 9.1 </td> <td> 8.5 </td> <td> 8.7 </td> </tr> <tr> <td> Patients rating a 10, % </td> <td> 88% </td> <td> 70% </td> <td> 74% </td> </tr> <tr> <td> Patients rating itch as the most severe symptomb </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No. of patients, n </td> <td> 8 </td> <td> 23 </td> <td> 31 </td> </tr> <tr> <td> Mean rating </td> <td> 5.8 </td> <td> 8.1 </td> <td> 7.5 </td> </tr> <tr> <td> Patients rating a 10, % </td> <td> 0% </td> <td> 48% </td> <td> 35% </td> </tr> <tr> <td> Patients rating itch as the most troublesome symptomc </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No. of patients, n </td> <td> 8 </td> <td> 16 </td> <td> 24 </td> </tr> <tr> <td> Mean rating </td> <td> 9.0 </td> <td> 8.0 </td> <td> 8.3 </td> </tr> <tr> <td> Patients rating a 10, % </td> <td> 63% </td> <td> 50% </td> <td> 54% </td> </tr> </table>

PMC2717072_table_3

<table border="1" class="dataframe"> <tr> <th> </th> <th> Total Responses </th> <th> FG 1 vs FG 2 </th> <th> FG 1–2 vs FG 3 </th> <th> FG 1–3 vs FG 4 </th> <th> FG 1–4 vs FG 5 </th> </tr> <tr> <td> Symptoms </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Itch </td> <td> 19 </td> <td> 4 vs 4 </td> <td> 8 vs 3 </td> <td> 11 vs 5 </td> <td> 16 vs 3 </td> </tr> <tr> <td> Bleeding </td> <td> 13 </td> <td> 3 vs 5 </td> <td> 8 vs 1 </td> <td> 9 vs 3 </td> <td> 12 vs 1 </td> </tr> <tr> <td> Cracking </td> <td> 12 </td> <td> 0 vs 5 </td> <td> 5 vs 4 </td> <td> 9 vs 3 </td> <td> 12 vs 0 </td> </tr> <tr> <td> Scaling </td> <td> 12 </td> <td> 2 vs 4 </td> <td> 6 vs 4 </td> <td> 10 vs 1 </td> <td> 11 vs 1 </td> </tr> <tr> <td> Dry skin </td> <td> 6 </td> <td> 1 vs 1 </td> <td> 2 vs 1 </td> <td> 3 vs 3 </td> <td> 6 vs 0 </td> </tr> <tr> <td> Impact on daily activities </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Choice of clothing </td> <td> 17 </td> <td> 2 vs 6 </td> <td> 8 vs 2 </td> <td> 10 vs 4 </td> <td> 14 vs 3 </td> </tr> <tr> <td> Effects on work </td> <td> 9 </td> <td> 3 vs 2 </td> <td> 5 vs 0 </td> <td> 5 vs 2 </td> <td> 7 vs 2 </td> </tr> <tr> <td> More laundry/replacing clothes and linens </td> <td> 2 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> </tr> <tr> <td> Household duties </td> <td> 1 </td> <td> 0 vs 1 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> </tr> <tr> <td> Impact on social life </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Interaction with others </td> <td> 15 </td> <td> 3 vs 5 </td> <td> 8 vs 3 </td> <td> 11 vs 3 </td> <td> 14 vs 1 </td> </tr> <tr> <td> Attending social events </td> <td> 5 </td> <td> 0 vs 2 </td> <td> 2 vs 2 </td> <td> 4 vs 0 </td> <td> 4 vs 1 </td> </tr> <tr> <td> Leisure activities </td> <td> 4 </td> <td> 2 vs 1 </td> <td> 3 vs 0 </td> <td> 3 vs 1 </td> <td> 4 vs 0 </td> </tr> <tr> <td> Impact on sleep </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Sleeping less than usual </td> <td> 2 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> </tr> <tr> <td> Difficulty waking up and feeling well rested </td> <td> 1 </td> <td> 0 vs 1 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> </tr> <tr> <td> Impact on emotions </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Embarrassed </td> <td> 17 </td> <td> 5 vs 0 </td> <td> 5 vs 3 </td> <td> 8 vs 4 </td> <td> 12 vs 5 </td> </tr> <tr> <td> Annoyed </td> <td> 7 </td> <td> 2 vs 2 </td> <td> 4 vs 2 </td> <td> 6 vs 1 </td> <td> 7 vs 0 </td> </tr> <tr> <td> Frustrated </td> <td> 4 </td> <td> 0 vs 3 </td> <td> 3 vs 0 </td> <td> 3 vs 0 </td> <td> 3 vs 1 </td> </tr> <tr> <td> Anxious </td> <td> 2 </td> <td> 0 vs 0 </td> <td> 0 vs 0 </td> <td> 0 vs 1 </td> <td> 1 vs 1 </td> </tr> <tr> <td> Nervous </td> <td> 1 </td> <td> 0 vs 0 </td> <td> 0 vs 1 </td> <td> 1 vs 0 </td> <td> 1 vs 0 </td> </tr> <tr> <td> Impact on sex </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Sexual activities </td> <td> 5 </td> <td> 2 vs 0 </td> <td> 2 vs 1 </td> <td> 3 vs 0 </td> <td> 3 vs 2 </td> </tr> <tr> <td> Decreased sexual desire </td> <td> 2 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> <td> 2 vs 0 </td> </tr> </table>

PMC2717072_table_4

<table border="1" class="dataframe"> <tr> <th> </th> <th> </th> <th colspan="2"> Sinus rhythm at 12 +- 3 days </th> </tr> <tr> <th> </th> <th> All </th> <th> Yes </th> <th> No </th> </tr> <tr> <td> Patients, n </td> <td> 111 </td> <td> 56 </td> <td> 55 </td> </tr> <tr> <td> Age, years </td> <td> 67 ± 12 </td> <td> 66 ± 11 </td> <td> 67 ± 13 </td> </tr> <tr> <td> Weight, kg </td> <td> 86 ± 20 </td> <td> 85 ± 17 </td> <td> 86 ± 22 </td> </tr> <tr> <td> Length, cm </td> <td> 178 ± 9 </td> <td> 177 ± 9 </td> <td> 178 ± 10 </td> </tr> <tr> <td> BMI </td> <td> 27 ± 5 </td> <td> 27 ± 5 </td> <td> 27 ± 5 </td> </tr> <tr> <td> Male, n (%) </td> <td> 89 (80) </td> <td> 46 (82) </td> <td> 43 (78) </td> </tr> <tr> <td> AF episode duration, months </td> <td> 5.8 ± 8.1 </td> <td> 4.8 ± 5.4 </td> <td> 6.9 ± 10.1 </td> </tr> <tr> <td> First episode of AF, n </td> <td> 36 </td> <td> 20 </td> <td> 16 </td> </tr> <tr> <td> Hypothyreosis, n </td> <td> 2 (2) </td> <td> 1 (2) </td> <td> 1 (2) </td> </tr> <tr> <td> Hyperthyreosis, n </td> <td> 2 (2) </td> <td> 2 (4) </td> <td> 0 </td> </tr> <tr> <td> Hypertension, n </td> <td> 45 (41) </td> <td> 26 (46) </td> <td> 19 (35) </td> </tr> <tr> <td> Angina pectoris, n </td> <td> 18 (16) </td> <td> 10 (18) </td> <td> 8 (15) </td> </tr> <tr> <td> Previous myocardial infarction, n </td> <td> 17 (15) </td> <td> 7 (13) </td> <td> 10 (18) </td> </tr> <tr> <td> Previous CABG, n </td> <td> 12 (11) </td> <td> 7 (13) </td> <td> 5 (9) </td> </tr> <tr> <td> Previous PCI, n </td> <td> 9 (8) </td> <td> 3 (5) </td> <td> 6 (11) </td> </tr> <tr> <td> Diabetes mellitus, n </td> <td> 13 (12 </td> <td> 5 (9) </td> <td> 8 (15) </td> </tr> <tr> <td> Heart failure, n </td> <td> 25 (23) </td> <td> 13 (23) </td> <td> 12 (22) </td> </tr> <tr> <td> Dilated cardiomyopathy, n </td> <td> 11 (10) </td> <td> 6 (11) </td> <td> 5 (9) </td> </tr> <tr> <td> Hypertrophic cardiomyopathy, n </td> <td> 3 (3) </td> <td> 3 (5) </td> <td> 0 </td> </tr> <tr> <td> Stroke, n </td> <td> 6 (5) </td> <td> 3 (5) </td> <td> 3 (5) </td> </tr> <tr> <td> TIA, n </td> <td> 7 (6) </td> <td> 0 </td> <td> 7 (13) </td> </tr> <tr> <td> Venous thrombosis, n </td> <td> 1 (1) </td> <td> 1 (2) </td> <td> 0 </td> </tr> <tr> <td> Pulmonary embolism, n </td> <td> 1 (1) </td> <td> 1 (2) </td> <td> 0 </td> </tr> <tr> <td> Peripheral arterial embolism, n </td> <td> 1 (1) </td> <td> 1 (2) </td> <td> 0 </td> </tr> </table>

PMC2717073_table_0

<table border="1" class="dataframe"> <tr> <th rowspan="2"> New symptoms scale </th> <th rowspan="2"> ICC (AF at 12 ± 3 days) </th> <th rowspan="2"> Lower 95% CI limit for ICC </th> </tr> <tr> </tr> <tr> <td> Dyspnoea at rest </td> <td> 0.82 </td> <td> 0.61 </td> </tr> <tr> <td> Dyspnoea on exertion </td> <td> 0.88 </td> <td> 0.72 </td> </tr> <tr> <td> Limitations in daily life due to AF </td> <td> 0.19 </td> <td> Neg </td> </tr> <tr> <td> Discomfort due to AF </td> <td> 0.04 </td> <td> Neg </td> </tr> <tr> <td> Fatigue due to AF </td> <td> 0.39 </td> <td> Neg </td> </tr> <tr> <td> Anxiety due to AF </td> <td> 0.93 </td> <td> 0.83 </td> </tr> <tr> <td> SF-36 domains </td> <td> </td> <td> </td> </tr> <tr> <td> Physical functioning </td> <td> 0.84 </td> <td> 0.64 </td> </tr> <tr> <td> Role – Physical </td> <td> 0.56 </td> <td> 0.17 </td> </tr> <tr> <td> Bodily pain </td> <td> 0.50 </td> <td> 0.09 </td> </tr> <tr> <td> General Health </td> <td> 0.75 </td> <td> 0.45 </td> </tr> <tr> <td> Vitality </td> <td> 0.77 </td> <td> 0.49 </td> </tr> <tr> <td> Social functioning </td> <td> 0.54 </td> <td> 0.14 </td> </tr> <tr> <td> Role – Emotional </td> <td> 0.57 </td> <td> 0.18 </td> </tr> <tr> <td> Mental Health </td> <td> 0.95 </td> <td> 0.10 </td> </tr> </table>

PMC2717073_table_1

<table border="1" class="dataframe"> <tr> <th> Items </th> <th> Dyspnoea at rest </th> <th> Dyspnoea on exertion </th> <th> Limitations in working </th> <th> Limitations in daily life </th> <th> Discomfort due to AF </th> <th> Fatiguedue to AF </th> <th> Anxiety due to AF </th> </tr> <tr> <td> pf_tran </td> <td> -0.36437 </td> <td> -0.58810 </td> <td> -0.12466 </td> <td> -0.61232 </td> <td> -0.20312 </td> <td> -0.48616 </td> <td> -0.24267 </td> </tr> <tr> <td> Physical functioning </td> <td> < .0001 </td> <td> < .0001 </td> <td> 0.4315 </td> <td> < .0001 </td> <td> 0.0325 </td> <td> < .0001 </td> <td> 0.0106 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 111 </td> <td> 111 </td> <td> 111 </td> <td> 110 </td> </tr> <tr> <td> rp_tran </td> <td> -0.35569 </td> <td> -0.47634 </td> <td> -0.20069 </td> <td> -0.62755 </td> <td> -0.22794 </td> <td> -0.49356 </td> <td> -0.31813 </td> </tr> <tr> <td> Role – Physical </td> <td> 0.0001 </td> <td> < .0001 </td> <td> 0.2025 </td> <td> < .0001 </td> <td> 0.0171 </td> <td> < .0001 </td> <td> 0.0008 </td> </tr> <tr> <td> n </td> <td> 109 </td> <td> 109 </td> <td> 42 </td> <td> 108 </td> <td> 109 </td> <td> 109 </td> <td> 108 </td> </tr> <tr> <td> bp_tran </td> <td> -0.44545 </td> <td> -0.26582 </td> <td> -0.34962 </td> <td> -0.37650 </td> <td> -0.31149 </td> <td> -0.32431 </td> <td> -0.38909 </td> </tr> <tr> <td> Bodily Pain </td> <td> < .0001 </td> <td> 0.0048 </td> <td> 0.0232 </td> <td> < .0001 </td> <td> 0.0009 </td> <td> 0.0005 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 110 </td> <td> 111 </td> <td> 111 </td> <td> 109 </td> </tr> <tr> <td> gh_tran </td> <td> -0.29357 </td> <td> -0.27723 </td> <td> -0.29889 </td> <td> -0.51705 </td> <td> -0.31705 </td> <td> -0.40835 </td> <td> -0.38909 </td> </tr> <tr> <td> General Health </td> <td> 0.0019 </td> <td> 0.0034 </td> <td> 0.0545 </td> <td> < .0001 </td> <td> 0.0007 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 110 </td> <td> 110 </td> <td> 42 </td> <td> 109 </td> <td> 110 </td> <td> 110 </td> <td> 109 </td> </tr> <tr> <td> v_tran </td> <td> -0.25704 </td> <td> -0.40008 </td> <td> -0.40877 </td> <td> -0.66652 </td> <td> -0.40433 </td> <td> -0.66056 </td> <td> -0.36696 </td> </tr> <tr> <td> Vitality </td> <td> 0.0084 </td> <td> < .0001 </td> <td> 0.0120 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> <td> 0.0001 </td> </tr> <tr> <td> n </td> <td> 104 </td> <td> 104 </td> <td> 37 </td> <td> 103 </td> <td> 104 </td> <td> 104 </td> <td> 103 </td> </tr> <tr> <td> sf_tran </td> <td> -0.14190 </td> <td> -0.25434 </td> <td> -0.08276 </td> <td> -0.46915 </td> <td> -0.38437 </td> <td> -0.42230 </td> <td> -0.37927 </td> </tr> <tr> <td> Social Functioning </td> <td> 0.1374 </td> <td> 0.0071 </td> <td> 0.6023 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 110 </td> <td> 111 </td> <td> 111 </td> <td> 110 </td> </tr> <tr> <td> re-tran </td> <td> -0.32767 </td> <td> -0.37072 </td> <td> 0.11359 </td> <td> -0.52260 </td> <td> -0.21609 </td> <td> -0.48442 </td> <td> -0.42472 </td> </tr> <tr> <td> Role – Emotional </td> <td> 0.0004 </td> <td> < .0001 </td> <td> 0.4738 </td> <td> < .0001 </td> <td> 0.0227 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 111 </td> <td> 111 </td> <td> 42 </td> <td> 110 </td> <td> 111 </td> <td> 111 </td> <td> 103 </td> </tr> <tr> <td> mh_tran </td> <td> -0.14611 </td> <td> -0.21271 </td> <td> -0.21615 </td> <td> -0.37553 </td> <td> -0.40701 </td> <td> -0.44899 </td> <td> -0.62826 </td> </tr> <tr> <td> Mental Health </td> <td> 0.1389 </td> <td> 0.0302 </td> <td> 0.1988 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> <td> < .0001 </td> </tr> <tr> <td> n </td> <td> 104 </td> <td> 104 </td> <td> 37 </td> <td> 103 </td> <td> 104 </td> <td> 104 </td> <td> 103 </td> </tr> </table>

PMC2717073_table_2

<table border="1" class="dataframe"> <tr> <th> Item number </th> <th> Raw count </th> <th> Measure </th> <th> Realse </th> <th colspan="2"> Infit </th> <th colspan="2"> Outfit </th> <th> Score </th> </tr> <tr> <th> </th> <th> </th> <th> </th> <th> </th> <th> MNSQ </th> <th> ZSTD </th> <th> MNSQ </th> <th> ZSTD </th> <th> corr. </th> </tr> <tr> <td> AF1 </td> <td> 108 </td> <td> 0,41 </td> <td> 0,08 </td> <td> 0,98 </td> <td> -0,1 </td> <td> 0,99 </td> <td> 0 </td> <td> 0,51 </td> </tr> <tr> <td> AF3 </td> <td> 40 </td> <td> 0,22 </td> <td> 0,17 </td> <td> 0,89 </td> <td> -0,4 </td> <td> 1,28 </td> <td> 0,4 </td> <td> 0,39 </td> </tr> <tr> <td> AF7 </td> <td> 107 </td> <td> 0,15 </td> <td> 0,05 </td> <td> 1,04 </td> <td> 0,2 </td> <td> 1,01 </td> <td> 0 </td> <td> 0,65 </td> </tr> <tr> <td> AF5 </td> <td> 108 </td> <td> 0,12 </td> <td> 0,05 </td> <td> 1,06 </td> <td> 0,4 </td> <td> 1 </td> <td> 0 </td> <td> 0,66 </td> </tr> <tr> <td> AF4 </td> <td> 107 </td> <td> -0,06 </td> <td> 0,05 </td> <td> 0,84 </td> <td> -1,2 </td> <td> 0,79 </td> <td> -1,1 </td> <td> 0,76 </td> </tr> <tr> <td> AF2 </td> <td> 108 </td> <td> -0,4 </td> <td> 0,05 </td> <td> 1,24 </td> <td> 1,7 </td> <td> 1,2 </td> <td> 1,2 </td> <td> 0,69 </td> </tr> <tr> <td> AF6 </td> <td> 108 </td> <td> -0,43 </td> <td> 0,05 </td> <td> 0,87 </td> <td> -1 </td> <td> 0,84 </td> <td> -1,2 </td> <td> 0,78 </td> </tr> <tr> <td> Mean </td> <td> 98 </td> <td> 0 </td> <td> 0,07 </td> <td> 0,99 </td> <td> -0,1 </td> <td> 1,01 </td> <td> -0,1 </td> <td> </td> </tr> <tr> <td> SD </td> <td> 24 </td> <td> 0,29 </td> <td> 0,04 </td> <td> 0,13 </td> <td> 0,9 </td> <td> 0,16 </td> <td> 0,8 </td> <td> </td> </tr> </table>

PMC2717073_table_3

<table border="1" class="dataframe"> <tr> <th> Score </th> <th> Description </th> </tr> <tr> <td> 0 </td> <td> No lesion </td> </tr> <tr> <td> 1 </td> <td> Hyperaemic area with erected pili </td> </tr> <tr> <td> 2 </td> <td> Moist, exudative and hyperaemic area with intact epidermis </td> </tr> <tr> <td> 3 </td> <td> Exudative area, exposed corium with no signs of healing </td> </tr> <tr> <td> 4 </td> <td> Exposed corium but in process of healing, dried-up lesion </td> </tr> <tr> <td> 5 </td> <td> Dark brown scab, completely or almost completely healed lesion </td> </tr> </table>

PMC2717074_table_0

<table border="1" class="dataframe"><tr><td>N° of cases</td><td></td></tr><tr><td>Total of</td><td>68</td></tr><tr><td>Distribution of parity groups (%)</td><td></td></tr><tr><td>Primiparous</td><td>75.0</td></tr><tr><td rowspan="2">Multiparous a</td><td>25.0</td></tr><tr><td></td></tr><tr><td rowspan="2">DIM* 0–120 to</td><td>35.3</td></tr><tr><td>38.2</td></tr><tr><td>DIM > 240</td><td>26.5</td></tr></table>

PMC2717074_table_1

<table border="1" class="dataframe"> <tr> <th> </th> <th> Median duration </th> </tr> <tr> <td> No stratification </td> <td> 42 (36–48) </td> </tr> <tr> <td> Stratification </td> <td> </td> </tr> <tr> <td> Primiparous </td> <td> 39 (35–48) </td> </tr> <tr> <td> Multiparous </td> <td> 48 (42–48) </td> </tr> <tr> <td> Lactation stage at lesion onset </td> <td> </td> </tr> <tr> <td> DIM* 0–120 </td> <td> 42 (39–56) </td> </tr> <tr> <td> DIM 121–240 </td> <td> 42 (35–48) </td> </tr> <tr> <td> DIM > 240 </td> <td> 41 (35–48) </td> </tr> </table>

PMC2717074_table_2

<table border="1" class="dataframe"> <tr> <th> </th> <th> Pre-contrast </th> <th> Post-contrast </th> <th> CER* </th> </tr> <tr> <td> Triolein Group (n = 12) </td> <td> 504 (56.5) </td> <td> 1793 (229.9) </td> <td> 2.61 (0.73) </td> </tr> <tr> <td> Saline Group (n = 18) </td> <td> 582 (519.1) </td> <td> 712 (704.0) </td> <td> 0.22 (0.37) </td> </tr> </table>

PMC2717075_table_0

<table border="1" class="dataframe"> <tr> <th> HPVgenotype </th> <th> Primer sequences </th> <th> Amplicon (pb)* </th> </tr> <tr> <td> 6/11 </td> <td> TGC AAG AAT GCA CTG ACC AC TGC ATG TTG TCC AGC AGT GT </td> <td> 334 </td> </tr> <tr> <td> 16 </td> <td> CAC AGT TAT GCA CAG AGC TGC CAT ATA TTC ATG CAA TGT AGG TGT A </td> <td> 457 </td> </tr> <tr> <td> 18 </td> <td> CAC TTC ACT GCA AGA CAT AGA GTT GTG AAA TCG TCG TTT TTC A </td> <td> 332 </td> </tr> <tr> <td> 31 </td> <td> GAA ATT GCA TGA ACT AAG CTC G CAC ATA TAC CTT TGT TTG TCA A </td> <td> 263 </td> </tr> <tr> <td> 33 </td> <td> ACT ATA CAC AAC ATT GAA CTA GTT TTT ACA CGT CAC AGT GCA </td> <td> 398 </td> </tr> <tr> <td> 42 </td> <td> CCC AAA GTA GTG GTC CCA GTT A GAT CTT TCG TAG TGT CGC AGT G </td> <td> 277 </td> </tr> <tr> <td> 52 </td> <td> TAA GGC TGC AGT GTG TGC AG CTA ATA GTT ATT TCA CTT AAT GGT </td> <td> 229 </td> </tr> <tr> <td> 58 </td> <td> GTA AAG TGT GCT TAC GAT TGC GTT GTT ACA GGT TAC ACT TGT </td> <td> 274 </td> </tr> </table>

PMC2717078_table_0

<table border="1" class="dataframe"> <tr> <th colspan="4"> HPV-DNA </th> </tr> <tr> <th> Type n = 18 </th> <th> Carcinogenic risk </th> <th> Frequency n = 82 </th> <th> % </th> </tr> <tr> <td> 6/11 </td> <td> LR </td> <td> 17 </td> <td> 20.7 </td> </tr> <tr> <td> 42 </td> <td> LR </td> <td> 13 </td> <td> 15.9 </td> </tr> <tr> <td> 16 </td> <td> HR </td> <td> 13 </td> <td> 15.9 </td> </tr> <tr> <td> 18 </td> <td> HR </td> <td> 9 </td> <td> 11 </td> </tr> <tr> <td> 58 </td> <td> HR </td> <td> 5 </td> <td> 6.1 </td> </tr> <tr> <td> 31 </td> <td> HR </td> <td> 3 </td> <td> 3.7 </td> </tr> <tr> <td> 35 </td> <td> HR </td> <td> 3 </td> <td> 3.7 </td> </tr> <tr> <td> 52 </td> <td> HR </td> <td> 3 </td> <td> 3.7 </td> </tr> <tr> <td> 51 </td> <td> HR </td> <td> 2 </td> <td> 2.4 </td> </tr> <tr> <td> 54 </td> <td> LR </td> <td> 2 </td> <td> 2.4 </td> </tr> <tr> <td> 59 </td> <td> HR </td> <td> 2 </td> <td> 2.4 </td> </tr> <tr> <td> 26 </td> <td> PHR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 33 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 34 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 45 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 68 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 70 </td> <td> LR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> 73 </td> <td> HR </td> <td> 1 </td> <td> 1.2 </td> </tr> <tr> <td> NC* </td> <td> - </td> <td> 3 </td> <td> 3.7 </td> </tr> </table>

PMC2717078_table_1

<table border="1" class="dataframe"> <tr> <th> Cohort (n = 223) </th> <th> Characteristic </th> <th> aSer/Ser (n = 170) </th> <th> aSer/Leu (n = 43) </th> <th> aLeu/Leu (n = 10) </th> </tr> <tr> <td> No (%) of patients </td> <td> Co-existing diseases </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 103 (46.2) </td> <td> Arterial hypertension </td> <td> 77 (74.8) </td> <td> 22 (21.4) </td> <td> 4 (3.9) </td> </tr> <tr> <td> 82 (36.8) </td> <td> Myocardial disease </td> <td> 67 (81.7) </td> <td> 14 (17.0) </td> <td> 1 (1.2) </td> </tr> <tr> <td> 53 (23.8) </td> <td> Diabetes </td> <td> 35 (66.0) </td> <td> 14 (26.0) </td> <td> 4 (7.5) </td> </tr> <tr> <td> 52 (23.3) </td> <td> Lung pathology </td> <td> 44 (84.6) </td> <td> 6 (11.5) </td> <td> 2 (3.8) </td> </tr> <tr> <td> 16 (7.2) </td> <td> Renal pathology </td> <td> 11 (68.8) </td> <td> 4 (25.0) </td> <td> 1 (6.3) </td> </tr> <tr> <td> No (%) of patients </td> <td> Type of surgery </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 76 (34.1) </td> <td> Upper-GI resection </td> <td> 58 (76.3) </td> <td> 16 (21.1) </td> <td> 2 (2.6) </td> </tr> <tr> <td> 62 (27.8) </td> <td> Colorectal resection </td> <td> 46 (74.2) </td> <td> 12 (19.4) </td> <td> 4 (6.5) </td> </tr> <tr> <td> 50 (22.4) </td> <td> bOther abdominal </td> <td> 37 (74.0) </td> <td> 10 (20.0) </td> <td> 3 (6.0) </td> </tr> <tr> <td> 15 (6.7) </td> <td> Thoracic </td> <td> 11 (73.4) </td> <td> 3 (20.0) </td> <td> 1 (6.7) </td> </tr> <tr> <td> 20 (9.0) </td> <td> Limb and others </td> <td> 18 (90.0) </td> <td> 2 (10.0) </td> <td> - - </td> </tr> <tr> <td> No (%) of infections </td> <td> Type of Infection </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 92 (41.3) </td> <td> Pneumonia </td> <td> 68 (73.9) </td> <td> 20 (21.7) </td> <td> 4 (4.3) </td> </tr> <tr> <td> 38 (17.0) </td> <td> Peritonitis </td> <td> 27 (71.1) </td> <td> 9 (23.7) </td> <td> 2 (5.3) </td> </tr> <tr> <td> 65 (29.2) </td> <td> Abscess </td> <td> 52 (80.0) </td> <td> 10 (15.4) </td> <td> 3 (4.6) </td> </tr> <tr> <td> 4 (1.8) </td> <td> Urinary tract infections </td> <td> 3 (75.0) </td> <td> 1 (25.0) </td> <td> - - </td> </tr> <tr> <td> 24 (10.8) </td> <td> Other </td> <td> 20 (83.3) </td> <td> 3 (12.5) </td> <td> 1 (4.2) </td> </tr> <tr> <td> No (%) of infectionsc </td> <td> Microorganisms </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 129 (57.9) </td> <td> Gram-negative </td> <td> 97 (75.2) </td> <td> 25 (19.4) </td> <td> 7 (5.4) </td> </tr> <tr> <td> 83 (37.2) </td> <td> Gram-positive </td> <td> 60 (72.3) </td> <td> 18 (21.7) </td> <td> 5 (6.0) </td> </tr> <tr> <td> 15 (6.7) </td> <td> Fungi </td> <td> 13 (86.7) </td> <td> 2 (13.3) </td> <td> - - </td> </tr> <tr> <td> 31 (13.9) </td> <td> Polymicrobial </td> <td> 19 (61.3) </td> <td> 9 (29.0) </td> <td> 3 (9.8) </td> </tr> <tr> <td> 24 (10.8) </td> <td> Clinically diagnosed </td> <td> 15 (62.5) </td> <td> 8 (33.3) </td> <td> 1 (4.2) </td> </tr> <tr> <td> No (%) of patients </td> <td> Morbidity and Mortality </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 114 (51.1) </td> <td> Sepsis without organ dysfunction </td> <td> 90 (78.9) </td> <td> 22 (19.3) </td> <td> 2 (1.8) </td> </tr> <tr> <td> 109 (48.9) </td> <td> Severe sepsis and septic shock </td> <td> 80 (73.4) </td> <td> 21 (19.3) </td> <td> 8 (7.3)d </td> </tr> <tr> <td> 28 (12.6) </td> <td> Mortality ICU </td> <td> 21 (75.0) </td> <td> 6 (21.4) </td> <td> 1 (3.6) </td> </tr> <tr> <td> 34 (15.3) </td> <td> Mortality hospital </td> <td> 26 (76.5) </td> <td> 7 (20.6) </td> <td> 1 (2.9) </td> </tr> </table>

PMC2717080_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th> </th> <th> </th> <th colspan="3"> No. of individuals with genotype (%) </th> <th> </th> </tr> <tr> <th> Population and disease </th> <th> No. </th> <th> Variant Allele Frequency (%) </th> <th> Ser/Ser </th> <th> Ser/Leu </th> <th> Leu/Leu </th> <th> P valuea </th> </tr> <tr> <td> Ghana, delivering women </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> P. falciparum positive </td> <td> 541 </td> <td> 0.1 </td> <td> 540 (99.8) </td> <td> 1 (0.2) </td> <td> 0 (0) </td> <td> 0.49 </td> </tr> <tr> <td> P. falciparum negative </td> <td> 554 </td> <td> 0 </td> <td> 554 (100) </td> <td> 0 (0) </td> <td> 0 (0) </td> <td> </td> </tr> <tr> <td> Germany </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Sepsis patients </td> <td> 223 </td> <td> 18.1 </td> <td> 170 (76.2) </td> <td> 43 (19.3) </td> <td> 10 (4.5) </td> <td> 0.19 </td> </tr> <tr> <td> Controls </td> <td> 188 </td> <td> 19.2 </td> <td> 138 (74.4) </td> <td> 48 (25.5) </td> <td> 2 (1.1)b </td> <td> </td> </tr> <tr> <td> Bangladesh </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Leprosy patients </td> <td> 263 </td> <td> 16.3 </td> <td> 186 (70.7) </td> <td> 68 (25.9) </td> <td> 9 (3.4) </td> <td> 0.22 </td> </tr> <tr> <td> Controls </td> <td> 280 </td> <td> 17.2 </td> <td> 188 (67.1) </td> <td> 88 (31.5) </td> <td> 4 (1.4) </td> <td> </td> </tr> <tr> <td> Turkey </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> 0.11 </td> </tr> <tr> <td> Leprosy patients </td> <td> 60 </td> <td> 10.8 </td> <td> 47 (78) </td> <td> 13 (21) </td> <td> 0 (0) </td> <td> </td> </tr> <tr> <td> Controls </td> <td> 100 </td> <td> 6.5 </td> <td> 88 (88) </td> <td> 11 (11) </td> <td> 1 (1) </td> <td> </td> </tr> </table>

PMC2717080_table_1

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="6"> Particle size (nm) (± SD) </th> </tr> <tr> <th> Samples </th> <th> N/P = 1 </th> <th> N/P = 3 </th> <th> N/P = 5 </th> <th> N/P = 7 </th> <th> N/P = 10 </th> <th> N/P = 15 </th> </tr> <tr> <td> PCFC-g-PEI/pDNA complexes </td> <td> 208.05 ± 15.55 </td> <td> 211.85 ± 11.95 </td> <td> 215.3 ± 12.2 </td> <td> 195.35 ± 6.95 </td> <td> 161.4 ± 23.2 </td> <td> 234.85 ± 10.25 </td> </tr> <tr> <td> PEI/pDNA complexes </td> <td> 118.5 ± 2.5 </td> <td> 88.89 ± 0.83 </td> <td> 99.115 ± 3.885 </td> <td> 136.35 ± 4.45 </td> <td> 159.1 ± 5.7 </td> <td> 98.59 ± 9.81 </td> </tr> </table>

PMC2717081_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="6"> Zeta potential (mV) (± SD) </th> </tr> <tr> <th> Samples </th> <th> N/P = 1 </th> <th> N/P = 3 </th> <th> N/P = 5 </th> <th> N/P = 7 </th> <th> N/P = 10 </th> <th> N/P = 15 </th> </tr> <tr> <td> PCFC-g-PEI/pDNA complexes </td> <td> 31.2 ± 2.1 </td> <td> 16.75 ± 0.85 </td> <td> 1.5125 ± 0.6575 </td> <td> 1.38 ± 0.02 </td> <td> 0.325 ± 0.19 </td> <td> 7.835 ± 1.675 </td> </tr> <tr> <td> PEI/pDNA complexes </td> <td> 25.15 ± 0.75 </td> <td> 21.25 ± 0.25 </td> <td> 13 ± 0.7 </td> <td> 14.8 ± 1.5 </td> <td> 1.855 ± 0.235 </td> <td> 0.651 ± 0.062 </td> </tr> </table>

PMC2717081_table_1

<table border="1" class="dataframe"> <tr> <th> </th> <th> Mean </th> <th> Minimum </th> <th> Maximum </th> <th> SD </th> </tr> <tr> <td> Age (year) </td> <td> 27.12 </td> <td> 19 </td> <td> 40 </td> <td> 4.84 </td> </tr> <tr> <td> Gestational age (week) </td> <td> 33.70 </td> <td> 5 </td> <td> 42 </td> <td> 9.50 </td> </tr> <tr> <td> HCHB1 (g/l) </td> <td> 126.35 </td> <td> 55 </td> <td> 163 </td> <td> 18.02 </td> </tr> <tr> <td> LAHB2 (g/l) </td> <td> 128.45 </td> <td> 78 </td> <td> 162 </td> <td> 14.84 </td> </tr> </table>

PMC2717084_table_0

<table border="1" class="dataframe"> <tr> <th> Characteristics </th> <th> % </th> </tr> <tr> <td> Age group </td> <td> </td> </tr> <tr> <td> 15–19 </td> <td> 35.8 </td> </tr> <tr> <td> 20–24 </td> <td> 49.2 </td> </tr> <tr> <td> 25–29 </td> <td> 12.7 </td> </tr> <tr> <td> 30 and above </td> <td> 2.3 </td> </tr> <tr> <td> Median age </td> <td> 21.0 </td> </tr> <tr> <td> Marital status </td> <td> </td> </tr> <tr> <td> Unmarried </td> <td> 88.3 </td> </tr> <tr> <td> Currently married </td> <td> 11.7 </td> </tr> <tr> <td> Districts </td> <td> </td> </tr> <tr> <td> Kathmandu valley (3 districts) </td> <td> 9.2 </td> </tr> <tr> <td> Outside Kathmandu valley (64 districts) </td> <td> 90.8 </td> </tr> <tr> <td> Level of education </td> <td> </td> </tr> <tr> <td> Intermediate </td> <td> 27.7 </td> </tr> <tr> <td> Undergraduate </td> <td> 53.9 </td> </tr> <tr> <td> Graduate degree </td> <td> 18.3 </td> </tr> <tr> <td> Type of accommodation </td> <td> </td> </tr> <tr> <td> With family </td> <td> 41.0 </td> </tr> <tr> <td> Alone </td> <td> 19.0 </td> </tr> <tr> <td> With friends </td> <td> 40.0 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 573 </td> </tr> </table>

PMC2717085_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th> % </th> </tr> <tr> <td> Experience of kissing a girl </td> <td> 57.4 </td> </tr> <tr> <td> Experience of dating </td> <td> 44.5 </td> </tr> <tr> <td> Experience of placing hand on a girl's breast </td> <td> 60.2 </td> </tr> <tr> <td> Experience of placing hand on a girl's sex organ </td> <td> 34.9 </td> </tr> <tr> <td> Experience of sexual intercourse </td> <td> 46.9 </td> </tr> <tr> <td> Experience of premarital sex </td> <td> 39.1 </td> </tr> <tr> <td> Having close unmarried friend with experience of premarital sex </td> <td> 53.0 </td> </tr> <tr> <td> N </td> <td> 573 </td> </tr> </table>

PMC2717085_table_1

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Premarital sex </th> <th colspan="2"> Total </th> </tr> <tr> <th> </th> <th> Yes </th> <th> No </th> <th> % </th> <th> Number </th> </tr> <tr> <td> Age group </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 15–19 </td> <td> 34.6 </td> <td> 65.4 </td> <td> 100.0 </td> <td> 205 </td> </tr> <tr> <td> 20 and above </td> <td> 41.6 </td> <td> 58.4 </td> <td> 100.0 </td> <td> 368 </td> </tr> <tr> <td> Level of education </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Intermediate </td> <td> 35.2 </td> <td> 64.8 </td> <td> 100.0 </td> <td> 159 </td> </tr> <tr> <td> Undergraduate </td> <td> 39.8 </td> <td> 60.2 </td> <td> 100.0 </td> <td> 309 </td> </tr> <tr> <td> Graduate degree </td> <td> 42.9 </td> <td> 57.1 </td> <td> 100.0 </td> <td> 105 </td> </tr> <tr> <td> Marital status </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Married </td> <td> 32.8 </td> <td> 67.2 </td> <td> 100.0 </td> <td> 67 </td> </tr> <tr> <td> Unmarried </td> <td> 39.9 </td> <td> 60.1 </td> <td> 100.0 </td> <td> 506 </td> </tr> <tr> <td> District </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Outside Kathmandu valley </td> <td> 39.8 </td> <td> 60.2 </td> <td> 100.0 </td> <td> 520 </td> </tr> <tr> <td> Kathmandu valley </td> <td> 32.1 </td> <td> 67.9 </td> <td> 100.0 </td> <td> 53 </td> </tr> <tr> <td> Living arrangement </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> With family </td> <td> 36.6 </td> <td> 63.4 </td> <td> 100.0 </td> <td> 232 </td> </tr> <tr> <td> Alone </td> <td> 43.4 </td> <td> 56.6 </td> <td> 100.0 </td> <td> 106 </td> </tr> <tr> <td> With friends </td> <td> 39.6 </td> <td> 60.4 </td> <td> 100.0 </td> <td> 235 </td> </tr> <tr> <td> Attitude towards female virginity*** </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Conservative </td> <td> 33.4 </td> <td> 66.6 </td> <td> 100.0 </td> <td> 305 </td> </tr> <tr> <td> Liberal </td> <td> 45.5 </td> <td> 54.5 </td> <td> 100.0 </td> <td> 268 </td> </tr> <tr> <td> Attitude towards male virginity*** </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Conservative </td> <td> 30.0 </td> <td> 70.0 </td> <td> 100.0 </td> <td> 290 </td> </tr> <tr> <td> Liberal </td> <td> 48.4 </td> <td> 51.6 </td> <td> 100.0 </td> <td> 283 </td> </tr> <tr> <td> Family structure </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Joint family </td> <td> 39.6 </td> <td> 60.4 </td> <td> 100.0 </td> <td> 139 </td> </tr> <tr> <td> Nuclear family </td> <td> 38.9 </td> <td> 61.1 </td> <td> 100.0 </td> <td> 434 </td> </tr> <tr> <td> Religion* </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Non-Hindu </td> <td> 20.0 </td> <td> 80.0 </td> <td> 100.0 </td> <td> 35 </td> </tr> <tr> <td> Hindu </td> <td> 40.3 </td> <td> 59.7 </td> <td> 100.0 </td> <td> 538 </td> </tr> <tr> <td> Has a friend who has experienced premarital sex*** </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No </td> <td> 14.9 </td> <td> 85.1 </td> <td> 100.0 </td> <td> 268 </td> </tr> <tr> <td> Yes </td> <td> 60.3 </td> <td> 39.7 </td> <td> 100.0 </td> <td> 305 </td> </tr> <tr> <td> Total </td> <td> 39.1 </td> <td> 60.9 </td> <td> 100.0 </td> <td> 573 </td> </tr> </table>

PMC2717085_table_2

<table border="1" class="dataframe"> <tr> <th rowspan="2"> In </th> <th> % </th> </tr> <tr> <td> 6.7 </td> </tr> <tr> <td rowspan="2"> 15–16 had </td> <td> 25.0 </td> </tr> <tr> <td> 32.0 </td> </tr> <tr> <td> 19 or more </td> <td> 36.3 </td> </tr> <tr> <td> Total (age range 10–25 years) </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 224 </td> </tr> </table>

PMC2717085_table_3

<table border="1" class="dataframe"> <tr> <th> How many sex partners did you have (total)? </th> <th> % </th> </tr> <tr> <td> One </td> <td> 45.1 </td> </tr> <tr> <td> Two </td> <td> 23.7 </td> </tr> <tr> <td> Three and more </td> <td> 31.3 </td> </tr> <tr> <td> Average number of sex partners </td> <td> 2.4 </td> </tr> <tr> <td> SD </td> <td> 2.1 </td> </tr> <tr> <td> Ranges </td> <td> 1–15 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 224 </td> </tr> </table>

PMC2717085_table_4

<table border="1" class="dataframe"> <tr> <th> </th> <th> % </th> </tr> <tr> <td> Have you ever had sex with CSW? </td> <td> </td> </tr> <tr> <td rowspan="2"> Yes was </td> <td> 22.8 </td> </tr> <tr> <td> 77.2 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 224 </td> </tr> <tr> <td> How often did you use condom with CSW? </td> <td> </td> </tr> <tr> <td> Every act of sexual intercourse </td> <td> 49.0 </td> </tr> <tr> <td rowspan="2"> Sometimes they </td> <td> 45.1 </td> </tr> <tr> <td> 5.9 </td> </tr> <tr> <td> Total </td> <td> 100.0 </td> </tr> <tr> <td> N </td> <td> 51 </td> </tr> </table>

PMC2717085_table_5

<table border="1" class="dataframe"> <tr> <th> </th> <th> Model I </th> <th> Model II </th> <th> Model III </th> </tr> <tr> <td> Individual characteristics </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Age group </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> 15–19 </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> 20 and above </td> <td> 1.34 </td> <td> 1.39 </td> <td> 1.69* </td> </tr> <tr> <td> Level of education </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Intermediate </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Undergraduate </td> <td> 0.93 </td> <td> 0.89 </td> <td> 0.52* </td> </tr> <tr> <td> Graduate degree </td> <td> 0.88 </td> <td> 0.79 </td> <td> 0.48* </td> </tr> <tr> <td> Marital status </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Married </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Unmarried </td> <td> 1.30 </td> <td> 1.29 </td> <td> 1.73 </td> </tr> <tr> <td> District </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Outside Kathmandu valley </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Kathmandu valley </td> <td> 0.82 </td> <td> 0.84 </td> <td> 0.97 </td> </tr> <tr> <td> Living arrangement </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> With family </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Alone </td> <td> 1.32 </td> <td> 1.39 </td> <td> 1.28 </td> </tr> <tr> <td> With friends </td> <td> 1.05 </td> <td> 1.07 </td> <td> 1.07 </td> </tr> <tr> <td> Attitude towards male virginity </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Conservative (ref) </td> <td> 1.0 </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Liberal </td> <td> 2.16*** </td> <td> 2.15*** </td> <td> 1.91** </td> </tr> <tr> <td> Family characteristics </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Family structure </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Joint family </td> <td> </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Nuclear family </td> <td> </td> <td> 0.91 </td> <td> 0.81 </td> </tr> <tr> <td> Religion </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Non-Hindu (ref) </td> <td> </td> <td> 1.0 </td> <td> 1.0 </td> </tr> <tr> <td> Hindu </td> <td> </td> <td> 2.63* </td> <td> 2.99* </td> </tr> <tr> <td> Peer characteristics </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> Has close unmarried friend who has experienced premarital sex </td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td> No (ref) </td> <td> </td> <td> </td> <td> 1.0 </td> </tr> <tr> <td> Yes </td> <td> </td> <td> </td> <td> 9.2*** </td> </tr> <tr> <td> Intercept </td> <td> 0.28 </td> <td> 0.124 </td> <td> 0.033 </td> </tr> <tr> <td> -2 log likelihood </td> <td> 741.7 </td> <td> 736.1 </td> <td> 611.1 </td> </tr> <tr> <td> Cox & Snell R square </td> <td> 0.043 </td> <td> 0.052 </td> <td> 0.238 </td> </tr> </table>

PMC2717085_table_6

<table border="1" class="dataframe"> <tr> <th> </th> <th> Method </th> <th> Threshold </th> <th> Clusters </th> <th> Singletons </th> <th> Max. cluster size </th> </tr> <tr> <td> Rice </td> <td> sHYB </td> <td> N/A </td> <td> 305 </td> <td> 0 </td> <td> 2,533 </td> </tr> <tr> <td rowspan="6"> Rice </td> <td> HYB </td> <td> 1.1 </td> <td> 2 </td> <td> 21 </td> <td> 22,459 </td> </tr> <tr> <td> </td> <td> 1.2 </td> <td> 50 </td> <td> 36 </td> <td> 22,078 </td> </tr> <tr> <td> </td> <td> 1.35 </td> <td> 853 </td> <td> 286 </td> <td> 10,773 </td> </tr> <tr> <td> </td> <td> 1.4 </td> <td> 1,361 </td> <td> 528 </td> <td> 4,052 </td> </tr> <tr> <td> </td> <td> 1.45 </td> <td> 1,863 </td> <td> 880 </td> <td> 359 </td> </tr> <tr> <td> </td> <td> 1.5 </td> <td> 2,341 </td> <td> 1,405 </td> <td> 143 </td> </tr> <tr> <td rowspan="8"> Rice </td> <td> RESTR </td> <td> 1e-8 </td> <td> 128 </td> <td> 125 </td> <td> 21,663 </td> </tr> <tr> <td> </td> <td> 1e-10 </td> <td> 1,247 </td> <td> 357 </td> <td> 258 </td> </tr> <tr> <td> </td> <td> 1e-12 </td> <td> 1,929 </td> <td> 855 </td> <td> 122 </td> </tr> <tr> <td> </td> <td> 1e-15 </td> <td> 2,959 </td> <td> 3,007 </td> <td> 79 </td> </tr> <tr> <td> </td> <td> 1e-17 </td> <td> 3,421 </td> <td> 5,799 </td> <td> 67 </td> </tr> <tr> <td> </td> <td> 1e-20 </td> <td> 3,085 </td> <td> 12,399 </td> <td> 59 </td> </tr> <tr> <td> </td> <td> 1e-25 </td> <td> 680 </td> <td> 20,925 </td> <td> 12 </td> </tr> <tr> <td> </td> <td> 1e-30 </td> <td> 8 </td> <td> 22,470 </td> <td> 2 </td> </tr> <tr> <td> Rice </td> <td> RAND </td> <td> N/A </td> <td> 1,901 </td> <td> 0 </td> <td> 113 </td> </tr> <tr> <td> Barley </td> <td> sHYB </td> <td> N/A </td> <td> 70 </td> <td> 0 </td> <td> 1,413 </td> </tr> <tr> <td rowspan="3"> Barley </td> <td> HYB </td> <td> 1.5 </td> <td> 311 </td> <td> 141 </td> <td> 14,471 </td> </tr> <tr> <td> </td> <td> 1.6 </td> <td> 318 </td> <td> 211 </td> <td> 14,375 </td> </tr> <tr> <td> </td> <td> 1.7 </td> <td> 2,124 </td> <td> 988 </td> <td> 2,880 </td> </tr> </table>

PMC2717093_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th> Clones </th> <th> Contigs </th> <th> Singl. </th> <th> Q-contigs </th> </tr> <tr> <td> Rice FPC Standard </td> <td> 22,486 </td> <td> 1,918 </td> <td> 860 </td> <td> 8 </td> </tr> <tr> <td> Rice Comp. sHYB </td> <td> 22,486 </td> <td> 2,032 </td> <td> 1,156 </td> <td> 6 </td> </tr> <tr> <td> Rice Comp. HYB </td> <td> 22,486 </td> <td> 2,070 </td> <td> 2,593 </td> <td> 3 </td> </tr> <tr> <td> Rice Comp. RESTR </td> <td> 22,486 </td> <td> 1,918 </td> <td> 860 </td> <td> 8 </td> </tr> <tr> <td> Rice Comp. RAND </td> <td> 22,486 </td> <td> 1,994 </td> <td> 862 </td> <td> 6 </td> </tr> <tr> <td> Barley FPC Standard </td> <td> 61,647 </td> <td> 8,852 </td> <td> 8,821 </td> <td> 869 </td> </tr> <tr> <td> Barley Comp. sHYB </td> <td> 61,647 </td> <td> 9,316 </td> <td> 10,866 </td> <td> 601 </td> </tr> <tr> <td> Barley Comp. HYB </td> <td> 61,647 </td> <td> 9,376 </td> <td> 13,024 </td> <td> 489 </td> </tr> </table>

PMC2717093_table_1

<table border="1" class="dataframe"> <tr> <th> </th> <th> Assembly score (%) </th> <th> Misplaced clones </th> <th> Misass. contigs </th> <th> Global ordering </th> </tr> <tr> <td> FPC Standard </td> <td> 96.43 </td> <td> 675 </td> <td> 493 </td> <td> 0.8252 </td> </tr> <tr> <td> Comp. sHYB </td> <td> 97.67 </td> <td> 343 </td> <td> 290 </td> <td> 0.8496 </td> </tr> <tr> <td> Comp. HYB </td> <td> 99.75 </td> <td> 10 </td> <td> 7 </td> <td> 0.8575 </td> </tr> <tr> <td> Comp. RESTR </td> <td> 96.43 </td> <td> 675 </td> <td> 473 </td> <td> 0.8254 </td> </tr> <tr> <td> Comp. RAND </td> <td> 96.48 </td> <td> 668 </td> <td> 492 </td> <td> 0.8252 </td> </tr> </table>

PMC2717093_table_2

<table border="1" class="dataframe"> <tr> <th> cor- </th> <th> MTP clones </th> <th> Coverage (%) </th> <th> Overlaps (%) </th> </tr> <tr> <td> FPC Standard </td> <td> 2,791 </td> <td> 84.89 </td> <td> 84.31 </td> </tr> <tr> <td> Comp. sHYB </td> <td> 2,874 </td> <td> 85.66 </td> <td> 86.94 </td> </tr> <tr> <td rowspan="2"> Comp. HYB a </td> <td> 2,810 </td> <td> 85.89 </td> <td> 94.05 </td> </tr> <tr> <td> 2,792 </td> <td> 84.85 </td> <td> 84.33 </td> </tr> <tr> <td> Comp. RAND </td> <td> 2,856 </td> <td> 85.08 </td> <td> 83.75 </td> </tr> </table>

PMC2717093_table_3

<table border="1" class="dataframe"> <tr> <th> </th> <th> TP (%) </th> <th> FN (%) </th> <th> Singl. (%) </th> </tr> <tr> <td> Rice FPC Standard </td> <td> 88.91 </td> <td> 8.53 </td> <td> 2.56 </td> </tr> <tr> <td> Rice Comp. sHYB </td> <td> 87.90 </td> <td> 7.05 </td> <td> 5.05 </td> </tr> <tr> <td> Rice Comp. HYB </td> <td> 83.87 </td> <td> 1.90 </td> <td> 14.23 </td> </tr> <tr> <td> Rice Comp. RESTR </td> <td> 88.91 </td> <td> 8.53 </td> <td> 2.56 </td> </tr> <tr> <td> Rice Comp. RAND </td> <td> 87.80 </td> <td> 9.64 </td> <td> 2.56 </td> </tr> <tr> <td> Rice Manual </td> <td> 92.09 </td> <td> 7.26 </td> <td> 0.65 </td> </tr> <tr> <td> Barley Standard </td> <td> 82.27 </td> <td> 9.63 </td> <td> 8.10 </td> </tr> <tr> <td> Barley Comp. sHYB </td> <td> 82.55 </td> <td> 9.25 </td> <td> 8.20 </td> </tr> <tr> <td> Barley Comp. HYB </td> <td> 72.55 </td> <td> 9.06 </td> <td> 18.40 </td> </tr> </table>

PMC2717093_table_4

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="3"> Day care attendees (N = 61) </th> <th colspan="3"> All participants (N = 213) </th> </tr> <tr> <th> Serotype </th> <th> DCC1 </th> <th> DCC2 </th> <th> DCC3 </th> <th> DCC1 </th> <th> DCC2 </th> <th> DCC3 </th> </tr> <tr> <td> 9V </td> <td> 15 </td> <td> 0 </td> <td> 0 </td> <td> 21 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 18C </td> <td> 0 </td> <td> 0 </td> <td> 13 </td> <td> 0 </td> <td> 0 </td> <td> 20 </td> </tr> <tr> <td> 3 </td> <td> 9 </td> <td> 2 </td> <td> 6 </td> <td> 11 </td> <td> 2 </td> <td> 6 </td> </tr> <tr> <td> 19F </td> <td> 0 </td> <td> 8 </td> <td> 0 </td> <td> 1 </td> <td> 14 </td> <td> 1 </td> </tr> <tr> <td> 15B/C </td> <td> 2 </td> <td> 4 </td> <td> 5 </td> <td> 3 </td> <td> 6 </td> <td> 6 </td> </tr> <tr> <td> 11A </td> <td> 1 </td> <td> 2 </td> <td> 3 </td> <td> 1 </td> <td> 4 </td> <td> 7 </td> </tr> <tr> <td> 19A </td> <td> 7 </td> <td> 0 </td> <td> 0 </td> <td> 8 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 35F </td> <td> 3 </td> <td> 2 </td> <td> 0 </td> <td> 3 </td> <td> 4 </td> <td> 1 </td> </tr> <tr> <td> 14 </td> <td> 0 </td> <td> 2 </td> <td> 2 </td> <td> 0 </td> <td> 4 </td> <td> 3 </td> </tr> <tr> <td> 6B </td> <td> 1 </td> <td> 1 </td> <td> 0 </td> <td> 1 </td> <td> 4 </td> <td> 1 </td> </tr> <tr> <td> 22 </td> <td> 0 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> <td> 4 </td> <td> 0 </td> </tr> <tr> <td> 33 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> <td> 3 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 38 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> <td> 2 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 6A </td> <td> 1 </td> <td> 1 </td> <td> 0 </td> <td> 1 </td> <td> 1 </td> <td> 0 </td> </tr> <tr> <td> 9N </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 1 </td> <td> 1 </td> </tr> <tr> <td> 10 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 16 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> </tr> <tr> <td> 18B </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> </tr> <tr> <td> 35B </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> </tr> <tr> <td> 7 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> <td> 0 </td> <td> 0 </td> <td> 1 </td> </tr> <tr> <td> Non-typables </td> <td> 0 </td> <td> 0 </td> <td> 0 </td> <td> 0 </td> <td> 3 </td> <td> 3 </td> </tr> <tr> <td> Total </td> <td> 45 </td> <td> 23 </td> <td> 30 </td> <td> 57 </td> <td> 48 </td> <td> 51 </td> </tr> </table>

PMC2717096_table_0

<table border="1" class="dataframe"> <tr> <th> Model parameter </th> <th> Posterior mean </th> <th> 5% quantile </th> <th> 95% quantile </th> </tr> <tr> <td> κ Community acquisition rate (per month) </td> <td> 0.0059 </td> <td> 0.0043 </td> <td> 0.0077 </td> </tr> <tr> <td> βfam Family transmission rate (per month) </td> <td> 0.36 </td> <td> 0.23 </td> <td> 0.52 </td> </tr> <tr> <td> βdcc DCC transmission rate (per month) </td> <td> 0.53 </td> <td> 0.38 </td> <td> 0.71 </td> </tr> <tr> <td> μ Clearance rate (per month) </td> <td> 0.69 </td> <td> 0.64 </td> <td> 0.75 </td> </tr> <tr> <td> θ Competition parameter </td> <td> 0.68 </td> <td> 0.35 </td> <td> 1.10 </td> </tr> <tr> <td> η Relative susceptibility (adults vs. children) </td> <td> 0.41 </td> <td> 0.28 </td> <td> 0.58 </td> </tr> <tr> <td> δ Relative clearance rate (adults vs. children) </td> <td> 1.23 </td> <td> 1.06 </td> <td> 1.41 </td> </tr> </table>

PMC2717096_table_1

<table border="1" class="dataframe"> <tr> <th> </th> <th colspan="2"> Vaginal (V19I, V12I, V11I) </th> <th colspan="2"> Ectocervical (3ECI) </th> <th colspan="2"> Endocervical (sA2EN) </th> </tr> <tr> <th> </th> <th> MOI 10 </th> <th> PBS </th> <th> MOI 10 </th> <th> PBS </th> <th> MOI 10 </th> <th> PBS </th> </tr> <tr> <td> IL-6 </td> <td> 127 ± 13.1* </td> <td> 69 ± 1.7 </td> <td> 63.7 ± 1.8* </td> <td> 21.3 ± 2.4 </td> <td> 348 ± 13* </td> <td> 196 ± 15 </td> </tr> <tr> <td> IL-8 </td> <td> 1458 ± 117* </td> <td> 785 ± 11.3 </td> <td> 3304 ± 300* </td> <td> 722 ± 98 </td> <td> 5e7 ± 1347* </td> <td> 6e4 ± 367 </td> </tr> <tr> <td> G-CSF </td> <td> 261 ± 46 </td> <td> 227 ± 37 </td> <td> 548 ± 143 </td> <td> 779 ± 122 </td> <td> 155 ± 6.2* </td> <td> 93 ± 21 </td> </tr> <tr> <td> GM-CSF </td> <td> 24 ± 1.8* </td> <td> 8 ± 3.1 </td> <td> 16 ± 2.6 </td> <td> 10 ± 1.0 </td> <td> 160 ± 9.4* </td> <td> 45 ± 12 </td> </tr> <tr> <td> MCP-1 </td> <td> 5.8 ± 1.4 </td> <td> 7 ± 2.1 </td> <td> 11.4 ± 1.3 </td> <td> 10 ± 3.1 </td> <td> 7.2 ± 1.1* </td> <td> 0.46 ± 0.02 </td> </tr> </table>

PMC2717097_table_0

<table border="1" class="dataframe"> <tr> <th> </th> <th> Primer combinations used </th> <th> Size of the expected PCR product [bp] </th> <th> PCR product obtained </th> </tr> <tr> <td> GI1 </td> <td> GI1–1/GI1–2 </td> <td> 1,331 </td> <td> - </td> </tr> <tr> <td> GI1* </td> <td> GI1–2/GI1–3 </td> <td> 677 </td> <td> + </td> </tr> <tr> <td> GI2 </td> <td> GI2-1/GI2–2 </td> <td> 624 </td> <td> + </td> </tr> <tr> <td> GI2* </td> <td> GI2–3/GI2–4 </td> <td> 902 </td> <td> - </td> </tr> <tr> <td> GI3 </td> <td> GI3–1/GI3–2 </td> <td> 967 </td> <td> + </td> </tr> <tr> <td> GI1+GI2 </td> <td> GI2–3/GI1–2 </td> <td> 1,175 </td> <td> - </td> </tr> <tr> <td> GI2+GI3 </td> <td> GI3-2/GI2-2 </td> <td> 578 </td> <td> + </td> </tr> <tr> <td> GI2*+GI3 </td> <td> GI3-3/GI2–4 </td> <td> 494 </td> <td> - </td> </tr> <tr> <td> GI1–GI3 </td> <td> GI3-2/GI1–2 </td> <td> 720 </td> <td> + </td> </tr> <tr> <td> GI4 </td> <td> GI4-1/GI4-2 </td> <td> 384 </td> <td> + </td> </tr> <tr> <td> GI5 </td> <td> GI5-1/GI5-2 </td> <td> 571 </td> <td> - </td> </tr> <tr> <td> GI6 </td> <td> GI6-1/GI6-2 </td> <td> 850 </td> <td> + </td> </tr> <tr> <td> GI7 </td> <td> GI7-1/GI7-2 </td> <td> 384 </td> <td> + </td> </tr> </table>

PMC2717098_table_0

<table border="1" class="dataframe"> <tr> <th> Designation </th> <th> DNA-Sequence </th> </tr> <tr> <td> GI1-1 </td> <td> 5'-TAC GGA CCT TCT CGG CGG-3' </td> </tr> <tr> <td> GI1–2 </td> <td> 5'-GAC CCA AGG CAA GAC GCT G-3' </td> </tr> <tr> <td> GI1–3 </td> <td> 5'-ATT ACC CGC ATT CCC TTG TTG-3' </td> </tr> <tr> <td> GI2-1 </td> <td> 5'-TCG TTG ACC TCG CTC CTC CA-3' </td> </tr> <tr> <td> GI2-2 </td> <td> 5'-TAC GAC AGT TGA CCA CAG TTG-3' </td> </tr> <tr> <td> GI2–3 </td> <td> 5'-CTC TGC CGT CCC TCC TTG-3' </td> </tr> <tr> <td> GI2–4 </td> <td> 5'-TCA AGA CCA TCG TAT AGC GG-3' </td> </tr> <tr> <td> GI3-1 </td> <td> 5'-AGG TCT AGG AAA ACT GGG CGA ATC-3' </td> </tr> <tr> <td> GI3-2 </td> <td> 5'-GTA TTC CTG TGC CTA GAT TGG-3' </td> </tr> <tr> <td> GI3–3 </td> <td> 5'-TCA GCC CCA GCA ACT ATC C-3' </td> </tr> <tr> <td> GI4-1 </td> <td> 5'-ATG AAC ACC CGG CGA CCC-3' </td> </tr> <tr> <td> GI4-2 </td> <td> 5'-GAG CTA ACC TAC TGT CCC AT-3' </td> </tr> <tr> <td> GI5-1 </td> <td> 5'-GTT TTG GGA TGT TTT GAA GCG TG-3' </td> </tr> <tr> <td> GI5-2 </td> <td> 5'-CGG TCG AAG AAG CCA GCA GT-3' </td> </tr> <tr> <td> GI6-2 </td> <td> 5'-GAT AGG GTT CGC TCA CAC GGC-3' </td> </tr> <tr> <td> GI6-1 </td> <td> 5'-CTC CTC CAG CAA CAA TAC GG-3' </td> </tr> <tr> <td> GI7-1 </td> <td> 5'-TTG AGA CGA CTA TGA ACC CAG-3' </td> </tr> <tr> <td> GI7-2 </td> <td> 5'-CGC CCA TTG CCA CGA CCG-3' </td> </tr> <tr> <td> Tet1 </td> <td> 5'-GAC GGC GGC CGC ATC TGG CAA AGC-3' </td> </tr> <tr> <td> Tet2 </td> <td> 5'-ATA CTA GTC ATC GCG TGA TCC TCG CGA A-3' </td> </tr> <tr> <td> Tet3 </td> <td> 5'-ATG AAT TCA ATA CGC CCG AGA CCC GCG-3' </td> </tr> <tr> <td> Tet4 </td> <td> 5'-CAT CTC GAG AAA ACG GTG AAG GCC AGC-3' </td> </tr> <tr> <td> tRNA45-1 </td> <td> 5'-CCG TCT CCA ATC CCA AGG C-3' </td> </tr> <tr> <td> tRNA45-2 </td> <td> 5'-CTG GAA CAA GAA GGC CG C-3' </td> </tr> </table>

PMC2717098_table_1

<table border="1" class="dataframe"> <tr> <th> MIC Mutant </th> <th> Design Score </th> <th> SEC Binding </th> </tr> <tr> <td> N69Q_Q108L_Q120I_K154S_T155D </td> <td> -8.1 </td> <td> + </td> </tr> <tr> <td> N69Q_Q120I_K154S_T155D_Y157L </td> <td> -7.1 </td> <td> - </td> </tr> <tr> <td> N69Q_D72F_K154S_T155D </td> <td> -7.1 </td> <td> + </td> </tr> <tr> <td> N69Q_Q120I_K154S_T155D </td> <td> -6 </td> <td> + </td> </tr> <tr> <td> N69Q_D72F_Q108L_K152V_Y157L </td> <td> -5.9 </td> <td> + </td> </tr> <tr> <td> K152V_K154S_T155D_Y157L </td> <td> -5.8 </td> <td> + </td> </tr> <tr> <td> N69Q_K154D </td> <td> -4.3 </td> <td> + </td> </tr> <tr> <td> K154S_T155D </td> <td> -4 </td> <td> - </td> </tr> <tr> <td> K152V_K154S_T155D </td> <td> -3.9 </td> <td> - </td> </tr> <tr> <td> N69Q_D72F_Q108L </td> <td> -3.9 </td> <td> + </td> </tr> <tr> <td> N69Q_D72F </td> <td> -3.6 </td> <td> + </td> </tr> <tr> <td> N69Q </td> <td> -2.8 </td> <td> + </td> </tr> <tr> <td> K152V_Y157L </td> <td> -2.2 </td> <td> + </td> </tr> <tr> <td> K154D </td> <td> -1.5 </td> <td> + </td> </tr> <tr> <td> Q108L </td> <td> -0.5 </td> <td> + </td> </tr> <tr> <td> Wild-type </td> <td> 0 </td> <td> + </td> </tr> <tr> <td> D72W </td> <td> 0.3 </td> <td> - </td> </tr> <tr> <td> Q120I </td> <td> 0.7 </td> <td> + </td> </tr> <tr> <td> Q120I_K154M </td> <td> 0.8 </td> <td> n/a </td> </tr> <tr> <td> N69W </td> <td> 1.8 </td> <td> ++ </td> </tr> <tr> <td> N69W_K152E_K154S </td> <td> 4.2 </td> <td> ++ </td> </tr> <tr> <td> N69W_K152E_K154D </td> <td> 4.3 </td> <td> ++ </td> </tr> <tr> <td> K152E_K154M </td> <td> 4.4 </td> <td> + </td> </tr> <tr> <td> N69W_D72F_K152E </td> <td> 4.5 </td> <td> ++ </td> </tr> <tr> <td> N69W_D72W_K152E </td> <td> 5.1 </td> <td> + </td> </tr> <tr> <td> N69W_K152E </td> <td> 5.5 </td> <td> ++ </td> </tr> </table>

PMC2717102_table_0

<table border="1" class="dataframe"> <tr> <th> Origin </th> <th> Sequence </th> <th> Reference </th> </tr> <tr> <td> Plasma proteins </td> <td> </td> <td> </td> </tr> <tr> <td> Complement factor C3 </td> <td> LGEACKKVFLDCCNYITELRRQHARAS </td> <td> [13,14] </td> </tr> <tr> <td> High molecular weight kininogen </td> <td> HKHGHGHGKHKNKGKKNGKH </td> <td> [15] </td> </tr> <tr> <td> Fibronectin </td> <td> QPPRARITGYIIKYEKPG </td> <td> [17] </td> </tr> <tr> <td> Protein C Inhibitor </td> <td> SEKTLRKWLKMFKKRQLELY </td> <td> [11] </td> </tr> <tr> <td> Histidine-rich glycoprotein </td> <td> GHHPHGHHPHGHHPHGHHPH </td> <td> [18,19] </td> </tr> <tr> <td> Extracellular proteins </td> <td> </td> <td> </td> </tr> <tr> <td> Amphiregulin </td> <td> LKKNGSCKRGPRTHYGQKAIL </td> <td> [17] </td> </tr> <tr> <td> Heparin-binding EGF-like growth factor </td> <td> GKRKKKGKGLGKKRDPCLRKYK </td> <td> [17] </td> </tr> <tr> <td> Fibroblast growth factor </td> <td> </td> <td> </td> </tr> <tr> <td> Hepatocyte growth factor </td> <td> LKIKTKKVNTADQCANRCTRNKGL </td> <td> </td> </tr> <tr> <td> Vitronectin </td> <td> AKKQRFRHRNRKGYR </td> <td> [11] </td> </tr> <tr> <td> PRELP </td> <td> QPTRRPRPGTGPGRRPRPRPRP </td> <td> [17] </td> </tr> <tr> <td> Laminin chains </td> <td> SRNLSEIKLLISQARK KDFLSIELFRGRVKV LGTRLRAQSRQRSRPGRWHKVSVRW RLRAQSRQRSRPGRWHKVSVRW </td> <td> [11] </td> </tr> </table>

PMC2717103_table_0

<table border="1" class="dataframe"> <tr> <th> Causes </th> <th> number </th> <th> % </th> </tr> <tr> <td> ≥ BMI** 30 kg/m2 </td> <td> 3 </td> <td> 6.8 </td> </tr> <tr> <td> PEGs suture-free technique </td> <td> 6 </td> <td> 13.6 </td> </tr> <tr> <td> PEGs could not be performed </td> <td> </td> <td> </td> </tr> <tr> <td> Non dilatable stenosis </td> <td> 26 </td> <td> 59.1 </td> </tr> <tr> <td> Neoplasias affecting stomach </td> <td> 3 </td> <td> 6.8 </td> </tr> <tr> <td> Gastric ulcer perforation </td> <td> 2 </td> <td> 4.5 </td> </tr> <tr> <td> Patients with ascites </td> <td> 2 </td> <td> 4.5 </td> </tr> <tr> <td> Partial gastrectomy </td> <td> 1 </td> <td> 2.3 </td> </tr> <tr> <td> Respiratory failure associated to supine position </td> <td> 1 </td> <td> 2.3 </td> </tr> </table>

PMC2717113_table_0